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Summary 
In the doses used in cancer chemo-radio-therapy of patients most cancer cells undergo 
accelerated senescence. Unfortunately, senescence induced by therapy may be reversible, the 
mechanisms of reverse needed exploration. For the first time we discovered activation of self-
renewal in tetraploid presenescent normal human fibroblasts and TP53 dependent simultaneous 
activation of self-renewal and senescence regulators in etoposide treated teratocarcinoma cells. 
Together these results indicate the generality of coupling between senescence and stemness 
programs occuring in DNA damage response. Furthermore, we described importance of senescence 
acompanying autophagy for support of bi-potentiality and survival of DNA damaged tumour cells, 
as well as expansion of chromosome territories in polyploid cells which may favour transcription 
activation and reprograming. 
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Introduction 
One of the major problems in cancer therapy is the formation of the secondary resistant 
tumour cells after initially successful genotoxic treatments, such as chemo- and radiotherapy, which 
cause relapse of the disease and metastases in up to 50% of cancer cases, which subsequently kill 
the patients. The cellular mechanisms of this resistance are not yet clear. Despite the 
recentdiscoveries made in the last decade in targeted therapy, which have helped making progress 
in overall treatment of cancer, the reductionist view fails to deal with cancer as it is in fact a moving 
target (Weinberg 2014). Therefore, new conceptual paradigms for explaining bigger picture are 
needed (Hanahan 2014; Weinberg 2014). 
In the doses used in cancer chemo-radio-therapy of patients most of cancer cells undergo 
accelerated senescence, defined as a permanent arrest of proliferation (Roninson et al., 2001). 
Unfortunately senescence induced by anticancer DNA damaging therapy may be insufficient or 
reversible (Wu et al., 2012) with the mechanisms currently unknown. 
Autophagy has for a long time been considered anear-death mechanism associated with 
senescence  (Young et al., 2009).  However, recent findings show that moderate autophagy works 
as a pro-survival mechanism in tumour cells depending on context, therefore either this process 
should be promoted or suppressed in cancer treatments is under debate (Gewirtz 2013) and the 
paradoxical nature of autophagy has been widely discussed (Hanahan and Weinberg 2011). 
One of the most intriguing facets that senescent cells share with cancer cells is polyploidy. 
Cells may enter polyploidy due to persistent damage during senescence and/or mitosis bypass 
(Davoli et al., 2011; Castedo et al., 2010). Highly malignant p53-mutated tumours under DNA 
damage may undergo mitotic slippage from G2/M arrest and re-enter G1 phase with doubled DNA 
amount, forming polyploidy (Erenpreisa et al., 2008; Illidge et al., 2000). 
The previous studies in our and other laboratories showed that recovery of resistant tumour 
cells after genotoxins is associated with induced polyploidy and its reverse (Erenpreisa et al., 2000, 
2005, 2008) and that resultant diploid descendants are mitotically active ( Illidge et al., 2000; Puig 
et al., 2008; Vitale et al., 2011). It was shown that tumour cells can acquire embryonal stemness as 
a result of ionizing irradiation or genotoxic drugs.  This occurs in reversibly polyploidised cells 
(Salmina et al., 2010). These observations were confirmed and extended in several laboratories 
(Ghisolfi et al., 2012; Lagadec and Pajonk 2012; Zhang et al., 2013c). These studies showed 
changed transcription profiles with expression of stemness signature,  the capability of sphere 
formation, the ability to undergo de-polyploidisation, and tumorigenicity at xenotransplantation of 
induced polyploid tumour stem cells, even just of one (Weihua et al., 2011). 
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To sum up, genotoxic treatments cause activation of as if two opposite programms: 
senescence and stemness, both are paradoxically linked to induced polyploidy. Therefore it is 
important to study the relationship of regulators of these programs in individual cells and their cell 
cycles for explaining this paradox. 
The aim and tasks of the study: 
The aim of this study was to investigate the relationship of self-renewal and senescence in 
tumour cells after genotoxic treatment and in normal cells during aging, and the place and role of 
associated polyploidy. 
For achieving the goal several tasks were set.  
• To explore the role of tetraploidy induced by senescence and DNA damage in normal 
and tumour cells;  
• To characterise co-expression of self-renewal and senescence regulators OCT4A and 
P21CIP1 after genotoxic damage in individual cells of  embryonal carcinoma, the model 
of cancer stem cells; 
• To explore the role of autophagy in survival of cancer cells after genotoxic therapy. 
• To explore changes in the volumes of chromosome territories in irradiated cancer cells. 
 
  
8 
 
1. Literature overview 
1.1. Cancer resistance to genotoxic treatments 
“War against cancer” was declared in USA about 40 years ago and now the scientists all 
around the world have to recognize that. Despite the fact that some of the battles have been won, we 
are yet to approach  this aim with the strategies currently in use. “Magical bullets”, famous 
metaphor of targeted therapy turned out to be mostly ineffective and showing only transient effect 
for treating cancer (Hanahan 2014). The targets are in fact ‘moving” and previous strategies based 
on reductionistic concepts such as mutational theory of cancer are  insufficient (Weinberg 2014). 
Therefore, a new concept dealing with the complexity of cancer is needed (Hanahan 2014; 
Weinberg 2014). 
Currently irradiation and chemotherapy are still used to treat most of the cancer types. The 
main problem with curing cancer is acquired resistance to genotoxic treatments. Several 
mechanisms of acquired resistance will be analyzed in further paragraphs. 
1.2. DNA damage and its cell cycle checkpoint 
“So, from the perspective of cancer, DNA damage causes the disease, it is used to treat the 
disease, and it is responsible for the toxicity of therapies for the disease” (Kastan and Bartek 
2004). 
Based on the “law of Bergonié and Tribondeau” formulated on 1906, cell sensivity against 
irradiation is proportional intensity of cell division (Haber and Rothstein 1969). Therefore agents 
used in traditional anti-cancer therapy are targeted against rapidly dividing cells and their acting 
mechanism is DNA damage that leads cells to a growth arrest, death and cellular senescence – the 
state when the cell stays alive, but is unable to further proliferate (Roninson et al., 2001). 
In proliferating somatic cells, the genome constancy is regulated through a cell cycle - 
DNA synthesis and following cell division. Cell cycle is regulated by several checkpoints, in which 
large enzyme complexes control physiological condition of a cell and decide whether cell may 
continue cycling or it has to stop for repairing the errors, or it is send to cell death or senescence in 
the case of irreparable damage (Elledge 1996). Defective cell cycle regulation can lead to 
unregulated cell division and cancer (Kops et al., 2005; Kastan and Bartek 2004). In tumours 
checkpoint tresholds are often evaluated via genetic mutation or epigenetic inactivation of 
checkpoint activator proteins (Kinzler and Vogelstein 1997), like tumour suppressor protein P53, so 
called the “guardian of the genome”, one of most commonly mutated gene in human cancers 
(Kastan 2007). 
For safeguarding DNA integrity the most important is G2/M (DNA damage) checkpoint 
(Kastan and Bartek 2004). DNA damage response starts with ATM (Lee and Paull 2007) or ATR 
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(Smith et al., 2010) signaling and the main axis is tumor suppressor P53 which activates cyclin 
kinase inhibitor P21CIP1 and halts the cell cycle, giving the time for cell to repair DNA and if it is 
impossible sending it to senescence or,  in case of too large damage, to apoptosis (Roninson et al., 
2001; Seviour and Lin 2010). While apoptosis is well studied, the mechanisms of cellular 
senescence, in particular whether it can be reversed, are not clear. 
1.3. Cellular senescence and cancer 
1.3.1. Replicative senescence 
Most commonly known type of senescence is replicative cellular senescence, basically 
defined as a final cell growth arrest, was firstly introduced by Leonard Hayflick (Hayflick 1965) 
when he noticed that human cells have a limited life span in the culture, dividing for about 40-60  
times. This process is associated with asymmetrical nature of DNA replication on its two strands, 
with each division the telomeres become shorter  (Harley et al., 1990) and finally are recognized as 
DNA breaks (d’Adda di Fagagna et al., 2003; Herbig et al., 2004). Then ATM/CHK2/P53/P21CIP1 
pathway is activated to inhibit G1/S transition and arrest the cell cycle. Senescent cells remain 
metabolically active, however further cell division is arrested (Gey and Seeger 2013). 
Another parallel senescence pathway is P16INK4a-RB pathway (Beauséjour et al., 2003), 
which is considered to be activated at deeper senescence than the state induced P21CIP1, the latter  
may be by some extent reversible (Atsumi et al., 2011; Yoshioka et al., 2012; Hayat 2013). 
There are several markers for detection of cellular senescence besides P16INK4a and 
P21CIP1 expression, like lack of proliferative marking for Ki67 and mitotic activity due to cell 
cycle arrest, flattened cell form, positive SA-β-gal activity. At deep senescence stage forming of 
senescence-associated heterochromatin foci SAHFs epigenetically depress proliferation genes 
(Narita et al., 2003). SAHFs can be detected by the preferential binding of DNA dyes (Funayama et 
al. 2006; Narita et al. 2003). 
In the doses used in cancer chemo-radio-therapy of patients most of cancer cells undergo 
accelerated senescence (Roninson et al., 2001; Gewirtz et al., 2008; Schmitt 2007). 
1.3.2. Premature (accelerated) senescence 
Premature senescence can be triggered by certain stresses independently of the number of 
cell divisions or telomere length (Shay and Roninson 2004). There are three main kinds of such 
stresses: action of DNA damaging agents, oncogene activation like RAS or MYC, RAF (Serrano et 
al., 1997; Bartkova et al., 2006) or ROS (reactive oxygen species) (Vigneron and Vousden 2010). 
However, DNA damage is a mutual feature of accelerated senescence independent on the origin of 
stress (d’Adda di Fagagna 2008). This senescence starts at the DNA damage checkpoint in G2 
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arrest, when damaged cells become resistant against apoptosis and it is mediated by P53/P21CIP1 
axis (Schmitt et al., 2002; Campisi and d’Adda di Fagagna, 2007). 
In general, in human cells, replicative senescence is usually dependent on 
P53/P21CIP1/pRb/E2F pathway, whereas accelerated senescence can be mediated through 
P53/P21CIP1/pRb/E2F or, P16INK4a/pRb/E2F pathway or both (Herbig et al., 2004; Serrano et al., 
1997). Drug induced DNA damage causes senescence in tumour cells both, in vitro and in vivo, 
P21CIP1 playing a role at initiation and P16INK4a maintaining senescence (te Poele et al., 2002). 
1.3.3. Senescence induced by genotoxic cancer treatment 
Senescence induced by anticancer DNA damaging therapy may be insufficient or 
reversible, likely most often due to inefficient P16INK4a or P53 pathway (Wu et al., 2012). It has 
been shown that lack of P53 may be responsible for reversibility of senescence (Roberson et al., 
2005; Bond et al., 1994) although P16INK4a can serve as a second barrier (Beauséjour et al., 
2003).  
Cancer therapy based on deepening of senescence works by inhibiting telomerase activity, 
modulating cyclin dependent kinase activity such as P21CIP1 and P16INK4a, c-myc inhibition, 
reactivation of P53 function, statins and recently – manipulation with secretome activity  (Acosta 
and Gil 2012; Wu et al., 2012). 
In general, cell senescence is a major barrier against tumour formation (Campisi 2001; 
Sharpless and DePinho 2005), supported by observations that  transgenic mice expressing 
additional copies of senescence regulators p53 or Ink4/Arf have increased protection against cancer, 
without side effects (Serrano and Blasco 2007) but their antagonistically pleiotropic effects 
eventually lead to organism aging (Campisi 2005). Interestingly, cell senescence is a process not 
exclusive for ageing organism. Senescent cells can be found as early as embryonal development 
where they regulate organogenesis (Muñoz-Espín et al., 2013), however the mechanisms are not 
clear. 
Paradoxically it has been shown that senescence in tissue may promote cell proliferation, 
in particular, due to senescence associated enhanced metabolism, autophagy and secretory 
phenotype (SASP), which has been shown to contain many ingredients, like interleukines and 
chemokines, that may induce senescence in neighbor fibroblasts (Nelson et al., 2012), 
proinflammatory cytokines such as IL-6, IL-8 and GROa may initiate an immune response required 
for tumor clearance (Xue et al., 2007) unfortunately they may fuel tumour growth and stimulate 
EMT in tumours as well (Gorgoulis and Halazonetis 2010). 
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1.3.4. Autophagy and aging  
Macroautophagy (further: autophagy) is the cellular process when autophagosome is 
formed around cargo that may carry different cellular structures, protein aggregates, nucleic acids, 
lipids, even entire organelles (Okamoto 2014) and later merge with a lysosome for digestion 
(Hurley and Schulman 2014). The end products of this process are amino and fatty acids, 
nucleotides, which are released back into the cytosol and recycled (Kuma and Mizushima 2010). 
Autophagy was generally thought to affect cytoplasmic organelles, however release of 
DNA patches was found in yeasts, while degradation of the whole nuclei has been described, in 
unicellular organism Tetrahymena (Lu and Wolfe 2001)  and filamentous fungi Aspergillus oryzae 
(Shoji et al., 2010).  
It has been found in polyploid tumour cells, induced after DNA damage, that a 
considerable amount of genetic material undergoes sequestration and extrusion as sub-nuclei and 
further autophagic digestion with possible role in genome sorting and stabilising effects  
(Erenpreisa et al., 2000). 
The autophagic pathway can be upregulated in response to a variety of stressful conditions 
and chemical triggers such as: starving, hypoxia, accumulation of misfolded proteins and typically 
by aging (Cuervo et al., 2005). The activity of SA-ß-gal, showing in fact acidification of cytoplasm 
by acid lysosomal content and macroautophagy activation, are well correlated during oncogene 
(RAS) induced senescence, and it was found that, under depletion of the autophagy genes ATG5 or 
ATG7 SA-ß-gal activity is inhibited (Young and Narita 2010). 
Autophagy has for a long time been considered as near-death mechanism associated with 
senescence  (Capparelli et al., 2012; Mosieniak et al., 2012; Young et al., 2009), however recent 
findings show that moderate autophagy works as a pro-survival mechanism in tumour cells 
depending on context, therefore either this process should be promoted or suppressed in cancer 
treatments is under debate (Gewirtz 2013; Kimmelman 2011) and the paradoxal nature of 
autophagy has been widely discussed (Hanahan and Weinberg 2011) Basically it is considered that 
autophagy, like cellular senescence,  may serve as a barrier to tumour initiation, but once cancer is 
established, then autophagy plays a role in promotion of malignant progression and in subsequent 
tumour maintenance by supplying metabolic substrates, limiting oxidative stress of mitochondria, 
etc (Rosenfeldt and Ryan 2011; Kimmelman 2011).  
One of the most intriguing facets that senescent cells share with cancer cells is polyploidy. 
Cells may enter polyploidy due to persistent telomere damage through prolonged G2 and mitosis 
bypass (Davoli et al., 2011; Castedo et al., 2010) and this eventually may lead to tumour formation 
(Davoli and de Lange 2011). Interestingly survivin, the protein which has been shown to have a role 
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in reverse of the therapy induced senescence, also promotes cell polyploidisation (Nagata et al., 
2005) and survivors also possess elevated survivin levels (Wang et al., 2011). 
 
1.4. Genetic instability and polyploidy of tumour cells 
“The main rule for cancer cells is the absence of any rules” (Hanseman 1890). 
1.4.1. Polyploidy in different normal cell types 
 Polyploidy - existence of more than two genome sets per one cell is a trait which is not 
common  in mammals and embryonal polyploidy is lethal, as a matter of fact (Kaufman 1991). Two 
types of polyploidy can  be distinguished –  (I) generative or stable, where all cells in organism are 
polyploid, often found  in cultivated plants; the only mammal with stable polyploidy is red vizcacha 
rat (Tympanoctomys barrerae) and its close relatives, which are tetraploid (Gallardo et al., 1999) 
and (II) somatic polyploidy or endopolyploidy. The controlled somatic polyploidisation, occurring 
mostly through aborted mitosis has a clear genome doubling which can make it till to some extent 
reversible (Lee et al., 2009). It is important that most cells undergoing endopolyploidisation do not 
exceed 32n/64C (normal cells in G1 – 2C) barrier, which provides cell with potential to return to 
diploidy. 32n is the largest ploidy size from which normal cells can still return to diploidy in very 
rare cases  (Nagl 1978). Somatic polyploidisation is part of normal development, for example, 
terminally differentiated nurse cells in Drosofila ovaries (Weaver and Cleveland 2001) and 
mammalian trophoblast. Polyploid trophoblast support rapid developing of embryo by producing 
vast amounts of protein, because of decreased surface-to-volume ratio, thereby minimizing 
membrane requirements, however lowering the efficiency of transport makes polyploid cells 
unstable for long periods of time (Comai 2005). As a similar somatic polyploidy example in the 
adult human organism megakaryocytes can be mentioned (Lee et al., 2009).  
Somatic polyploidy in normal adult human cells can be seen in hepatocytes, vascular 
smooth muscle cells induced as reaction to stress, such as hypoxy. It was found, that in hepatocytes 
(Celton-Morizur et al., 2010) and vascular smooth muscle cells (Hixon and Gualberto 2003)  the 
frequency of polyploidy increases with age; also human fibroblasts and endothelial cells in vitro 
become tetraploid with replicative aging (Walen 2008; Davoli et al., 2011). Therefore, polyploidy 
was for a long time considered as a senescence marker and was thought to be cell proliferation dead 
end, but in later years it was shown to be not, rodent hepatocytes has been shown to polyploidise 
and de-polyploidise and increase their genetic variability under stress conditions (Duncan et al., 
2010). It has been shown that senescent human fibroblasts in vitro undergo a similar process (Walen 
2013). 
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Interestingly spindle checkpoint activation in somatic cells or in embryonal stem cell-
derived early differentiated cells results in cell death, yet the same treatment does not trigger 
apoptosis in embryonal stem cells (ESC). It is therefore possible that such tolerance of ploidy 
changes by ESCs can contribute to their karyotypic instability  (Mantel et al., 2008). 
In normal somatic polyploidy, the metabolism is changed to more energy saving pathways 
under stress conditions (Anatskaya and Vinogradov 2010). Polyploidy and glycolytic flux has been 
found associated in yeast (Conant and Wolfe 2007) and  in endopolyploid mouse hepatocytes and 
human cardiomyocytes (Anatskaya and Vinogradov 2007). 
Increased glycolytic flux  is also a well-known trait in tumours (Kim and Dang 2006). 
Tumour cells also preferentially use glycolysis as an energy source, in aerobic condition and also 
used in anaerobic obstacles formed due to rapid growth and deficiency of blood supply, process 
called a Warburg effect and is known as one of main cancer hallmarks (Kim and Dang 2006; Ward 
and Thompson 2012). The increased glycolysis is coupled to increased nucleotide and lipid 
synthesis, therefore supporting rapid growth in different tumours (Hu et al., 2013). 
1.4.2. Stable polyploidy and genomic instability in tumours  
Stable aneupolyploidy can be often found  in epithelial and other types of cancers (Haroske 
et al., 2001).  Recently tetraploidy was found to have a role in colorectal cancer evolution through 
increase of genomic instability, where tetraploidization is an early event in the most colorectal 
cancers (Dewhurst et al., 2014). 
Two types of genetic instability can be discriminated – microsatellite instability (MIN) and 
chromosomal instability (CIN) Most of sporadic cancers have increased CIN (Ganem et al., 2007). 
Two types of CIN have been defined – segmental – translocations, deletions and amplifications and 
whole genome CIN (Geigl et al., 2008). CIN is mostly induced by breakage-fusion-bridge cycle, 
when chromosomes repeatedly fuse and then break in a following anaphase (McClintock 1942; 
Gisselsson et al., 2000), caused by telomere shortening during the replicative senescence. Most 
noticeable features of CIN are chromosome bridges in anaphase, mitotic death, polyploidy and 
irregular nuclear shape (Gisselson et al., 2001).  
CIN has important role in carcinogenesis, as it increases genetic and epigenetic mutability 
up to 100-1000 times (Ganem et al., 2007). Furthermore, 70% of mutations are due to chromosome 
translocations (Futreal et al., 2004; Ye et al., 2009), also mathematical modeling shows that CIN 
may be even an initiating step in colon cancer formation (Nowak et al., 2002). CIN-caused 
aneuploidy in tumours correlates with poor clinical prognosis (Krämer et al., 2002).  
Although chromosomal instability (CIN) has capacity of increasing cell survival due to 
induced variability and clonal selection, tumor progression requires balanced aneuploidy which 
would not interfere with cell division (Duesbery and Woude 2002; Weaver and Cleveland 2007; 
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Gordon et al., 2012). Among the most important advantages of polyploidy is capability of 
increasing genetic variability by unequal divisions of endopolyploid cells (Storchova and Kuffer 
2008), by masking deleterious mutations between several genomes, and in recombination and 
exchanges between homologous chromosomes (Coward and Harding 2014).  
1.4.3. Reversible polyploidy in tumours after DNA damage 
Among other advantages, polyploidy can provide tumour cells with durability against 
genotoxic damage. Highly malignant TP53-mutated tumours under DNA damage can undergo 
mitotic slippage from G2/M arrest and re-enter G1 phase with doubled DNA amount, forming 
polyploidy (Erenpreisa et al., 2008; 2000; Illidge et al., 2000). After acquiring tetraploid state, cell 
with functional TP53 will enter apoptosis, senescence or cell cycle arrest, but mutation or 
inactivation of TP53 can lead to arrest escape and further polyploidisation (Aylon and Oren 2011). 
Several genomes in one cell increase capacity of DNA repair as it has several copies for performing 
homologic recombination (HR). It has been shown that after DNA damage the polyploid tumour 
cells increase expression of recombinase RAD51 , which is acting anti-apoptotically (Ivanov et al., 
2003). 
It has been shown that small proportion of polyploid tumour cells induced by genotoxic 
treatments can return to diploidy (Illidge et al., 2000; Puig et al., 2008; Vitale et al., 2011), possibly 
through meiosis-like reduction divisions (Erenpreisa et al., 2009; Ianzini et al., 2009) and that 
resultant diploid cells are mitoticaly active (Illidge et al., 2000; Puig et al., 2008; Vitale et al., 
2011). Interestingly, depolyploidisation can also decrease aneuploidy (Vitale et al., 2010). As 
mentioned before, balancing of aneuploidy by getting just the right amount has important role in 
tumour cell propaation after therapy, as polyploidisation is always associated with increased 
chromosome instability and aneuploidy (Storchova and Kuffer 2008).  
Nevertheless, these polyploid cells possessing persistent DNA damage still mostly undergo 
cell death (Illidge et al., 2000). The reversible polyploidisation observed in tumour cells after DNA-
damage can give clonogenic escape only in 104-106 of the treated cells (Puig et al., 2008).  
In summary, tetraploidy favours transformation towards cancer in four ways. First, 
inducing CIN and aneuploidy, second – buffering cells against deleterious effects of chromosomal 
loss, third – escape from genotoxic agent induced death or senescence, forth – changing metabolism 
towards hypoxy- and toxicity-resistant type; all this makes polyploidy a tumour gateway and 
important target for anticancer drugs (Coward and Harding 2014) 
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1.5. Stem-like features of tumour cells 
1.5.1. Cancer stem cell concept 
Cancer stem cells (CSC) as a concept of carcinogenesis and tumour growth appeared as an 
alternative for a traditional microevolution model (Nowell 1976), which stated that cells acquire 
random  mutations while dividing and every cell has a potency to form cancer under a pressure of 
microevolution. It has helped to expand dimensions of how we see cancer and drive away from 
simply plain genetics and broken genes (Soto and Sonnenschein 2014; Tu 2013; Wang and 
Armstrong 2008). The model suggests that cancer has a similar hierarchy as an organism, with stem 
cells which are slowly dividing, progenitors – dividing usually rapidly, and less potent cells and 
differentiated cells which cannot form a cancer, if transplanted alone (Cabrera et al., 2015). Cancer 
stem cells are defined through their ability to form new tumors upon inoculation into recipient host 
mice (Cho and Clarke 2008). 
 Starting with lymphoma, CSC where found in practically all cancer types. The presence of 
CSC in the tumour is considered as the main cause of malignancy  which correlates with poor 
clinical outcome (Shekhani et al., 2013). CSC hypothesis suggests that only these cells support self-
renewal in tumours. The most used terms in literature are cancer stem cells (Jordan et al., 2006), 
stem-like cancer cells (Liang et al., 2010), tumour-initiating cells (Singh et al., 2004) etc. 
Cancer stem cell hypothesis made research society reconsider traditional therapies, as some 
tumour cells may have adult stem cell property to rest and not divide till receiving stimulus, 
therefore making anti-proliferative therapy ineffective against them (Blagosklonny 2007; Singh and 
Settleman 2010).  
Further research showed that truth is not so simple and that these cancer stem cells do not 
have exclusive rights to form cancer but just have an increased capability to do so (Marjanovic et 
al., 2013). Further experiments with cell sorting revealed that being a cancer stem cell is just a state 
of a tumour cell and not a perpetuating its property (Zhou et al., 2013; Zapperi and La Porta 2012). 
In fact, this means that the microevolution and cancer stem cell models should be rather merged 
than opposed (Csermely et al., 2014; Magee et al., 2012; Beck and Blanpain 2013). 
1.5.2. Embryonal core cassete expression in human tumours 
The concept of cancer cell similarity to embryonal cells has been around since the 19th 
century (Erenpreiss 1993). As one of examples, one of the most powerful oncogenes c-myc has 
roles in cancer, embryonal development, and induction of pluripotency of normal cells (Kim et al., 
2010; Rothenberg et al., 2010). Gene array analysis suggests that cancer stem cells resemble rather 
embryonal than adult stem cells (Wong et al., 2008).  
Embryonal stem cells (ECS) have a unique degree of autonomy, as being self-sufficient 
and self-replicating and this likely underlies their potential to form teratocarcinomas (Chambers and 
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Smith 2004). Self-renewal in ECS is closely associated with pluripotency (capacity to form three 
layers in embryogenesis). It is supported by three core ESC transcription factors OCT4, SOX2 and 
NANOG, which activate their target genes (and suppress silencing Polycomb protein genes) and 
also activate each other with a positive feedback loop (Boyer et al., 2005) It is known that a certain 
threshold level of ESC factors is required to start the positive feed-back circuit of transcription 
activation (Hemberger et al., 2009).  
OCT4 (POU5F) is a POU domain transcription factor. Currently OCT4 has several 
splicing isoforms described, from which OCT4A has a role in target gene activation, OCT4B has 
cytoplasmatic localisation without transactictivation role (Cantz et al., 2008) and OCT4B1 with an 
unknown role (Atlasi et al., 2008). One of OCT4 main functions is to form in conjunction with 
SOX2 heterodimer active NANOG chromatin domain, a central factor in pluripotency network 
(Rodda et al., 2005; Silva et al., 2009). OCT4 expression in normal cells is not exclusive for 
embryonal and germline cells and has also been found in neural stem cells (Chin et al., 2009). 
OCT4 is required for survival of chemoresistent cancer stem cells in colorectal cancer and 
its supression reduces STAT and Survivin overexpression (Wen et al., 2013; de Resende et al., 
2013; Peng et al., 2010). Some researchers have determined SOX2 (Piva et al., 2014; Tam and Ng 
2014; Boumahdi et al., 2014; Lee et al., 2014; Leis et al., 2012) or NANOG (Elsir et al., 2014; 
Zhang et al., 2013d; Lu et al., 2014) as being a most critical factors for cancer stem cell survival. 
1.5.3. Stemness of tumour cells increases after DNA damage 
Cancer stem cells may be formed or increase in proportion  through DNA damage and 
genetic instability (Liang et al., 2010). The  enrichment with cancer stem cells in tumour cell 
population after irradiation has been shown, which was initially explained by their positive selection 
after treatments (Phillips et al., 2006).  
It was shown in lymphoma and HeLa cells that shift to pluripotency by ionizing 
irradiation, treatments takes place, particularly in transiently induced polyploid cells,  and it 
depends on deficiency of TP53 function (Salmina et al., 2010). These observations were confirmed 
and extended in several laboratories (Ghisolfi et al., 2012; Lagadec and Pajonk 2012; Zhang et al., 
2013c). These studies showed acquisition of stemness transcription profiles, capability of embryoid 
sphere formation, the ability to undergo de-polyploidisation and resume  cell growth, the tumour 
arising activity at xenotransplantation of selected polyploidy tumour cells, even just of one (Weihua 
et al., 2011). 
In summary, genotoxic treatments cause activation of  two opposite programms: 
senescence and stemness, on the bacground of induced polyploidy. Therefore it seems important to 
study regulators of both in individual cells for explaining this paradox.  
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2. Materials and methods 
2.1. Cell culture and treatment.  
The Burkitt's lymphoma cell lines Namalwa and Ramos was obtained from the American 
Type Culture Collection (ATCC), the human B-lymphoblastoid cell lines WI-L2-NS were obtained 
from Dr. P. Olive (Canada) and all cell lines are TP53 function deficient. Lymphoma cell-lines were 
maintained in RPMI-1640 containing 10% heat-inactivated 10% foetal bovine serum (FBS; Sigma) 
at 37 °C in a 5 % CO2 humidified incubator. 
The wild-type TP53 human embryo lung fibroblast cell line IMR90 was obtained from 
ATCC and also from Coriell collection kindly donated by Dr. A. Ivanov (Beatson Institute, 
Glasgow) after 21–23 population doublings (PDL). Cells were cultured in DMEM (Sigma) 
supplemented with 10% FBS (Sigma), without antibiotics, as monolayers in a humidified incubator 
in 5% CO2/95% air atmosphere. The early passage cells were split 1 : 3 (∼50× 104 of cells per 
flask (25cm2) twice weekly. Mid-passage cells were split 1 : 2 weekly, and late-passage cultures 
were split 1 : 2 once cultures attained confluence. Culture medium was changed two or three times 
between subculture. This way, several subsequent passages were carried out until the cells failed to 
undergo > 0.8 population doublings in a 7-day culture period. Under the given conditions of 
cultivation, the cells typically reached this state after 40–50 PDL. 
PA-1 is an ovarian teratocarcinoma (a germline tumour) cell-line, obtained from ATCC, 
with a stable near-diploid karyotype (Zeuthen et al., 1980). It possesses functional TP53, 
despitepossible acquisition of one mutated allele reported at passages over 407 (Gao et al., 1999). 
PA-1  and HEK- 293 (Human Embryonic Kidney 293) cells were cultured in Dulbecco’s modified 
Eagle’s media (DMEM) supplemented with 10% foetal bovine serum (FBS). Cells were grown 
without antibiotics in 5% CO2 incubators at 37 °C. For the sphere formation assay, PA1 cells were 
inoculated in DMEM/ F12 media supplemented with 20 ng/ml EGF (236-EG, R&D Systems), 10 
ng/ml FGF (233-FB-025/CF, R&D Systems), 0.5 ng/ml hydrocortisone (H0888, Sigma), 10 ng/ml 
insulin (I9278, Sigma), 1× antibiotics/antimycotics (15240-062, Invitrogen), 1% L-glutamine 
(25030024, Invitrogen) and 20% methylcellulose (high viscosity, 4,000 cP; M0512, Sigma), and 
grown in 5% CO2 at 37 °C. 
HeLa clone 3 cells of human cervix carcinoma were kindly provided by Fiorenza Ianzini 
(University of Iowa). The cells were grown on slides in Ham’s F12 or HAM-1 medium (Sigma–
Aldrich) medium supplied with 10% FCS (Biochrom) and penicillin/streptomycin (Life 
Technologies) at 37 °C in a 5% CO2 humidified incubator (Binder) on glass cover slides in medium 
supplied with 10% FCS Suspension culture were grown in suspension under constant rotation in 
Joklik’s MEM containing 10% heat-inactivated calf serum (Hyclone) and antibiotics.  
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For experimental studies, cells were maintained in log phase of growth and treated with a 
single acute 10 Gy dose of gamma irradiation (1–2 Gy/min, Clinac 600 C, Varian Medical Systems 
or using a Gulmay D3 225 X-ray source at a dose rate of 0.77 Gy/min), ETO (etoposide; Sigma) – 8 
mM for 20 h or PXT (paclitaxel, Ebewe Pharma) – 50 nM for 20 h. Following treatment, cell 
cultures were maintained by replenishing culture medium every 48h and sampled over a 2-week 
period posttreatment. In certain experiments Bafilomycin A (Baf A, Cayman Chemicals) 50 nM 
was added to the PA1 cell culture medium for 24h between day 3 to 4 after 20h treatment with 8 
µM ETO. 
To determine the capacity of cells to replicate DNA, BrdU was added at 5 mM to the cell 
culture for 24 h prior to fixation. 
2.2. Silencing 
Small interfering RNA (siRNA). TP53 protein Hs_TP53_9 FlexiTube siRNA (Qiagen) 
was used to silence TP53 expression and ON-TARGET plus non-targeting siRNA #1 (Dharmacon) 
was used as a negative control. PA-1 cells were transfected with siRNA using HiPerfect (Qiagen) 
according to the manufacturer’s protocol.  
Small interfering RNA (siRNA) silencing FlexiTube siRNA (SI04950274, SI04950267, 
SI04153835 and SI00690382; Qiagen) was used to silence OCT4A expression, and FlexiTube 
siRNA (SI00604905, SI00604898 and SI00299810; Qiagen) was used to silence p21Cip1 
expression. ON-TARGET plus non-targeting siRNA #1 (Dharmacon) was used as a negative 
control. Cells were transfected with siRNA using HiPerfect (Qiagen) according to the 
manufacturer’s protocol. 
Small hairpin RNA (shRNA). The following plasmids were purchased from Addgene: 
pMKO.1 puro TP53 plasmid (Addgene plasmid 19119) deposited by Bob Weinberg and pMKO.1 
puro (Addgene plasmid 8452) deposited by Bob Weinberg. PA-1 cells were transfected with 
plasmid using Fugene 6 (Promega) accord- ing to the manufacturer’s protocol and then selected 
using puro- mycin (0.3 µg/ml). After 2 wk, growing colonies were sub-cloned, stable cell lines 
established and maintained in media containing puromycin. Selection was removed 3 d prior to 
experiments. Expression of HA-tagged forms of OCT4A and OCT4A- pseudogene-1. Expression 
vectors encoding HA-tagged forms of OCT4A or OCT4A-pseudogene-1 (OCT4A-PG1), a kind gift 
from Professor Aijun Hao, were transfected into HEK-293 cells using Fugene 6 (Promega) 
according to the manufacturer’s protocol.  
2.3. The senescence β-galactosidase   
The senescence β-galactosidase (sa-β-gal) staining kit (Cell Signaling Technology, UK) 
was used to detect sa-β-gal activity in cells according to the manufacturer’s protocol.  
19 
 
2.4. Cell cycle and ploidy analysis 
DNA Image Cytometry. Cells grown on coverslips were rinsed in PBS and serum. 
Alternatively trypsinised cells were washed in warm PBS and suspended in FBS and cytospun onto 
glass slides. Both preparations were then fixed in ethanol/acetone (1 : 1, v/v) overnight at 4◦C and 
air dried. For stoichiometric DNA staining (Erenpreisa and Freivalds 1979), slides were hydrolysed 
with 5N HCl for 20min washed in distilled water (5 x 1 min) and stained for 10 min with 0.05% 
toluidine blue in 50% citrate-phosphate McIlvain buffer pH 4  for 10min at room temperature, 
rinsed, dehydrated in warm butanol, and passed through xylene prior to embedding in DPX (Sigma-
Aldrich). DNA content was measured as the integral optical density in at least 200 cell nuclei in the 
green channel of the calibrated video camera, using Image Pro Plus 4.1 software (Media 
Cybernetics). In parallel, optical density and nuclear area were registered. The stoichiometry of 
DNA staining was verified using the values obtained for metaphases compared to anaphases and 
telophases (ratio 2.0). The estimated sum of device and measurement error was <5%. The 2C DNA 
content was determined by the modal value of the first G1 peak. Mitotic indices were counted per 
1,000–2,000 cells in the same samples. 
After shortened hydrolysis, interactive segmentation of mitotic figures was applied. 
Stoichiometry of DNA staining was verified using rat hepatocytes. With conventional 20-min acid 
hydrolysis, the 4C:2C ratio was 1.970; measurement error 1.5% (n5309); with 30-s hydrolysis, the 
4C:2C ratio was 1.994; measurement error 0.3% n=182. Diploid DNA values for tumour cells 
determined after shortened hydrolysis were calculated by measuring metaphases and anaphase 
halves in 50 untreated cells, in which the variability coefficient was 7.7% 
Cell cycle detection with flow cytometry. Cells (including those in media) were 
harvested at indicated time points, washed in PBS and re- suspended in hypotonic fluorochrome 
solution [50 µg/ml propidium iodide (PI), 0.1% (w/v) sodium citrate, 0.1% (v/v) Triton-X-100] and 
stored for at least 1 h in the dark at 4 °C. Flow cytometry was performed using a FACScan (BD 
Biosciences) or Accuri™ C6 Cytometer (BD Biosciences). Data was analyses using FlowJo 
analysis software. 
2.5. Fluorescent in situ hybridisation (FISH) 
FISH probes used for chromosome labelling in cell nuclei. Chromosome territories in 
five different specimens [non-irradiated control cells (NT); irradiated HeLa cells at day 2, 5, 6 and 7 
(d2, d5, d6, d7) post radiation exposure] were hybridized with chromosome painting probes 
(MetaSystems). The slides of NT and d2 were hybridized with a combination of three chromosome 
painting probes (#1, #4 and #12). This combined probe set had the following spectral signatures: (a) 
Chromosome #1: Texas Red (red signature: λex/em = 586 nm/605 nm); (b) chromosome #4: FITC 
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(green signature: λex/em = 488 nm/518 nm); (c) chromosome #12: 1/1 mixture of Texas Red and 
FITC resulting in a yellow signature. The slides of d5, d6, and d7 were simultaneously hybridized 
with two probes for chromosome #1 (Texas Red) and chromosome #4 (FITC). Chromosome #12 
was separately hybridized with a probe showing the same spectral signature as the chromosome #4 
probe. Pericentric satellite probes (QBIOGENE – Molecular Cytogenetics/Diagnosticsfor 
chromosomes #6, #10, and #X were applied in addition to whole chromosome painting probes and 
hybridized according to the manufacturer’s protocol. Slides of non-irradiated control cells (NT), and 
irradiated specimens at day 1 and 2 (d1, d2) were inspected visually for chromosome counting. 
FISH (chromosome painting, centromere labelling) of cell nuclei. For quantitative 
microscopy, the cells fixed on SuperFrost Plus slides (Menzel Gläser) were treated according to the 
following protocol: For permeabilization of the membrane, the slides were incubated in 0.7 mL 
Triton-X100/99.3 mL 1× SSC for 30 min and washed with 2× SSC for 5 min. The specimens were 
incubated in RNase A (Sigma–Aldrich) for 30 min at 37 °C [2 µl stock solution (100 mg/mL) and 
98 µL 2× SSC per slide]. After washing with 2× SCC for 3 min and 1× PBS for 5 min, proteins 
were digested in pepsin (Sigma–Aldrich) [21 µL stock solution (100 mg/mL) + 70 µL 0.01 M HCl 
in PBS] for 45 s. This was followed by a washing procedure in 1× PBS for 5 min, and in an ethanol 
series of 70%, 90%, and 100% for 3 min each. Denaturation was done in 70% formamide/2× SSC 
(at pH 7–7.2) for 5 min at 75◦C. Afterwards the slides were washed in 70%, 90%, and 100% ice-
cold ethanol for 3 min each. As for  the slides NT and d2, 2 µL of the probe mix combined with 2 
µL of 60% formamide were dropped on the specimens. The in situ hybridization took place for 48 h 
at 37 °C. For the specimens d5, d6, and d7, the procedure was slightly different: 7 µL or 14 µL, 
respectively, of the probe mix were denatured during incubating at 75 °C for 5 min. The tubes were 
briefly  cooled on ice. After that, the probes were incubated at 37 °C for 30 min and centrifuged for 
a short time. Then, the probe mix was pipetted onto the thermally denatured specimens and 
hybridized at 37 °C for 24 h. For post hybridization treatment, all slides were washed with 1× SSC 
at 75◦C and 2× SSC/0.01% Tween at room temperature. The cell nuclei were either counterstained 
with DAPI (Sigma–Aldrich) or with TO-PRO®-3 (Invitrogen) (λex/em = 642 nm/661 nm) 1:1000 in 
1× PBS. The specimens NT, d1 and d2 were incubated with the antifade reagent ProLong® Gold 
(Invitrogen) at 37 °C for two days. The specimens were mounted in Immuno MountTM antifade 
solution (GeneTex Inc).  
Chromosome preparation and FISH painting of metaphases. Half confluent HeLa 
clone 3 cultures were arrested at metaphase with 0.05 mg/mL Colcemid (GIBCO) for 3 h and then 
harvested by trypsin treatment. Chromosome spreads were obtained according to standard acetic 
acid:methanol (1:3) fixation protocols. Slides were stored at −20 °C until use. Three-colour 
chromosome painting (FISH) with a combination of chromosome #1, #4 and #12 paint probes 
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(MetaSystems) was performed. The hybridization mix was heated to 72 °C for 5 min and then 
incubated at 37 °C for 10 min prior to applying the mixture to the denatured chromosomes. 
Metaphase chromosomes were denatured on slides for 2 min at 72 °C in 70% formamide/2× SSC 
and then dehydrated in a series of 70%, 90% and 100% ethanol. Slides carrying denatured 
chromosomes were pre-warmed to 37 °C prior to the application of the denatured hybridization 
mixture, then covered by a 20 mm × 50 mm coverslip and sealed with rubber cement (Marabu). 
Hybridization was performed overnight at 37 °C in a moist chamber. The slides were then washed 
three times in 50% formamide/2× SSC, pH 7.0, at 42 °C for 15 min each followed by washes at 42 
°C in 2× SSC, pH 7.0, for 15 min, in PN buffer (100 mM Na2HPO4, 50 mM NaH2PO4, 0.1% 
Triton X-100 (v/v))/0.1% Nonidet P40,  pH 8.0, for 15 min, and in 3% bovine serum in 2× SCC for 
30 min. At least 20 metaphases were analysed visually. 
2.6. Reverse transcriptase(RT)-PCR, and sequencing  
RT-PCR of NANOG. Total RNA was extracted from cells by using TRIZOL (Invitrogen) 
and treated with DNase I (Fermentas MBI). cDNA was synthesized using First Strand cDNA 
Synthesis Kit (Fermentas MBI) according to the protocols of the manufacturer. The absence of 
contamination with chromosomal DNA was verified by PCR using primers DQA-1 and KIR3DL2. 
Expression of Nanog was verified in comparison to embryonal stem cells cDNA (Millipore, 
SCR063). cDNA from peripheral blood lymphocytes (PBL) was kindly provided by Dr. HTC Chan, 
Southampton University, UK. Primers for PCR were designed using Primer 3 software (Rozen 
2000) NANOG foreward  primer sequence 5’→3’ – CACCTACCTACCCCAGCCTT, reverse 
primer sequence 5’→3’ CTCGCTGATTAGGCTCCAAC, lenght of fragment 585bp, GenBank 
accession number of the template used for design is: NM_024865. Amplification was carried out in 
a total volume of 50 µl with 1 – 4 µl cDNA in standard conditions using 0.5 units of Taq DNA 
polymerase (Fermentas MBI) with a BioCycler TC-S (BioSan). PCR conditions were as follows: 94 
°C for 5min 94 °C for 30 s, 60 °C for 20 s, 72 °C for 1min; final extension step at 72 °C for 7 min. 
Amplified PCR products were resolved on 1.2 % agarose gels. The resulting PCR products 
fragments were analyzed by sequencing after ExoI/SAP treatment (Fermentas, MBI) using the 
fluorescent Big DyeTerminator v. 3.1 Cycle Sequencing protocol on a 3130xl Genetic Analyzer 
(Applied Biosystems). 
RT-PCR analysis of Oct4-splicing forms. Total RNA was extracted from cells using 
TRIZOL (Invitrogen). cDNA was synthesized using First Strand cDNA Synthesis Kit (Fermentas 
MBI) according to the manufacturer’s protocol and then diluted 10×. The absence of contamination 
with genomic DNA was verified by PCR using actin primers as described (Salmina et al., 2010). 
cDNA from peripheral blood lymphocytes (PBL) as a control of somatic cells was kindly provided 
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by Dr Inta Vasiljeva. Amplification was performed with 1–4 µl of diluted cDNA and the following 
primers, β-actin F/R; Oct4A AF/AR; Oct4B/B1 BF1/BR2 under conditions previously described 
(Salmina et al., 2010). Amplified PCR products were analyzed on an agarose gel after various PCR 
cycles and their identity determined by direct sequencing after ExoI/SAP treatment (Fermentas, 
MBI) using the fluorescent Big DyeTerminator v. 3.1 Cycle Sequencing protocol on a 3,130 xl 
Genetic Analyzer (Applied Biosystems).  
Western blotting. Cells were harvested using trypsin digestion and lysed using RIPA 
buffer with protease inhibitor cocktail (Sigma P8340). Total protein was quantified using BCA 
protein assay kit (Pierce) or Bradford assay (Thermo Scientific), and equal quantities 10-30 µg of 
denatured protein verified by Ponceau S staining were subjected to electrophoresis on SDS 
polyacrylamide gels, blotted onto Immobilon-FC or BA85 nitrocellulose (Schleicher & Schuell 
GmbH) transfer membranes and probed with specific primary antibodies listed in Table 1 and 
secondary antibodies listed in Table 2 (Supplement). The signal was visualized using a LICOR 
Odyssey imaging system or ECL Western Blotting Substrate (Pierce, 32106).  
For comparison of OCT4 isoforms protein was transferred onto immobilon-FC transfer 
membrane and probed with primary antibodies. Blots were then probed with fluorescent secondary 
antibodies and the signal was visualized using a LICOR Odyssey imaging system. 
Subcellular fractionation. For cellular fractionation, the Subcellular Protein Fractionation 
Kit for Cultured Cells (Thermo Scientific) was used according to the manufacturer’s instructions. 
Cytoplasmic, membrane, nuclear soluble, karyosol and chromatin-bound protein extracts were 
obtained. Protein concentrations were determined by Bio-Rad (Bio-Rad Inc.) protein assay, using a 
BSA standard set (Fermentas MBI) for quantitation. Proteins (10 or 15 µg) were separated on 10, 
12, 5 or 20% SDS PAGE gels, followed by electrophoretic transfer onto BA85 nitro-cellulose 
membranes (Schleicher and Schuell GmbH) overnight.  
2.7. Flow cytometry  
Cells were harvested at relevant time points, washed in cold PBS and fixed with 70% 
ethanol for 20 min at room temperature. After two washes in tris buffered saline (TBS), cells were 
permeabilised with TBS/4% bovine serum albumin (BSA)/0.1% Triton X-100 for 10 min at room 
temperature. Samples were then incubated with primary antibodies (Table 1, supplement)  in 
TBS/4% BSA/0.1% Triton X-100 for 1h at room temperature. Following two washes in TBS, cells 
were incubated with secundary antibodies (Table 2, supplement) in TBS/4% BSA/0.1% Triton X 
100, for 30 min in the dark. DNA was counterstained with 10 µg/ml propidium iodide (PI) in PBS, 
and assessed by flow cytometry using a FACS Aria (BD Biosciences) using Cell Quest Pro 
Software). Data was analysed using FlowJo analysis software. 
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2.8. Immunofluorescence (IF)  
Cells were trypsinized, pelleted, washed in warm PBS, resuspended in FBS and cytospun 
on to polylysine-coated slides. For detailed cytological studies, the cells were also grown on glass 
cover slips. Cells on coverslips were rinsed in PBS and FBS, then fixed in methanol at −20 °C for 
7min (30min for γ-H2AX staining) followed by 10 short rinses in cold acetone at −20 °C. Slides 
were washed in TBS/0.01% Tween-20 (TBST) (0.05% Tween-20 for γ-H2AX staining) three times 
for 5min each, after which they were blocked with 1% bovine serum albumin in TBS/0.05% 
Tween-20 for 15min. Samples were covered with 50 µL of TBS, 0.025% Tween 20%, 1% BSA 
containing primary antibody and incubated overnight at 4 °C in a humidified chamber.  Samples 
were washed thrice for 5min each time in TBST. The sources of the primary and secondary 
antibodies are listed in Tables 1 and 2 (supplement). Cells were conterstained with DAPI (0.25 
µg/mL). Cells were finally embedded in Prolong Gold (Invitrogen). When staining for p-
AMPKα1/2 (alone or in combination with the antibody for OCT4), fixation in 4% 
paraformaldehyde for 15 min was used, followed by washing thrice in PBS 0,1% glycine.  
To detect protein disulfide isomerase, SelectFX Alexa Flour 488 Endoplasmic Reticulum 
Labeling Kit (S34200, Molecular Probes) was used according to the manufacturer’s instructions. 
2.9. Microscopy 
Slides were evaluated using a Leitz Ergolux L03-10 microscope equipped with Sony DXC 
390P colour video camera, for microscopic observations; in addition to separate optical filters, a 
three-band BRG (blue, red, green) optical filter (Leica) was used. Image cytometry was carried out 
by semi-automatic measuring fluorescence values for each cell nuclei in all three channels and 
analysed using Image-Pro Plus 4.1 software (Media Cybernetics). Apoptotic cells, determined by 
nuclear morphology, were omitted from measurements. 
Phase contrast photography was performed using a light microscope (AxioImager A1, Carl 
Zeiss). 
2.10. Other stainings 
To reveal NORs (nucleolar organizers), prefixed cytospins were stained with a 50% 
aqueous solution of AgNO3 (Ural Factory of Chemical Reagents) diluted with 2% gelatin (2:1) at 
60uC for 5–6 min and counterstained with 0.1% Methyl Green (Sigma–Aldrich) at room 
temperature for 1 min. This method is recognized as the universal indicator of NOR activity 
(Bancroft and Stevens 1996).  
Lysosomal activity and autophagic vacuoles were detected by staining for cathepsin B (see 
below) and with MDC (monodansyl- cadaverin, Sigma). For MDC staining, cell cultures were 
incubated with 0.05 mM MDC at 37uC for 1 h followed by fixation in 4% paraformaldehyde and 
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two washes in PBS. The slides were counterstained with PI (propidium iodide; BD Biosciences 
Pharmingem), mounted into Permount (Thermo Fisher Scientific) and immediately imaged. 
3D-Microscopy of FISH staining. Up to 50 cells of NT and d2 each were imaged with a 
Leica TCS NT confocal laser scanning microscope using a high numerical aperture lens (63×/NA 
1.4 oil) and appropriate filter settings. Up to 50 cell nuclei each of the data sets d5, d6, and d7 were 
imaged with the Nikon TE2000-E Perkin Elmer UltraVIEW ERS Spinning Disc confocal 
microscope also using high numerical aperture lenses (63×/NA/1.2 water) and appropriate filter 
settings. For 3D-reconstructions the axial step size was 203 nm for all z-stacks.  
3D Image evaluation. The numbers and positions of the chromosome territories #1, #4, 
and #12 in the irradiated specimens d2, d5, d6, and d7 were analysed and compared to data obtained 
from non-irradiated control cells (NT). 3D-microscopy image data stacks were evaluated by means 
of the freely available software ‘Nemo’, version 1.5 (https://www-lgc.toulouse.inra.fr/nemo/) 
implemented into the image analysis software package “ImageJ”. For the different fluorescent 
objects within the cell nuclei, the shortest geometrical distances of the barycentres to the nuclear 
bor- der were calculated. For all chromosomes, a difference or change of ploidy did not influence 
the result since only the distances of the most peripherally (pCT) and the most centrally (cCT) 
located chromosome territories were always determined. These values were statistically compared 
over the course of time. The results were expressed as cumulative frequency histograms of 
distances. 
2.11. Methods of statistical analysis. 
Statistical analysis was performed by Minitab and GraphPad (GraphPad Software Ltd) 
systems. A paired t-test was used to calculate the statistical significance of difference of means 
where appropriate. Statistical significance was accepted when p < 0.05. Graphs were plotted by 
GraphPad Prism 5, IBM SPSS Statistics 22 and Statistica 6. 
The Kolmogorov–Smirnov test was used for the statistical pairwise analysis of 
chromosome territory histogram curves. The null hypothesis of this test is that two samples are 
drawn from the same frequency distribution. On acceptance of the alternative hypothesis, namely 
that the two fre quency histograms belong to different distributions, the significance level of this 
test defines an error probability for the two distance distributions being equal, i.e. two distributions 
being of the same entity. In general, this error level was taken to be up to 5% or even less because 
the Kolmogorov–Smirnov test tends to be conservative. On the other hand, the test is robust and can 
be easily applied to distributions with rather large deviations in sample numbers. For volume 
calculations of the cell nuclei and chromosome territories, the voxels covered by the object were 
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counted and multiplied with the respective voxel volume of the image. Finally, the average volumes 
of all detected nuclei or chromosome territories were determined.  
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3. Results 
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Endopolyploidy and genomic instability are shared features of both stress-induced cellular senescence andmalignant growth. Here,
we examined these facets in the widely used normal human fibroblast model of senescence, IMR90. At the presenescence stage,
a small (2–7%) proportion of cells overcome the 4n-G1 checkpoint, simultaneously inducing self-renewal (NANOG-positivity),
the DNA damage response (DDR; γ-H2AX-positive foci), and senescence (p16inka4a- and p21CIP1-positivity) signalling, some
cells reach octoploid DNA content and divide. All of these markers initially appear and partially colocalise in the perinucleolar
compartment. Further, with development of senescence and accumulation of p16inka4a and p21CIP1, NANOG is downregulated
in most cells. The cells increasingly arrest in the 4n-G1 fraction, completely halt divisions and ultimately degenerate. A positive
link between DDR, self-renewal, and senescence signalling is initiated in the cells overcoming the tetraploidy barrier, indicating
that cellular and molecular context of induced tetraploidy during this period of presenescence is favourable for carcinogenesis.
1. Introduction
Cellular senescence is a condition in which the cells remain
alive but are unable to proliferate. Premature senescence can
be triggered by certain stresses independently of the number
of cell divisions or telomere length [1], possibly as a result of
protracted DNA damage signalling [2]. Oncogene-induced
senescence is thought to behave similarly, driven at the very
early stages of tumour development where it serves as a
barrier to cancer progression [3]. Subsequent progression
to full-blown malignancy is favoured when tumour stem
cells acquire further mutations that impair the senescence
pathway, for example, mutations in TP53 or CDKN2a [4, 5].
During in vitro culture, human fibroblast cells undergo
a presenescence phenomenon whereby they display evidence
of chromosome instability (CIN)within an apparently highly
heterogenous population with signs of chromosomal dam-
age, and the appearance of polyploid interphase cells and
their divisions [4, 6–12]. Whereas the frequency of diploid
mitotic cells at presenescence is declining, the number of
polyploidmitoses increases to a peak before a sharp fall as the
cells change to the characteristic flat morphology indicative
of replicative senescence [13, 14]. These data stimulated the
hypothesis that telomeric loss at senescence may represent a
“genetic time bomb” causally involved in both cell senescence
and malignant transformation [13, 15].
In is clear that CIN associated with polyploidy at the
presenescence stage may substantially increase the mutability
and risk of malignant transformation [16–18]. Moreover,
there are reports from normal cell cultures of revertant cells
escaping senescence by acquiring mutations [19] and their
ability to depolyploidise and restart mitoses [9–12, 17]. The
features of CIN, including polyploidy, are also characteristic
of malignant tumors where the degree of CIN is correlated
with aggression [20]. Induced endopolyploidy is a typical
response of tumour cells with deficient p53 function to
the action of DNA or spindle-damaging agents [21–24].
For a decade, it has been generally accepted that sublethal
genotoxic damage to cancer cells associated with anticancer
clinical modalities accelerates cellular senescence [1, 25],
with concomitant induction of polyploidy as a component.
However, we and others have recently shown that the
induction of endopolyploidy followed by arrest and subse-
quent slippage from a spindle checkpoint is accompanied
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Table 1: Antibodies: source and use.
Primary antibodies
Secondary antibodies
(dilution, if not stated otherwise, 1 : 400)
Mouse monoclonal anti-hNANOG (N3038, Sigma) 1 : 75
Goat anti-mouse IgG-Alexa Fluor 488 (A31619, Invitrogen) or
594 (A31623, Invitrogen)
Rabbit polyclonal anti-hOCT4 (ab19857, Abcam) 1 : 200 Goat anti-rabbit-IgG-Alexa Fluor 594 (A31631, Invitrogen)
Goat polyclonal anti-hOCT3/4 (N-20) (sc-8630X, Santa Cruz) 1 : 400 Rabbit anti-goat IgG-Cy3 (C2821, Sigma) 1 : 500
Rabbit polyclonal anti-hP21 C-19 (sc-397, Santa Cruz) IF 1 : 50 Goat anti-rabbit-IgG- .Alexa Fluor 594 (A31631, Invitrogen)
Rabbit polyclonal anti-hP16 N-20 (sc-467, Santa Cruz) IF 1 : 50 Goat anti-rabbit-IgG- .Alexa Fluor 594 (A31631, Invitrogen)
Mouse monoclonal anti-hPML (sc-966, Santa Cruz) 1 : 150 Goat anti-mouseIgG-Alexa Fluor 488 (A31627, Invitrogen)
Rabbit polyclonal anti-hAURORA B (ab2254, Abcam) 1 : 300 Goat anti-rabbit-IgG- .Alexa Fluor 594 (A31631, Invitrogen)
Rabbit polyclonal anti-h-γH2AX (4411-PC-100, R&D Systems) 1 : 200 Goat anti-rabbit-IgG- .Alexa Fluor 594 (A31631, Invitrogen)
in p53-mutant tumour cells by the activation of meiotic
proteins [24, 26, 27] and key self-renewal transcription
factors (OCT4, NANOG, and SOX2) [28]. The majority
of these polyploid cells senesce. However, a minor fraction
retains divisional activities (thus counteracts or reverses
senescence), accumulate self-renewal factors in their sub-
nuclei, and subsequently undergo depolyploidisation to
paradiploid descendants that provide clonogenic regrowth
[28, 29].
Cycling tetraploidy, an illicit deviation from the normal
cell cycle, is considered to serve as a crucial step from
diploidy to cancer-related aneuploidy and from senescence
to malignancy [17, 30–32]. Together, these data highlight the
need tomore closely investigate the role of endopolyploidy in
the relationship between self-renewal and senescence. These
investigations will greatly assist the current endeavours being
made to induce reprogramming of somatic cells that are
free from genomic damage and provide further information
regarding the use of senescence-induction as a potential
anticancer strategy [33, 34].
Therefore, we chose to examine these phenomena using
a well-established model of cell senescence, involving in vitro
cultured normal human fibroblast IMR90 cells. We show
here that a small proportion of cells undergoing senescence
are able to overcome the tetraploidy barrier and that these
cells appear to simultaneously upregulate self-renewal and
senescent factors.
2. Materials and Methods
2.1. Cell Culture. The wild-type p53 human embryo lung
fibroblast cell line IMR90 was obtained from ATCC and
also from Coriell collection kindly donated by Dr. A.
Ivanov (Beatson Institute, Glasgow) after 21–23 population
doublings (PDL). Cells were cultured in DMEM (Sigma)
supplemented with 10% FBS (Sigma), without antibiotics,
as monolayers in a humidified incubator in 5% CO2/95%
air atmosphere. The early passage cells were split 1 : 3 (∼50
× 104 of cells per flask (25 cm2) twice weekly. Mid-passage
cells were split 1 : 2 weekly, and late-passage cultures were
split 1 : 2 once cultures attained confluence. Culture medium
was changed two or three times between subculture. In this
way, several subsequent passages were carried out until the
cells failed to undergo >0.8 population doublings in a 7-day
culture period. Under the given conditions of cultivation, the
cells typically reached this state after 40–50 PDL.
2.2. Immunofluorescence (IF). Cells were trypsinized, pel-
leted, washed in warm PBS, resuspended in FBS and
cytospun on to polylysine-coated slides. For detailed cyto-
logical studies, the cells were also grown on glass cover
slips. Cells on coverslips were rinsed in PBS and FBS, then
fixed in methanol at −20◦C for 7min (30min for γ-H2AX
staining) followed by 10 short rinses in cold acetone at
−20◦C. Slides were washed in TBS/0.01% Tween-20 (TBST)
(0.05% Tween-20 for γ-H2AX staining) three times for
5min each, after which they were blocked with 1% bovine
serum albumin in TBS/0.05% Tween-20 for 15min. Fifty
microliters of the appropriate dilution of antibody was
applied to each sample and the slides incubated overnight
at 4◦C. Samples were washed thrice for 5min each time
in TBST. The sources and dilutions of the primary and
secondary antibodies are listed in Table 1. Poststaining was
with DAPI (0.25 μg/mL). Cells were finally embedded in
Prolong Gold (Invitrogen).
2.3. Microscopy. A fluorescence microscope (Leitz, Ergolux
L03-10) equiped with a colour videocamera (Sony DX-
S500) was used to examine cell preparations, record images,
and perform image cytometry. For three-colour images and
colocalisation studies, the BRG filter system (Leica) provid-
ing nonoverlapping excitation and transmission emission of
blue, red, and green bands was used. In addition, confocal
microscopy (Leica, DM 600) was used with the images
scanned in the three diﬀerent colour channels in sequence.
2.4. DNA Image Cytometry. Cells grown on coverslips were
rinsed in PBS and serum. Alternatively trypsinised cells
were washed in warm PBS and suspended in FBS and
cytospun onto glass slides. Both preparations were then
fixed in ethanol/acetone (1 : 1, v/v) overnight at 4◦C and
air dried. For stoichiometric DNA staining [35], slides were
hydrolysed with 5N HCl for 20min and stained with 0.05%
toluidine blue in McIlvain 50% buﬀer pH 4 for 10min
at room temperature, rinsed, dehydrated in warm butanol,
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Figure 1: Phenotypic characteristics of IMR90 in the process of senescing showing cell enlargement and the accumulation of principal
growth inhibitors involved in the regulation of senescence, p16 and p21, in three stages: ((a), (d)) presenescence, ((b), (e)) senescence, ((c),
(f)) degeneration phase. ((a)–(c)) p16 (red) and DAPI (blue); ((d)–(f)) p21(red) and DAPI (blue). Scale bar = 20 μm.
and passed through xylene prior to embedding in DPX
(Sigma-Aldrich). DNA content was measured as the integral
optical density in 200 cell nuclei in the green channel of the
calibrated video camera, using Image Pro Plus 4.1 software
(Media Cybernetics; REO 2001, Latvia). In parallel, optical
density and nuclear area were registered. The estimated sum
of device and measurement error was <5%. The 2C DNA
content was determined by the modal value of the first G1
peak. Mitotic indices were counted per 1,000–2,000 cells in
the same samples.
2.5. RNA Extraction, RT-PCR, and DNA Sequencing of
NANOG. These studies were performed on IMR90 cells in
a logarithmic phase of growth as described before [28].
3. Results
3.1. Kinetics and Characteristics of Senescing Cells. Subcul-
tivation of IMR90 cells invariably leads to diminishing
growth after a number of passages. Under our experimental
conditions, this was reached prematurely at passage 32–34
corresponding to 40–50 PDL. This was likely due to growing
the cells in the air atmosphere shortening their lifespan [36].
During further passaging, full growth arrest was achieved,
characterised by the mitotic index reaching zero and the cells
attaining typical features of senescence such as cytoplasm
enlargement and flattening and bi- and multinuclearity, as
well as accumulation of senescence markers p16inka4a (p16)
and p21inka4a (p21) as illustrated on Figures 1(a), 1(b),
1(d), and 1(e). Degenerative phase was characterised by
nuclear swelling and cell lysis (Figures 1(c) and 1(f)).
3.2. DNA Cytometry Reveals a Minor Fraction of Cycling
Tetraploid Cells. As the cells underwent this senescence
phenomenon, they were analysed by DNA image cytometry
in three independent experimental series. The following
cytometric regularities were observed. In the stage of loga-
rithmic growth (typified in Figure 2(a)), where the mitotic
index was 4.5–3.0%, the cell population had a normal
cell cycle, with typical DNA distribution of the major
fractions between 2C and 4C. During presenescence, with
the mitotic indices progressively lowering, the histogram
of DNA distribution remained generally similar (exampled
on Figure 2(b)), however the proportion of cells in the
G1-2C phase increased and the S-phase decreased. At
senescence, where no mitoses were observed, the proportion
of interphase cells in the 4C-fraction was again increased
(Figure 2(d)). This change was already noticeable at late
presenescence, one-two passages earlier (Figure 2(c)). The
average proportions of 4C cytometric fractions at the stages
of logarithmic growth, presenescence and senescence, and
corresponding proportions of the cells with p21-positive
nuclei are presented on Figure 3.
In addition to the major DNA cytometric fractions, we
also observed a small proportion (1–7%) of hypertetraploid
cells, some of them reaching octoploidy. The number of
hypertetraploid cells strongly inversely correlated with
mitotic indices in each experimental series (Figure 4(a)).
Furthermore, the number of octoploid cells was found
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Figure 2: Histograms of IMR90 DNA content in several passages showing typical changes in the time course: (a) logarithmic growth,
(b) presenescence, (c) late presenescence, and (d) senescence showing the accumulation of 4C cells and the increase of the proportion of
hypertetraploid cells, some of which reach octoploidy.
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Figure 3: Quantitative data showing changes obtained from the
DNA cytometry results, at the growth phase, presenescence, and
senescence averaged from all experiments and the corresponding
proportions of cells displaying nuclear positivity for p21. Significant
increase of the 4C fraction accompany transition from presenes-
cence to senescence (P = .015). Increase of the proportion of
hypertetraploid cells, in parallel to considerable increase of the
proportion of p21-positive cells, accompany the whole process.
increasing with hypertetraploidy (Figure 4(b) and can be
seen from Figure 2). These data indicate that the process
of (accelerated) senescence encourages the cells to leave the
normal cell cycle favouring their cycling as tetraploids.
3.3. Self-Renewal Markers Appear at Presenescence in Tetrap-
loid Cells Simultaneously with Senescence and DDR Markers.
We were further interested to see the association of these
polyploid features with DDR, self-renewal, and senescence
markers. At presenescence, we found that the embryonal
transcription factors of pluripotency and self-renewal OCT4
(mostly cytoplasmic) and NANOG (nuclear) were activated
in parallel with the initial activation of senescence factors in
the same cells. Notably, this occurred in the cells with larger
nuclei and larger (often polygonal) p16-positive cytoplasm,
suggesting that these were hypertetraploid cells which had
initiated the process towards senescence (illustrated in
Figure 5). In an eﬀort to better characterise the position of
these particular cells in the cell cycle, we undertook two kinds
of analysis.
First, we stained samples stoichiometrically with Tolui-
dine blue for DNA and recorded the integral optical density
(DNA content), nuclear area, and subsequently optical den-
sity (OD, concentration of DNA) of 200 cells in each sample
using Image Pro Plus software. Importantly, this imaging
method is interactive and excludes any cell aggregates, which
are either excluded or separated for single cells before the
measurement by the operator. Using this approach, the
concentration of DNA remained constant in all samples (the
data are not shown), with dispersion of OD around the
average within only 2-3%, up to the degeneration phase. The
positive correlation between the DNA content per nucleus
and its area counted for each sample is high (r = 0.57–0.76);
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Figure 4: Tetraploidy increases in the course of IMR90 senescence. (a) The number of hypertetraploid cells increases with senescence and
strongly inversely correlates with mitotic indices in each experimental series; (b) the number of cells with octoploid DNA content increases
with hypertetraploidy indicating to increase of tetraploid cycling (the united data from three experiments).
OCT4 NANOG DNA
(a)
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Figure 5: Examples of pre-senescent IMR90 fibroblasts grown on the coverslip, which diﬀer from the surrounding cells by enlarged nuclei,
cytoplasm volume, and the tendency of flattening. These cells express: (a) enhanced OCT4 (mostly in cytoplasm) and nuclear NANOG and
(b) paranucleolarly localized NANOG, which is combined with enhanced expression of the senescence regulator, p16. Both, self-renewal and
senescence regulators are undetectable or at the background level in the neighbouring fibroblasts possessing small nuclei. Scale bars = 10 μm.
On (a) OCT4 was stained with the antibody for both A and B isoforms (Abcam polyclonal antibody, see Table 1).
an example is shown in Figure 6(a). This confirms the
accepted observation that nuclear area is proportional to
DNA content; hence, its concentration remains constant
[37, 38]. In Figure 6(a), sampled from presenescence phase,
it is seen that the nuclear size of the 4C nuclei cluster
is roughly twice as large as that of the 2C nuclei cluster,
while the nuclear size of the cells with hypertetraploid DNA
content exceeds that of the average 4C nuclei. It follows
that the cells with a nuclear area visibly larger than that for
G1 and G2 cells should contain the hypertetraploid DNA
content.
Second, we stained samples for NANOG and one of the
main senescence regulators (p16 or p21) in combinationwith
DAPI. Using this approach, we identified cells possessing
visibly larger nuclei as compared with G1- and G2-sized
nuclei of surrounding fibroblasts which simultaneously
expressed markers of both self-renewal (NANOG) and
senescence. We subsequently applied DNA measurement
of the integral nuclear fluorescence (INF) of these and
neighbouring cell nuclei as exemplified on Figures 7(a) and
7(b), through 16 optical fields (total 242 cells); a selection
of seven microscopic fields is also presented in supplemental
6 Journal of Aging Research
Pre-senescence
r = 0.76
0 200 400 600 800 1000 1200
IOD (DNA content (a.u.))
0
2
4
6
8
10
12
14
A
re
a
(μ
m
2
)
×103
(a)
Pre-senescence versus degenerative phase
0 500 1000 1500
IOD (DNA content (a.u.))
0
5
10
15
20
×103
Degenerative phase
A
re
a
(μ
m
2
)
Presenescence
(b)
Figure 6: The relationship between the nuclear area and the DNA content (IOD) per each cell nucleus in: (a) a typical sample of
presenescence phase and (b) the comparison of the latter and a sample in the degeneration phase. It is seen that the nuclear size is increasing
roughly proportionally to the DNA content in the presenescence phase, while in the degeneration phase, the nuclear size is much larger
indicating to nuclear swelling.
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Figure 7: Examples of DNA content measurements by integral fluorescence in the DAPI channel using Image Pro Plus software in
microscopic fields including cells with enlarged nuclei and stained for: ((a), (b)) NANOG, p16, and DNA by DAPI, ((c), (d)) Aurora B-
kinase and DNA by DAPI. The selected hyperoctoploid cell (∗) shown in (a) has an enlarged p16-positive cytoplasm and some amount of
both NANOG and p16 in the nuclear region, and this region is magnified in the insertion; the paraoctoploid cell in (c) is positive for Aurora
B-kinase.
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Figure 8: Mitoses of IMR90: (a) normal mitosis of a diploid cell in the growth stage, ((b)–(d)) mitoses in the presenescence stage. (b)
Anaphase of the tetraploid cell, chromosome bridge (arrowhead) indicates to CIN. (c) Metaphase of the large tetraploid cell (∼8C). (d) An
attempt of the tetrapolar mitosis indicating to CIN. ((a),(b)) stoichiometric staining for DNA with Toluidine blue pH 4.0 after extraction of
RNA. ((c),(d)) Similar staining after partial extraction of RNA. Scale bar = 10 μm.
Figures 1–6 in Supplementary Material available online
at doi: 10.4061/2011/103253. The standard error of such
nuclear measurements comparing the INF recorded on
the smallest cell nuclei (2C-G1) was around 20%. The
selected cells which expressed markers of self-renewal and
senescence contained tetraploid, hypertetraploid, or octo-
ploid amounts of DNA more frequently than surrounding
cells.
We were interested subsequently if these cells retained
proliferation capacity. Using immunostaining for Aurora B-
kinase as a marker of cell division potential for endopoly-
ploid cells [39], we often found that cells with enlarged nuclei
containing the tetraploid or octoploid amounts of DNA
(as also detected in DAPI channel), were Aurora B-positive
(exemplified on Figures 7(c) and 7(d)). At presenescence, we
also found mitoses of tetraploid cells. Although commonly
aberrant or pycnotic, some proceed to anaphase with signs
of CIN such as chromosome bridges or multipolar mitoses
(Figure 8).
The enlarged nuclei were also often labelled by the
DDR marker γ-H2AX coupled to the NANOG staining
(Figures 9(a) and 9(f)). Thus, at the presenescence stage, the
cells with enlarged nuclei possessing enlarged p16-positive
cytoplasm, simultaneously expressing small amounts of self-
renewal, senescence, and DDR markers in their nuclei were
found to be tetraploid, had overcome the 4n-G1 barrier, were
cycling to octoploidy, and possessed division potential.
3.4. Self-Renewal, DDR, and Senescence Markers Are Initially
Localised in the Perinucleolar Compartment of Tetraploid Cells.
Interestingly, manifestations of all three kinds of response
(γ-H2AX, NANOG, and p16/p21) were seen to be partialy
colocalised as foci detected by BRG three-band optical filter
(with nonoverlapping excitation and emission bands); and
confirmed by confocal microscopy (supplemental Figure 7).
These concentrated in the perinucleolar compartment either
to one side of the large central nucleolus or surrounding
it (Figures 9(a)–9(c)). Initial signs of senescence-associated
heterochromatin foci (SAHF) also appear to emerge from
the perinucleolar chromatin in such cells (Figure 9(d)). The
initially observed PML-bodies, partially colocalised with
γ-H2AX -positive speckles, were also found in this area
(Figure 9(e)). The IMR90 cells at the logarithmic stage of
growth had very low background IF staining for NANOG
confirmed by RT-PCR and DNA sequencing (data not
shown). The amount of NANOG usually seen by IF in
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Figure 9: Characteristic cytological nuclear IF features of the tetraploid cells in the presenescence phase showing synergism of several
labels located near the nucleoli. (a) Initial DDR in the perinucleolar chromatin indicated by the γ-H2AX-positive label (arrowheads), NL-
nucleolus. (b) The accumulation of p16 and NANOG-positive, partly colocalising granules in the perinucleolar region (arrowheads). (c) The
accumulation of p21 and NANOG—partial colocalisation around the central nucleolus (arrowheads). (d) The emergence of initial gentle
SAHFs revealed by DNA-specific metachromatic staining with Toluidine-blue in the perinucleolar chromatin (arrowheads). (e) PML bodies
in the vicinity of the central lobulated nucleolus, where they partly colocalise with γ-H2AX-foci. (f) The tetraploid cell from the mid-
presenescence with the network of γ-H2AX and some amount of NANOG, partially colocalised. Images were obtained using BRG three-
colour optical filters system. Scale bars =10 μm.
the enlarged cell nuclei at early presenescence exceeded the
background of surrounding cells with normal nuclei by ∼2–
4-fold (supplemental Figure 7).
We compared the frequency of this coexisting self-
renewal and senescence nuclear landmarks (mostly perin-
ucleolar) in the cells with enlarged nuclei with that in the
surrounding fibroblasts possessing normal 2C–4C-sized cell
nuclei in one of early presenescence passages (Figure 11).
From these counts, it can be seen that initial DDR and
simultaneous senescence and self-renewal signalling were
found in 84–96% of the cells with enlarged nuclei at far
greater frequency (many-fold) than in the cells of the
normal cell cycle. It should be stressed that it was practically
impossible to find at this stage the cells where the nuclear
enlargement and initial expression of DDR, NANOG, and
senescence landmarks were dissociated. As such, also this
approach confirmed that the expression of key markers of
both senescence and pluripotency become selectively and
simultaneously activated in tetraploid cells.
3.5. Through Intermediate Stage, NANOG Is Gradually Lost
fromMost Tetraploid Cell Nuclei, Correlating with an Accumu-
lation of Senescence Markers during the Time Course of Senes-
cence. Development of the tetraploid cells in subsequent
passages of the culture as it progresses towards terminal
senescence is characterised by the shaping of clear SAHFs,
further increase of p16 in the enlarging cytoplasm, while
smaller was this increase in the nuclei, and much stronger
positivity of nuclear p21. p21 begins to extend from the
perinucleolar region into the nucleoplasm (Figure 9(c)). Like
p21, γ-H2AX also forms an elaborate network mostly in
polyploid cells (Figure 9(f)). In these cells, NANOG can still
be found, albeit in a more disseminated form, sometimes
colocalised with regions of the p21 (Figure 9(c)) and γ-
H2AX network (Figure 9(f)).
Figure 9(f) shows some intermediate state, when the both
markers are still expressed. However, in mid-presenescence
passages, γ-H2AX vanishes from the cells with the stronger
expression of NANOG, and contrary to that, 2-3% of cells
Journal of Aging Research 9
NANOG DNAp16
SAHF
(a)
NANOG DNAp16
SAHF
(b)
Figure 10: Relatively rare flattening giant fibroblasts displaying at presenescence a considerable accumulation of NANOG filling the whole
nucleus in parallel to clear DAPI-positive SAHFs; in addition, the cells contain p16-positive material in the cytoplasm. Images were obtained
using BRG three-colour optical filters system. Scale bars = 10 μm.
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Figure 11: Proportions of the fibroblasts with enlarged (hyperte-
traploidy) nuclei and with conventional small nuclei in the early
presenescence stage, estimated in one of the samples by the labelling
frequency for γ-H2AX (n = 400 cells), NANOG/p16 positive (n =
300 cells), and NANOG/p21-positive nuclear granules (n = 300
cells). All nuclear labels were mostly present in this phase in the
perinucleolar region. Evaluation reveals a many-fold prevailing sig-
nalling for DDR, self-renewal, and senescence regulators occurring
simultaneously in the enlarged hypertetraploidy cells, which left
normal cell cycle.
which develop very clear thick γ-H2AX foci do not contain
NANOG (not shown). The cells with large nuclei and
stronger expression of NANOG are more notable in the
“midpassages” of the presenescence (2–5%), a few may
accumulate it in their nuclei in the considerable amounts
(Figure 10). However, the main tendency towards further
senescing, contrary to the early phase of presenescence,
when the initial expression of self-renewal and senescence
markers appears positively linked, at more extended passages
the expression of NANOG in the giant nuclei generally de-
creases proportionally to the accumulation of cytoplasmic p16
and of the enhanced nuclear expression of p21, as illustrated
on Figure 12.
In the very last passages, approaching terminal senes-
cence with the mitotic index tending to zero (<0.1%), this
trend is further extended as illustrated in Figures 1(b), 1(c),
1(e), and 1(f), where the giant polyploid cells with large
cytoplasm display considerable accumulation of p21 and
p16. They are void of the NANOG expression or contain
it at the background level. However, rare exceptions of the
NANOG-positive cells with the only background expression
of senescence factors were encountered (Figures 12(d)–12(e),
arrowed). Further, the senescent cells appear to enter the
terminal degeneration phase. Figures 1(c) and 1(f) show the
appearance of cells at the terminal degeneration phase of
the senescent culture, sampled from one typical experiment.
These cells are characterised by the accumulation of p16
and p21 in the cell nuclei, absence of NANOG, lysis of the
cytoplasm (Figures 1(c) and 1(f)), and by swelling of the
nuclei as testified by DNA image cytometry presented in
Figure 6(b).
4. Discussion
Here, we have documented the cellular behaviour of IMR90
cells as they undergo senescence after protracted in vitro
culture. A notable observation in this process is the appear-
ance of tetraploid cells. Clearly, tetraploid cells appearing in
senescing cultures represent a deviation from normal cell
cycle regulation. Such cells and their aberrant proliferative
activities were reported from the very early studies of in vitro
senescing cultures of normal fibroblasts occurring before
terminal arrest of proliferation [6–8], and confirmed more
recently [10]. Our results are entirely in accord with them.
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Figure 12: The antagonism between expression of NANOG and senescence regulators at the late presenescence and senescence phases:
((a)–(c)) late presenescence (MI = 0.1%): in the group of ten cells it is seen that nuclear staining of NANOG is found only in the cells with
enlarged nuclei, where NANOG staining intensity is inverse to the staining for p21; ((d), (e)) senescence (MI = 0)—a rare NANOG-positive
cell was encountered (arrowed), which has the weakest staining for p16 in its cytoplasm among five cells of the group. ((a), (d)) were imaged
through the BRG filter; ((b), (e))—through blue, and (c)—through green filter. Scale bars = 10 μm.
These deviations, indicative of chromosomal instability
during presenescence, were shown to be related to telomeric
dysfunction [13–15, 40].
It is diﬃcult to judge to what extent the induction
of polyploidy is associated with the stress due to in vitro
cultivation. Previously, more stressful conditions of passage
were shown to have a slight increase in polyploidy induction,
although the same results could have been obtained, if
more laboriously, from unstressed cells [10]. On the whole,
our present data and that generated previously show that
in the senescing culture, there is a tendency for a small
proportion of normal human fibroblasts to increasingly form
tetraploid cells, to cycle to octoploidy, and then divide.
Cycling tetraploidy is generally considered as a dangerous
step towards carcinogenesis as it brings CIN and can result in
aneuploidy [30, 32]. It is known that functional p53/p21CIP1
should prevent tetraploidy at the 4n-G1/S checkpoint [41,
42], the existence of which was also disputed [16]. Our
DNA cytometric data showed that at presenescence, this
barrier is leaky and is linked to accumulation of 4C cells
during the senescence process as the cells approach full
growth arrest. The same increase in the 4C cell fraction in
senescing IMR90 cells, then interpreted as arrest at the 4n-
G1 checkpoint, was previously reported by Sherwood and
colleagues [43] following analysis by DNA flow cytometry
and karyotyping and the same was found in an accelerated
senescence model of Ras-oncogene transfected IMR90 cells
[44].
In addition, we found here that illegitimate cycling of
tetraploid cells at the early presenescence phase was asso-
ciated with activation of the self-renewal response mani-
fested by expression of the embryonal transcription factor
NANOG. In our preliminary studies, we have also observed
that the OCT4B splicing form (POU5F1 B) was activated;
however, as its function is unknown, we concentrated here
mostly on studies of NANOG expression.
The homeodomain gene, NANOG, is a key intrinsic de-
terminant of self-renewal and pluripotency in embryonic
stem cells. Beside its transactivation function, NANOG was
also reported to directly propagate the G1-S transition by
ativating cdk6 [45]. As the senescence regulator, p16 prevents
endogenous Cdk6 and Cdk4 from associating with its
catalytic unit cyclin D1 [46], NANOG should counteract this
activity of p16. Moreover, normal embryonal stem cells in
response to damage were shown to upregulate self-renewal
transcription factors (Oct4 and Nanog) readily undergo-
ing mitotic slippage and reversible tetraploidy [47]. There-
fore, it remains possible that NANOG expression may force
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the normal fibroblasts (or their stem cells) in stressed senesc-
ing cultures to bypass this tetraploidy limiting control.
Our IF observations showed directly that NANOG is
expressed in tetraploid cells of pre-senescing cultures unless
the cells accumulate considerable amounts of senescence
regulators (which occurs increasing as the cultures approach
terminal senescence); in particular, clear antagonism was
found at late passages between NANOGand accumulation of
nuclear p21. These observations are entirely in line with the
suggestion that p16 represents a second barrier to senescence,
which in the absence of the main barrier p53/p21 may be
reversible [48]. Our observations on more accumulation
of NANOG in some tetraploid cells, which lose the DDR
signalling in the intermediate presenescence stage, may be
cautiously interpreted as tendency to revert senescence.
It follows that at the presenescence phase, the amount
of the p53/p21 growth inhibitor appears insuﬃcient to
downregulate NANOG, which may to some extent neutralise
p16 and that, therefore, more time (or activation of more p53
activators including for example, the p38 pathway [16, 49]) is
needed for p53 to become an eﬃcient enforcer of senescence
barrier. This explanation of our observations is in line with
the data that activated p53 suppresses the NANOG gene
promoter [50].
Recently, Davoli and colleagues [40] showed that simul-
taneous elimination of telomerase and p53 causes chronic
DDR resulting in the prolonged G2 arrest and tetraploidis-
ation through licensing DNA rereplication origins. This data
also well fit our observations as senescing is associated with
telomere dysfunction (however, induction of self-renewal
may counteract it by activating telomerase; this aspect needs
further research), while found delay of p21 accumulation
means relatively retarded activation of p53.
Although IMR90 are normal, nonmalignant cells con-
taining wild-type p53, our observations importantly show
for the first time that these normal cells can temporarily
activate the self-renewal factor NANOG and enter “a win-
dow” when senescence regulators are as yet insuﬃciently
active to irreversibly neutralise its activities. In line with
this suggestion, upregulation of several embryonal pluripo-
tency and self-renewal factors have also been reported by
Riekstina and coauthors [51] in putative stem cells obtained
from explanted adult human mesenchymal tissues during
their first adaptive passages of in vitro cultivation. The
step into tetraploidy is associated with DDR and genome
instability, known to greatly increase the probability of
chromosomal and genetic mutations and escape of revertants
[30]. The same concern was formulated by Romanov
et al. [19] and Walen [17], who showed that in presenes-
cence the tetraploid cells display depolyploidisation activi-
ties and can ultimately escape senescence with a mutated
genotype.
Although the IMR90 model is one of replicative or accel-
erated senescence in vitro, it has clear relevance to pathologic
conditions in vivo where adult stem cells may be involved
such as chronic inflammation and/or trauma.
However, a puzzle remains for the seemingly simultane-
ous initial induction of the opposing responses of DDR, self-
renewal, and senescence in the early pre-senescent tetraploid
cells. The site of convergence may be the RAS-RAF-MEK-
ERK pathway priming both the mitogenic and accelerated
senescence pathways [52]. It was shown that moderate
activation of the wild-type Ras is mitogenic, while over-
expression causes p38-MAPK-dependent senescence [49].
This trigger leads, in particular, to positive versus negative
regulation of Cyclin D1 [53], the catalytic unit of cdk6
activated by Nanog [45]. In the negative loop, suppression of
Nanog byMEK-ERKwas shown through chemical inhibition
of MEK [54]. Clearly, the impact of the MEK/ERK pathway
on NANOG and its role in the signalling of senescence
require further attention.
The data, somewhat supportive for our observations,
were reported by Banito and colleagues [55] who showed
upregulation of cellular senescence by transduction in
IMR90 cells of the four pluripotency-inducing oncogenes.
Interestingly, all three kinds of the initial response, self-
renewal, DDR and senescence, were found spatially confined
to the perinucleolar compartment, and their partial or full
colocalisation suggests a cross-talk between these pathways.
Moreover, it is likely that the SAHFs which represent regions
of epigenetically changed chromatin also start to form
from the same region of the perinucleolar chromatin and
are associated with the emergence of the DNA double-
strand breaks. The question is why these various aspects are
appearing in the nucleolus.
The nucleolus is involved in the regulation of senescence
in several ways. Nucleostemnin, a nucleolar protein specifi-
cally involved in regulating the cell cycle in stem and tumour
cells, can sequestrate MDM2 and MDM4 and, thus, favour
accumulation of p53, the main player in senescence induc-
tion [56, 57]. Similarly nucleolar Arf will activate p53 in the
senescence response [58]. In addition, relocation of hTERT
to the nucleolus is associated with initiation of senescence
[59]. Finally, PML binds MDM2 and sequesters it into
the nucleolus [60], thus protecting p53 from proteosome-
mediated degradation.
However, the most important aspect may be that, in
eukaryotic systems, rDNA contains fragile sites that are
extremely sensitive to replication-induced stress [61, 62].
This replication stress may be related to the p53 independent
license of rereplication origins fired at prolonged G2 arrest
[40]. The level of the DNA Polymerase I in IMR90 tetraploid
cells may be insuﬃcient at this time-point, causing stalling
of replication forks and converting the underreplicated sites
into rDNA strandbreaks [63]. This idea is compatible with
cancer development from its earliest stages being associated
with DNA replication stress, leading to DNA strandbreaks
and subsequently to DDR [3, 64, 65].
In relation to p53-function-deficient tumours, our data
[28, 29] also show that endopolyploid cells induced after
genomic insult undertake sustainable activation of the
pluripotency and self-renewal genes, and undergo a stage
of competition between self-renewal and senescence with
an improved chance for self-renewal to succeed. A pro-
portion of these p53-mutated polyploid cells is capable of
accumulating considerable amounts of self-renewal factors
and subsequently depolyploidise into mitotic paradiploid
descendants.
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5. Conclusion
Our findings on senescing normal human IMR90 fibroblasts
clearly provide us with insight into the risks of cancer
development. Since it is assumed that a cancer clone develops
from a single adult stem cell which receives a mutation(s),
including those compromising the senescence barrier, our
observations suggest that this may be favoured in the normal
stressed tissue due to the unique cellular and molecular
setting of the presenescence stage. It is hypothesised that
telomere dysfunction causing DDR and temporary activa-
tion of self-renewal on a background of insuﬃcient activity
of senescence inducers may allow putative adult stem cells to
overcome the G1 tetraploidy limit controlled by p53 leading
to their replicative stress and aberrant divisions. This would
favour acquisition of CIN, aneuploidy, and tumorigenic
mutations, thereby driving tumorigenesis.
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Introduction
Aggressive somatic tumors possess a gene expression profile simi-
lar to embryonic stem (ES) cells, suggesting that key signaling 
pathways and biological links exist between them.1 Importantly, 
both appear to display characteristics of self-renewal and differ-
entiation potential, with current data implying that these prop-
erties underlie the resistance of cancer to genotoxic treatment 
modalities and help explain disease relapse.2,3 The characteristic 
self-renewal, extensive proliferation and differentiation potential 
of ES cells is also evident in cancer stem cells, which are highly 
proliferative and phenotypically plastic.4 The ability of cancer 
cells to utilize equivalent stem cell transcription networks is of 
Recent studies have highlighted an apparently paradoxical link between self-renewal and senescence triggered by DNa 
damage in certain cell types. In addition, the finding that Tp53 can suppress senescence has caused a re-evaluation of its 
functional role in regulating these outcomes. To investigate these phenomena and their relationship to pluripotency and 
senescence, we examined the response of the Tp53-competent embryonal carcinoma (eC) cell line pa-1 to etoposide-
induced DNa damage. Nuclear pOU5F1/OCT4a and p21CIp1 were upregulated in the same cells following etoposide-
induced G2M arrest. however, while accumulating in the karyosol, the amount of OCT4a was reduced in the chromatin 
fraction. phosphorylated ChK2 and RaD51/γh2aX-positive nuclear foci, overexpression of aURORa B kinase and 
moderate macroautophagy were evident. Upon release from G2M arrest, cells with repaired DNa entered mitoses, while 
the cells with persisting DNa damage remained at this checkpoint or underwent mitotic slippage and gradually senesced. 
Reduction of Tp53 using sh- or si-RNa prevented the upregulation of OCT4a and p21CIp1 and increased DNa damage. 
subsequently, mitoses, micronucleation and senescence were all enhanced after Tp53 reduction with senescence 
confirmed by upregulation of CDKN2a/p16INK4a and increased sa-β-galactosidase positivity. Those mitoses enhanced 
by Tp53 silencing were shown to be multicentrosomal and multi-polar, containing fragmented and highly deranged 
chromosomes, indicating a loss of genome integrity. Together, these data suggest that Tp53-dependent coupling of self-
renewal and senescence pathways through the DNa damage checkpoint provides a mechanism for how embryonal stem 
cell-like eC cells safeguard DNa integrity, genome stability and ultimately the fidelity of self-renewal.
DNA damage causes TP53-dependent coupling of 
self-renewal and senescence pathways  
in embryonal carcinoma cells
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great interest for the subsequent understanding and treatment of 
cancer.
Recent data shows that even normal somatic cells can be repro-
grammed to become induced pluripotent stem (iPS) cells, and that 
upregulation of only a very small set of genes is sufficient to initi-
ate de-differentiation to provide them with stem-like properties. 
OCT4A (POU5F1), SOX2 and NANOG are master transcription 
factors responsible for the maintenance and tight coordination of 
pluripotency and self-renewal in ES cells.5 The first human iPS 
cells were created from somatic fibroblasts ectopically expressing 
two of these factors (OCT4A and SOX2) along with KLF4 and 
c-MYC.6 Since then, expression of OCT4A and SOX2 alone has 
been shown to be sufficient to convert human somatic cells to iPS 
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key cassette of ES cell transcription factors, OCT4A, SOX2 and 
NANOG.20,21 At the same time, these tumors are highly malig-
nant and so may be used to closely model the features of aggressive 
tumors that show ES cell transcription profiles.1,8-10 Therefore, 
in this current study, we chose to investigate the relationship 
between senescence and self-renewal regulation following DNA 
damage in the ovarian teratocarcinoma PA1 cell-line, which pos-
sesses functional TP53. For inducing DNA damage, we used the 
topoisomerase II inhibitor etoposide (ETO), which was previ-
ously used for studies of senescence in tumor and immortalized 
cells lines,15,22,23 and which is also in clinical use for the treatment 
of various cancer types.
Results
Characterization of PA-1 cells. The PA-1 cell line used in this 
study was established from the metastases of a malignant ovar-
ian teratocarcinoma. It possesses the features of embryonal 
carcinoma (EC), as testified by its ability to form OCT4A/
NANOG-positive spheres in serum-free medium (Fig. S1).24 It 
has a stable, near-diploid karyotype with a single chromosome 
translocation [t(15;20)(p11.2;q11.2)]25 and functional (although 
heterozygotic) TP53.26 Several sources show that PA1 expresses 
the key self-renewal genes OCT4A, SOX2 and NANOG.11,24,27
Response of PA-1 cells to DNA damage. To determine the 
response of PA-1 cells to DNA damage, the cells were assessed 
following ETO treatment over time. Phosphorylated CHK2 
(pCHK2) and γH2AX staining were used to report on the 
presence of DNA damage, and the cell cycle response of surviv-
ing cells was monitored using DNA cytometry. In response to 
ETO treatment, virtually all cells became arrested in G
2
 within 
2 days and displayed pCHK2 and γH2AX-positive nuclear foci 
as evidence of DNA damage and subsequently attempted DNA 
repair as judged by the presence of RAD51/γH2AX foci (Fig. 1A 
and B). The cells remained in G
2
 for up to 4 days. Simultaneously, 
small G
1
, 2C and polyploid (> 4C) cell fractions then appeared, 
increased for a few days before the polyploid fraction was over-
come by the mitotic cycling fraction and disappeared by day 7 
(Fig. 1C). Substantial apoptosis appeared from day 3, reached a 
maximum on day 5 and disappeared with the recovery of clono-
genic growth after day 7 (data not shown and Fig. 5A).
In addition, the G
2
-arrested cells showed enhanced nuclear 
staining of Aurora B kinase (Fig. S2), indicating the mitotic 
potential of these cells.
From day 3 onwards, pCHK2 nuclear staining disappeared 
in some cells, while persisting and even becoming enhanced in 
others (Fig. 1A). To elucidate which cells entered mitosis and 
which polyploidized, we examined them on day 5 using DAPI-
integrated fluorescence to assess their DNA content and size as 
well as pCHK2 nuclear staining levels. Two distinct cell types 
were observed: those with small nuclei (G
1
, 2C-sized) and those 
with large (G
2
 and polyploid, 4C and > 4C) nuclei. As seen in 
Figure 1D, the majority of large cells (≥ 4C) were pCHK2-posi-
tive, and all pCHK2-positive cells were large cells. In contrast, all 
cells with small nuclei (G
1
) were pCHK2-negative. These results 
indicate that ~30% of cells have repaired DNA and are returning 
cells.7 These results suggest that cancer cells may be able to access 
ES cell properties through the upregulation of these genes alone. 
In keeping with this proposition, the prognostic significance of 
these two markers was recently reported for several kinds of cancer 
(lung, squamous cell carcinoma, colorectal and breast).8-10
We have previously reported the upregulation of OCT4A/
SOX2/NANOG in TP53 mutant lymphoma cell lines as a 
response to DNA damage and highlighted the potential role of 
this ectopically upregulated embryonic self-renewal program as 
a survival strategy in TP53-deficient cells following genotoxic 
damage.11
Self-renewal and pluripotency factors have paradoxically also 
been linked to accelerated cellular senescence (termed senes-
cense hereon). When Banito and colleagues transfected IMR90 
human fibroblasts with the Yamanaka transcription factors 
(OCT4A, SOX2, c-MYC and KLF4), they found senescence 
was induced rather than pluripotency, which was associated with 
DNA damage.12 A study of normal IMR90 fibroblasts showed 
that at pre-senescence, cells signaling DNA damage in the ≥ 4C 
compartment simultaneously express cyclin-dependent kinase 
inhibitors p16inka4a and p21cip1, as well as the self-renewal tran-
scription factor NANOG,13 further indicating that the properties 
of pluripotency, self-renewal and senescence are tightly coordi-
nated by DNA damage.
The relationship between mitogenic activation of proliferation 
and cell senescence is also complex. For example, the concept of 
hyper-mitogenic arrest intimates that simultaneous stimulation 
of mitogen-activated pathways (integrated by mTOR) and down-
stream inhibition of cyclin-dependent kinases promotes senes-
cence.14 Similarly, DNA damage-induced senescence occurs in 
immortalized WI38 fibroblasts only when mitogenic growth fac-
tors are present.15 In this context, the role of TP53 in regulating 
proliferation and senescence is critical, with evidence of its ability 
to both block and promote senescence. On one hand, TP53 sig-
nals to prevent cellular senescence, but conversely it can cause cell 
cycle arrest, thereby providing the cellular context from which 
the senescence program can start.16 These data imply that senes-
cence is not in fact a barrier to cancer but almost a prerequisite 
for it.17 This concept and observations showing the complexity of 
the inter-regulation between these various cellular outcomes may 
help to understand how self-renewing (cancer) stem cells respond 
to DNA damage.
Together, these data indicate that intrinsic links exist between 
self-renewal, senescence and the DNA damage checkpoints of 
the cell. Further complexity arises from the fact that the regula-
tion of the cell cycle in stem cells is evidently different from that 
in normal somatic cells and not yet fully understood. Current 
reports indicate that the cell cycle in stem cells lacks G
0
, has a 
short G
1
, absent G
1
-S checkpoint18 and a preferential activation 
of the G
2
M DNA damage checkpoint, which is responsible for 
the augmented resistance of stem cells to genotoxic damage.19 
Presumably, these differences in cell cycle regulation are associ-
ated with the particular biological properties of ES cells, such as 
self-renewal (immortality).
EC cell lines, which are derived from germ cell tumors, can 
serve, to a certain extent, as a model of ES cells and express the 
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recovering mitotic cells and clones (Fig. S4A). In contrast, rare 
cells expressed high levels of NANOG in both control and ETO-
treated conditions (Fig. S4B). The NANOG-overexpressing cells 
observed after ETO treatment were large and presumably poly-
ploid. We hypothesize that they arose by overcoming the G
1
−4N 
checkpoint and avoiding senescence. These cells have the poten-
tial to reach 8–16C and then de-polyploidize. Such a response is 
typical of mutant TP53 lymphoma cells after DNA damage,11,29 
but is a rare event with PA-1.
Upregulation of OCT4A and P21CIP1 in response to 
DNA damage. We next assessed key molecular regulators of 
the DNA damage response by immunofluorescence (IF). As 
expected, TP53 and, subsequently, P21CIP1 (CDKN1A), were 
upregulated in response to ETO treatment. However, the plu-
ripotency self-renewal transcription factor OCT4A was also 
upregulated (Fig. 2A–C). In fact, paradoxically, OCT4A and 
P21CIP1 were shown by IF to be both expressed in the same 
cells (Fig. 2B and C). Expression of high levels of both proteins 
to the mitotic cell cycle, while the remainder display persistent 
DNA damage and are either maintained in the 4C fraction or 
become polyploid.
During this period, macroautophagy was observed in 
response to ETO treatment as seen by LC3B and P62 lysosomal 
staining being compatible with the enhanced OCT4A stain-
ing (Fig. S3A– D) and gradually increasing from day 1 to 5. 
Macroautophagy returned to resting levels in cells as they re-
entered mitotic cycling, but remained elevated in cells that per-
sisted in G
2
 and in most polyploid cells. TERT staining revealed 
nuclear foci in NT cells (not shown) and in the small cells re-
entering the mitotic cycle following ETO treatment. Most large 
cells lacked nuclear foci and showed elimination of TERT in 
perinuclear LC3B-lined vacuoles; however, in parallel, large 
amounts of TERT also appeared in their cytoplasm (Fig. S3E 
and F), possibly due to the stress-protecting binding of TERT 
to mitochondria.28 Most PA-1 cells displayed low NANOG 
expression, which was more evident around chromosomes in 
Figure 1. DNa damage response of pa-1 cells to eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, then washed and assessed at the 
indicated time point. Cells were pelleted, cytospun, fixed and stained for (A) pChK2 (red) or (B) γh2aX (red) and RaD51 (green) in combination with 
DapI (blue). Bar = 10 μM. (A) NT pa-1 cells show very faint background pChK2 staining in non-dividing cells and increased staining of centrosomes in 
dividing cells (white arrowheads). On day 2 post-eTO, small pChK2-positive foci accumulate in the nuclei of all cells. By day 4, some small nuclei have 
lost pChK2 staining (yellow arrowheads), while large cells remain pChK2 positive. (B) NT pa-1 cells show no positive staining for γh2aX or RaD51. On 
day 2, the majority of cells show accumulation of γh2aX or RaD51 positive foci in the nuclei. (C) Cells were cytospun, fixed and stained for DNa image 
cytometry. DNa content was determined for at least 200 cells in each condition and represented as a percentage. profound G2 arrest on day 2 was 
observed followed by the simultaneous emergence of a polyploid (> 4C) and G1 fraction on day 5 before the recovery of the normal cell cycle profile 
by day 7. (D) The proportion of pChK2-positive cells was examined in the context of DNa content with cells sub-divided into small or large cells. In the 
NT control sample, all cells were pChK2-negative with an expected nuclei size distribution (2C 80%; ≥ 4C 20%). On day 2, all cells were pChK2-positive 
and the vast majority of nuclei were large (≥ 4C). By day 5, cells with small nuclei appear, all of which are pChK2-negative. Data are representative of > 
three independent experiments.
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treatment, both TP53 and OCT4A levels partially decreased, 
while P21CIP1 continued to increase. Transfection of PA-1 
cells with TP53-siRNA successfully silenced TP53 expression 
throughout the time-course and, as expected, inhibited the 
increase in P21CIP1 in response to ETO treatment. However, 
unexpectedly, silencing of TP53 also largely inhibited the upreg-
ulation of OCT4A. Thus, the increase in OCT4A in response 
to ETO is largely TP53-dependent. To confirm this surprising 
finding, we repeated these experiments using PA-1 cells stably 
transfected with a shRNA vector directed against a different 
region of TP53 and saw the same results (Fig. S6) with dimin-
ished OCT4A upregulation.
Previous studies have indicated that the expression of OCT4A 
in cancer cell lines may have been misreported due to the presence 
displayed a strong positive correlation (Fig. 2D) in the first 3 days 
post-treatment in the G
2
 (4C by DNA content) and polyploid 
(> 4C) fractions described above (Fig. 2E; Fig. S5A). However, 
individual cells were shown to vary greatly in their expression of 
both of these factors after treatment as indicated by their mean 
expression levels, standard deviations and extended outliers 
(Fig. 2D; Fig. S5B).
The TP53 dependency of the OCT4A response. To fur-
ther investigate the link between increased OCT4A expression 
and TP53 induction after DNA damage in PA-1 cells, siRNA 
directed against TP53 was used. Western analysis of whole-cell 
lysates confirmed that ETO treatment strongly upregulated 
TP53, OCT4A and P21CIP1 (CDKN1A), confirming our IF 
results (Fig. 3). In the post-G
2
 period, from day 4 after ETO 
Figure 2. Regulation of Tp53, p21CIp1 and OCT4a in pa-1 cells after eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, then washed and 
assessed at the indicated time point. Cells were pelleted, cytospun, fixed and stained for (A) Tp53 (red) (B) p21CIp1 (red) or (C) p21CIp1 (red) and OCT4a 
(green) in combination with DapI (blue); Bar = 10 μM. Results representative of nine separate experiments. (A) NT cells showed very faint background 
staining for Tp53. On day 3 post-eTO treatment, Tp53 accumulated in the majority of nuclei. (B and C) NT cells had faint background staining for 
p21CIp1 and weak staining of OCT4a. On day 3 post-eTO treatment, p21CIp1 and OCT4a accumulated in the majority of cell nuclei. (D) Using image 
analysis on fixed cytospins, the fluorescence intensity of p21CIp1 and OCT4a during the first 3 d post-eTO treatment was determined and plotted 
for 500 cells in four independent experiments. There was substantial increase and a clear positive correlation between the fluorescent intensity of 
staining for OCT4a and p21CIp1 after eTO treatment. at the same time, the amplitude of the expression of both factors greatly increased: Non-treated 
OCT4a expression mean = 2,448, sD = 1,236; OCT4a expression on day 3 mean = 12,641, sD = 6,189; non-treated p21CIp1 expression mean = 2,875, sD 
= 1,594; p21CIp1 expression on day 3 mean = 10,291, sD = 5,795. (E) Two-channel flow cytometry was used to measure DNa content (pI fluorescence) 
and OCT4a expression. In NT samples, the OCT4a expression was similar in the 2C and 4C fractions. after eTO treatment, OCT4a was highly elevated 
in the 4C and 8C fractions and to a lesser extent in the G1−2C fraction. These data indicate that OCT4a accumulation was mostly induced in the DNa 
damage checkpoint and persisted in the polyploid cells.
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encoding HA-tagged forms of OCT4A or OCT4-pseudogene 1 
were produced, transfected into HEK-293 cells and the ability of 
OCT4 antibodies to detect them examined. It was revealed that 
although both proteins were equivalently expressed as judged by 
detection with anti-HA antibodies, only the OCT4A form was 
detected with the anti-OCT4A monoclonal antibody reagent 
(Fig. S7). Together, these data confirm that the increase in 
OCT4A described here was attributed to bona fide OCT4A and 
not alternative splicing or pseudogene forms. However, it should 
be noted that an additional smaller protein species of OCT4A 
was also observed in our experiments, which increased in inten-
sity in response to ETO treatment. As discussed above, the size of 
this protein does not correspond to OCT4B1, nor does this anti-
body detect other isoforms of OCT4. It therefore may reflect a 
of other OCT4 isoforms (OCT4 B, B1 and/or transcribable pseu-
dogenes-1, -3 and -4). To address this issue here, we performed 
RT-PCR and revealed that OCT4A transcription was present 
but not particularly enhanced after ETO treatment (Fig. 4A), 
whereas isoform B was entirely absent. The splicing isoform 
OCT4 B1 (characteristic for ES/EC cells and poorly differen-
tiated cancer)30,31 was induced after ETO treatment (Fig. 4A). 
In addition, our results indicated that pseudogene-1 was tran-
scribed, whereas pseudogenes-3 and -4 were not (not shown). 
The OCT4B1 splicing form is appreciably smaller in size in com-
parison to OCT4A, and was not detected in our immunoblot-
ting analysis with either OCT4A or OCT4A/B antibodies and so 
can be disregarded. However, to evaluate our IF and immunob-
lotting findings in relation to pseudogene-1, expression vectors 
Table 1. primary antibodies
Target Description Specifity/immunogen
Product nr and  
manufacturer
Use*
Tp53 Rabbit polyclonal against full-length human p53 fusion protein
#9282 Cell signalling 
Technology
W, IF
OCT Mouse mab
peptide raised against amino acids 1–134 of OCT-3/4 
of human origin non-cross-reactive with OCT-3/4 iso-
forms B and B1.
sc-5279, santa Cruz W, IF, F
OCT4a/B
Rabbit polyclonal, ChIp 
grade
peptide derived from within residues 300 to  
the C terminus of human OCT4.
ab19857,  abcam W, IF, F
NaNOG
Mouse mab, clone 
NNG-811
against human NaNOG. N3038, sigma IF
p16INK4a Rabbit polyclonal human p16, C-terminal. ab7962, abcam IF
p16INK4a Rabbit polyclonal
Raised against a peptide mapping at the N terminus of 
p16 of human origin.
sc-467, santa Cruz W, IF
aURORa B kinase Rabbit polyclonal
peptide derived from within residues 1–100 of human 
aURORa B.
ab2254, abcam IF
Telomerase reverse tran-
scriptase (TeRT)
Mouse mab against human TeRT. ab5181, abcam IF
p62 (sQsTM1) Rabbit polyclonal
epitope corresponding to amino acids 151–440 of 
sQsTM1 of human origin.
sc-25575, santa Cruz IF
pChK2 
 (phosphorylated T68)
Rabbit polyclonal
epitope around the phosphorylation site of Threonine 
68 (VsT pQe) of human ChK2.
ab38461, abcam W, IF
α-tubulin Mouse mab
Recognizes an epitope located at the C-terminal end of 
the α-tubulin isoform in a variety of organisms.
T5168, sigma IF
γ-h2aX Rabbit polyclonal
Recognizes mammalian, yeast, D. melanogaster  
and X. laevis γ-h2aX.
4411-pC-100, Trevigen IF
RaD51 Mouse mab Targeted to amino acids 1–138 of human RaD51. ab213, abcam IF
LC3B Rabbit polyclonal
peptide derived from within residues 1–100 of human 
LC3B.
ab63817, abcam IF
p21CIp1 Rabbit polyclonal
Raised against a peptide mapping at the C terminus of 
p21 of human origin.
sc-397, santa Cruz W, IF
GapDh Mouse mab, clone 6C5 Rabbit muscle GapDh. ab8245, abcam W
β-actin Rabbit polyclonal
synthetic peptide derived from within residues 1–100 
of human β-actin.
ab8227, abcam W
*W, western; IF, immunofluorescent staining; F, flow cytometry.
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enumerated (for examples of normal and abnormal patterns, see 
Fig. S9). The results of this analysis showed that all mitoses in 
TP53-silenced samples were multicentrosomal and most of them 
multipolar, with a smaller proportion showing coalescence of 
multiple centrosomes at two poles, indicating a high degree of 
chromosome and centrosome instability (Fig. 6A). Conversely, 
the mitoses in control cells after ETO treatment were mostly 
bipolar and bicentrosomal, with a smaller proportion of multi-
centriolar multipolarity. Inspection of metaphases by DNA stain-
ing after TP53 silencing revealed that they were highly aberrant 
with deranged plates, partly uninemic, fragmented and clumped 
chromosomes and no anaphases, while only rare aberrant mitoses 
were seen in the control sample (characteristic patterns are shown 
in Fig. S10A and B). Some of these aberrant metaphase plates 
in ETO-treated controls had chromosomes separated from the 
mitotic spindle and, when stained for γH2AX, displayed DNA 
damage (Fig. S10C). Intense DNA damage was also observed 
in the polyploid cells with micronuclei, while cells with small 
nuclei were free of γH2AX staining or contained only residual 
damage (Fig. S10D). Presumably, these observations explain the 
link between damaged DNA, aberrant mitoses, spindle check-
point arrest and the induction of polyploidy by mitotic slippage. 
Therefore, we conclude that in spite of increased entrance into 
mitosis after TP53 silencing, these cells are arrested in metaphase 
and delay proliferation, enhancing their propensity to undergo 
mitotic slippage, and become tetraploid. However, the eventual 
recovery of the cell population from small clones re-entering 
mitosis was comparable in both TP53-silenced and control cells, 
suggesting that TP53-silenced cells compensate for their initial 
delay in proliferation.
Effect of TP53-silencing on micronucleation. Next, we 
examined the effect of TP53-silencing on chromosome stabil-
ity using the presence of micronuclei as a marker (Fig. 6B). As 
expected, treatment with ETO caused an increase in micronu-
cleation and, thus, nuclear instability. Chromosome instability 
was substantially increased by silencing of TP53 as judged by the 
~4-fold increase in micronucleation index.
Effect of TP53-silencing on senescence. Subsequently, 
we addressed how TP53 affected the induction of senescence 
after ETO treatment, initially by assessing the expression of 
P16INKA4A. We found that an increase in P16INKA4A expres-
sion was detected from days 4–5 post-treatment in TP53-silenced 
cells (Fig. 7A), corresponding with the partial release from G
2
 
arrest and increase in (aberrant) mitoses. In contrast, mock-trans-
fected control cells had only marginal expression of P16INKA4A 
during this time. To confirm whether the increase in P16INKA4A 
expression corresponded with other indicators of senescence, 
senescence-associated β-galactosidase (sa-β-gal) staining and 
morphological analysis were performed. In control cells, ETO 
treatment evoked a modest but measurable increase in cell size 
(hypertrophy) and weak sa-β-gal staining at later time points. 
However, this was greatly accelerated by the silencing of TP53 
with strong sa-β-gal staining in a significantly (p < 0.05, n = 3) 
higher proportion of cells in TP53-silenced (mean = 70.7%) vs. 
control (mean = 38.7%) samples at day 5 post-treatment, corre-
sponding with the accelerated increase of DNA damage marked 
post-translational change in OCT4A that increases in response 
to DNA damage.
OCT4A does not bind chromatin during the DNA dam-
age response. Subcellular fractionation was subsequently used to 
establish the location of the OCT4A within the cell. Cytoplasm, 
membrane-bound, nuclear (karyosolic) and chromatin-bound 
fractions were obtained, and OCT4A presence was assessed by 
immunoblotting. This analysis revealed a considerable increase 
of OCT4A in response to ETO treatment in the nuclear (karyo-
solic) fraction as attested to by two different antibodies, directed 
to the N or C terminus of OCT4. However, OCT4A was shown 
to be depleted after ETO treatment from the chromatin-bound 
fraction as compared with non-treated cells (Fig. 4B), indicating 
that although it is elevated, it may lack the ability to bind its own 
promoter or the promoters of its cooperative partners (SOX2 and 
Nanog) and influence the downstream transactivation targets.
Effect of TP53 on the cell cycle response. We next sought to 
examine the effect of TP53 on the cell cycle response of PA-1 cells 
after ETO treatment using flow cytometry and DNA image anal-
ysis (Fig. 5A–C). As indicated above using DNA image cytom-
etry, ETO treatment of TP53-competent PA-1 cells resulted in a 
pronounced G
2
 arrest by day 1–2, followed by its release from day 
3–4 and a degree of polyploidy and apoptosis. When TP53 was 
silenced by shRNA in transfected cell lines, a larger proportion of 
cells accumulated in the 4C and polyploid fractions. Subsequently, 
less cells recovered in the G
1
-2C fraction (Fig. 5A and B). These 
relationships were more evident upon DNA image analysis that 
omitted apoptotic cells (Fig. 5C; Fig. S8). Surprisingly, despite 
an apparent delay in proliferation, mitotic counts revealed a 
significant increase in the mitotic index (MI) of TP53-silenced 
samples compared with TP53-sufficient controls. (Fig. 5D; and 
shown for an individual experiment in Fig. 5C). To address the 
nature of this response further, pCHK2 and α-tubulin staining 
was performed on adherent cells on day 4 after ETO treatment. 
Using this approach, bipolar and bicentrosomal mitotic cells 
and aberrant multipolar mitotic cells were distinguished and 
Figure 3. Immunoblot analysis of Tp53, OCT4a and p21CIp1 in pa-1 cells 
after eTO treatment. pa-1 cells were treated with non-target (ntg) siRNa 
(−) or siRNa-Tp53 (+) for 24 h before treatment with 8 μM eTO, washing 
after 20 h and cell lysates made and assessed by immunoblotting for 
Tp53, p21CIp1, OCT4a or GapDh as a loading control at the indicated 
time points (day 3 and day 5). Tp53 was upregulated in response to eTO 
treatment and suppressed by siRNa-Tp53. p21CIp1 and OCT4a were also 
upregulated by eTO treatment, and the upregulation was restricted by 
treatment with siRNa-Tp53. Data are representative of three indepen-
dent experiments.
436 Cell Cycle Volume 12 Issue 3
to enter mitosis, so retained a clear plasticity of response, not yet 
terminally committed to senescence.
The DNA damage response in the PA-1 cells appears to couple 
the upregulation of the pluripotency and self-renewal-promoting 
master molecule, OCT4A, with cell cycle arrest and senescence-
promoting molecules (TP53 and P21CIP1) in the same cells, pro-
viding them with bipotentiality in the DNA damage checkpoint. 
Furthermore, the expression levels of these proteins in individ-
ual cells after treatment was highly varied. Although heteroge-
neous expression of NANOG within ES cell cultures has been 
observed,32 and this, in turn, has been attributed to fluctuation of 
NANOG levels,33 it is generally accepted that OCT4A expression 
is tightly regulated and expressed relatively uniformly in ES cell 
populations and does not fluctuate.34 In the context of TP53-
dependent upregulation of OCT4A, the heterogeneity observed 
here may be due to fluctuation in TP53 expression itself, which is 
well-documented in cell stress responses.35,36
Artificially reducing the level of TP53 using si- or shRNA 
resulted in precocious mitosis and, subsequently, an increase in 
chromosome and centrosome instability in response to ETO 
treatment. In addition, TP53 silencing caused an increase in 
DNA damage and enhanced senescence. This is in agreement 
with previous studies that demonstrated TP53 can suppress cel-
lular senescence.16 We therefore propose that unrepaired DNA 
damage and the increase in chromosome instability may link 
TP53 suppression to senescence.
by pCHK2 (Fig. S6) and the senescence marker P16INKA4A 
(Fig. 7A) seen above.
Discussion
In this study, we investigated the DNA damage response of the 
ovarian teratocarcinoma cell line PA-1, with particular focus on 
the relationship between self-renewal and senescence and the role 
of TP53 in regulating these different cell fates. Despite express-
ing functional TP53, PA-1 cells showed a preferential G
2
M arrest 
following ETO-induced DNA damage, a characteristic feature 
and cause of genotoxic resistance of ES cells.19 We also observed 
equivalent results with other forms of DNA damage such as X-ray 
irradiation (data not shown).
This arrest was typically characterized by extensive DNA 
damage signaling (indicated by the upregulation pCHK2 and 
γH2AX) and by attempted repair through homologous recom-
bination (as shown by the induction of RAD51/γH2AX foci). 
The subsequent cellular response varied: while most cells died, 
some cells successfully repaired, halted DNA damage signaling 
and returned to mitotic cycling, whereas others displayed persis-
tent DNA damage, remained in the 4C fraction or became poly-
ploid. These latter cells underwent upregulated macroautophagy, 
indicative of a move toward senescence. However, these cells were 
also OCT4A and AURORA B kinase-positive, contained a large 
amount of cytoplasmic TERT and were therefore potentially able 
Figure 4. analysis of OCT4 regulation in pa-1 cells after eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, then washed and examined at 
the indicated time points by (A) semi-quantitative pCR or (B) cell fractionation and immunoblotting using antibodies against OCT4a or OCT4a and B, 
actin or histone h3 (h3), the latter two as loading controls. (A) OCT4a transcription was shown to be modestly upregulated in response to eTO after 3 
d (upper panel). OCT4B was not substantially detected (middle panel). OCT4B1 was upregulated in response to eTO. OCT4-pG-1 was also upregulated 
in response to eTO (lower panel). Controls were NTC, non-template control; pBL, peripheral blood lymphocytes. equivalent amplification of actin 
after 30 cycles was used as a control for cDNa input (bottom panel). Data representative of three independent experiments. (B) OCT4a protein was 
upregulated in response to eTO treatment in the cytosol, membrane and nuclear fractions. OCT4a was downregulated in the chromatin-bound frac-
tion. No additional bands were detected with the OCT4a/B dual specificity (C-terminal) antibody compared with the mono-specific OCT4a antibody 
(N-terminal), indicating only OCT4a species are expressed. Data representative of two independent experiments.
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chromosome and centrosome instability and, thus, safeguards 
the fidelity of self-renewal in the damage-resistant EC cells.
The question again follows, how are these opposing processes 
coordinated at the molecular level? The explanation may be 
provided by the observation that the OCT4A induced by TP53 
at the DNA damage checkpoint is unable to bind chromatin. 
Presumably then, OCT4A is unable to execute its transactiva-
tion role in binding to the NANOG promoter regulatory ele-
ment essential for the pluripotency function.34,38 Conversely, 
the NANOG promoter should be directly blocked by activated 
TP53.39 However, importantly, in ETO-treated PA-1 cells, 
The question then becomes how. Precocious aberrant mitoses 
containing DNA damage readily undergo mitotic slippage (to 
become G
1
-4N cells with micronuclei), which may undergo apop-
tosis or alternatively trigger terminal senescence through TP53-
independent P21CIP1 and P16INKA4A targeting of the cyclin 
kinases governing the G
1
−S transition. Weaver and Cleveland 
also suggested adaptation of the spindle checkpoint as a path-
way to cell survival vs. senescence through tetraploidy.37 Based 
upon our observations, we suggest that coupling the expression 
of self-renewal and senescence regulators through TP53 at the 
DNA damage checkpoint favors DNA damage repair, reduces 
Figure 5. effect of silencing Tp53 on the cell cycle response of pa-1 cells after eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, then 
washed and examined at the indicated time points by (A and B) flow cytometry, (C) DNa image cytometry and (D) mitotic counts. (A) Both control 
plasmid and shRNa p53-silenced cells undergo a G2M arrest after eTO treatment, which is, however, more profound from day 3 in Tp53-silenced cells. 
The Tp53-silenced cells also show a larger increase in the ≥ 4C cell fraction in response to eTO treatment. Conversely, the recovering G1−2C fraction is re-
duced. By day 5, the relative proportion of the G2 fraction is diminished in both samples, due to the increase in apoptosis. (B) The proportion of cells in G2 
was enumerated over the time course in three independent experiments with the mean and seM plotted (* p < 0.05). (C) DNa image cytometry analysis 
was also performed on day 4 after eTO treatment. apoptotic cells were excluded from the measurements, and highlighted more clearly the relationship 
between the increased 4C fraction and relative delay in recovery of the proliferating G1−2C fraction (reduced 2.5-fold) after Tp53-silencing. The cor-
responding mitotic index (MI) at this time point is also shown. For full cell cycle dynamics over the time course in this experiment, please see Figure S6. 
Data representative of two similar experiments. (D) Mitotic counts were performed on control plasmid or shRNa p53-silenced cells over time after eTO 
treatment. The results from three independent experiments show a significant increase in the proportion of mitoses after Tp53 silencing (* p < 0.05).
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stable cell lines established and maintained in media containing 
puromycin. Selection was removed 3 d prior to experiments.
Expression of HA-tagged forms of OCT4A and OCT4A-
pseudogene-1. Expression vectors encoding HA-tagged forms 
of OCT4A or OCT4A-pseudogene-1 (OCT4A-PG1), a kind 
gift from Professor Aijun Hao,43 were transfected into HEK-293 
cells using Fugene 6 (Promega) according to the manufacturer’s 
protocol.
DNA image cytometry. Cytospins were prepared and fixed 
in ethanol:acetone (1:1) for > 30 min at 4°C and air-dried. Slides 
were then treated with 5N HCl for 20 min at room temperature, 
washed in distilled water (5 × 1 min) and stained for 10 min 
with 0.05% toluidine blue in 50% citrate-phosphate McIlvain 
buffer pH 4. Slides were rinsed with distilled water, blotted dry 
and dehydrated by incubating twice in butanol for 3 min each 
at 37°C. Samples were then incubated twice in xylene for 3 min 
each at room temperature before being embedded in DPX. Slides 
were then evaluated using a Leitz Ergolux L03-10 microscope 
equipped with a calibrated Sony DXC 390P color video camera. 
OCT4A accumulates in the cell nucleus, and this should be a pre-
requisite for its effective upregulation of NANOG through a pos-
itive feedback loop, when the NANOG promoter becomes free 
from inhibition by TP53 after DNA damage repair. Therefore, 
accumulation of OCT4A can be considered as a precursor for 
self-renewal potential. Simultaneously, the cell is primed for 
senescence through the accumulation of P21CIP1, again in a 
TP53-dependent manner, but is prevented from its full execu-
tion, possibly by the pre-mitotic molecular environment of the G
2
 
cell. It follows that the PA-1 cells in the G
2
M damage checkpoint 
are in a state of bi-potential metastability between self-renewal 
and senescence, akin to the situation of bi-potentiality between 
self-renewal and differentiation in stem cells.
This interpretation fits well with the extensive heterogeneity 
in OCT4A and P21CIP1 levels observed in the individual cells 
held at the G
2
 arrest, potentially suggesting that their expres-
sion levels are dynamically fluctuating.40 To our knowledge, this 
notion of bi-potential metastability has not previously been con-
sidered as a key result of DNA damage, and we believe our data 
support further study of this area.
In conclusion, our studies have described two previously 
unknown phenomena relating to the intrinsic link between self-
renewal and senescence in DNA damaged cells expressing stem 
cell-like transcriptional networks and revealed the role of TP53 
in this process. This knowledge may be of use in improving our 
understanding of normal stem cells and also in designing better 
strategies to eliminate cancer stem cells.
Materials and Methods
Cell culture and ETO treatment. PA-1 (ATCC) and HEK-
293 cells were cultured in Dulbecco’s modified Eagle’s media 
(DMEM) supplemented with 10% fetal calf serum. Cells were 
grown without antibiotics in 5% CO
2
 incubators at 37°C. For 
the sphere formation assay, PA1 cells were inoculated in DMEM/
F12 media supplemented with 20 ng/ml EGF (236-EG, R&D 
Systems), 10 ng/ml FGF (233-FB-025/CF, R&D Systems), 
0.5 ng/ml hydrocortisone (H0888, Sigma), 10 ng/ml insu-
lin (I9278, Sigma), 1× antibiotics/antimycotics (15240-062, 
Invitrogen), 1% L-glutamine (25030024, Invitrogen) and 20% 
methylcellulose (high viscosity, 4,000 cP; M0512, Sigma), and 
grown in 5% CO
2
 at 37°C. Exponentially growing PA-1 cells 
were incubated with an 8 μM dose of ETO for 20 h.
Small interfering RNA (siRNA). TP53 protein Hs_TP53_9 
FlexiTube siRNA (Qiagen) was used to silence TP53 expression 
and ON-TARGET plus non-targetting siRNA #1 (Dharmacon) 
was used as a negative control. PA-1 cells were transfected with 
siRNA using HiPerfect (Qiagen) according to the manufacturer’s 
protocol.
Small hairpin RNA (shRNA). The following plasmids were 
purchased from Addgene: pMKO.1 puro TP53 plasmid (Addgene 
plasmid 19119) deposited by Bob Weinberg;41 and pMKO.1 puro 
(Addgene plasmid 8452) deposited by Bob Weinberg.42 PA-1 cells 
were transfected with plasmid using Fugene 6 (Promega) accord-
ing to the manufacturer’s protocol and then selected using puro-
mycin (0.3 μg/ml). After 2 wk, growing colonies were sub-cloned, 
Figure 6. effect of silencing Tp53 on genome instability in pa-1 cells 
after eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, 
then washed and examined at the indicated time points for the (A) the 
proportion of normal (2 centrosomal; 2 cen), ≥ 4 cen bipolar and ≥ 4 
cen multipolar mitoses and (B) micronucleation. (A) Cells were treated 
as before and then examined by IF staining for pChK2 and α-tubulin. 
silencing of Tp53 caused multi-centrosomal mitoses (≥ 4 cen) that were 
mostly multi-polar or showed coalescence of centrosomes in two poles. 
(B) Cells were treated as before and then assessed for the extent of 
micronucleation following DNa in situ staining. an increase in the pro-
portion of interphase cells with micronuclei was observed in response 
to eTO treatment. silencing of Tp53 significantly increased the amount 
of micronucleation, which was further enhanced in response to eTO 
(p < 0.05). Data are representative of three independent experiments.
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DNA flow cytometry. Cells were trypsinized, har-
vested at indicated time points, washed in PBS and sus-
pended in hypotonic fluorochrome solution [50 μg/ml 
propidium iodide (PI), 0.1% (w/v) sodium citrate, 0.1% 
(v/v) Triton X-100] and stored for at least 1 h in the dark 
at 4°C. Flow cytometry was performed using a FACScan 
(BD Biosciences) using Cell Quest Pro Software.
Two-channel flow cytometry. Cells were harvested at 
relevant time points, washed in cold PBS and fixed with 
70% ethanol for 20 min at room temperature. After two 
washes in TBS, cells were permeabilized with TBS/4% 
bovine serum albumin (BSA)/0.1% Triton X-100 for 10 
min at room temperature. Samples were then incubated 
with rabbit polyclonal anti-OCT4 antibody solution 
(ab19857, Abcam) (5 μg/ml) in TBS/4% BSA/0.1% 
Triton X-100 for 1 h at room temperature. Following two 
washes in TBS, cells were incubated with goat anti-rabbit 
Alexa Fluor 488 solution (1:200) in TBS/4% BSA/0.1% 
Triton X 100, for 30 min in the dark. DNA was coun-
terstained with 10 μg/ml PI solution in PBS, containing 
200 μg/ml RNase (Sigma) and assessed by flow cytometry 
using a FACS Calibur (BD Biosciences) using Cell Quest 
Pro Software.
Immunofluorescent (IF) staining. IF was performed 
as described previously.44 Cytospins were fixed in metha-
nol for 7 min at −20°C and dipped 10 times in ice-cold 
acetone. Slides were then washed three times in TBS 
0.01% Tween 20 (TBST) for 5 min. Slides were subse-
quently blocked for 15 min in TBS, 0.05% Tween 20%, 
1% BSA at room temperature. Samples were covered with 
50 μL of TBS, 0.025% Tween 20%, 1% BSA contain-
ing primary antibody and incubated overnight at 4°C in 
a humidified chamber. Samples were then washed three 
times in TBST and covered with 50 μL of TBST contain-
ing the appropriate secondary antibody before incubation 
for 40 min at room temperature in the dark. Slides were 
washed three times for 5 min with PBST and once for 
2 min in PBS. Samples were then counterstained with 
0.25 μg/ml DAPI for 1 min, mounted using ProLong 
Gold antifade reagent (Invitrogen) and evaluated using a 
Leitz Ergolux L03-10 microscope equipped with a Sony 
DXC 390P color video camera. Antibodies and their 
source are listed in Tables 1 and 2. Note: when stain-
ing for tubulin, the fixation step using acetone was omit-
ted and detergent was absent from all buffers. For TERT 
staining alone, the fixed cells were pre-treated with 2N 
HCl for 20 min at room temperature.
Detection of sa-β-galactosidase activity. The senes-
cence β-galactosidase (sa-β-gal) staining kit (Cell 
Signaling, 9860) was used to detect sa-β-gal activity in 
cultured cells at indicated time points according to the manufac-
turer’s protocol.
Western blotting (whole-cell lysate). Cells were harvested 
using trypsin digestion and lysed using RIPA buffer with prote-
ase inhibitor cocktail (Sigma P8340). Total protein was quanti-
fied using BCA protein assay kit (Pierce) and equal quantities 
DNA content was measured as the integral optical density in 
the green channel, using Image-Pro Plus 4.1 software (Media 
Cybernetics). Apoptotic cells were omitted from measurements. 
The stoichiometry of DNA staining was verified using the values 
obtained for metaphases compared with anaphases and telophases 
(ratio 2.0); the method error was estimated to be less than 5%.
Figure 7. senescence response of pa-1 cells to eTO treatment. pa-1 cells stably 
transfected with shRNa-p53 or plasmid control were treated with 8 μM eTO for 
20 h, then washed and assessed at the indicated time point by (A) immunoblot-
ting or (B) for sa-β-gal expression and cellular morphology. (A) Cell lysates were 
made and assessed by immunoblotting for p16INKa4 and GapDh as a loading 
control. an accumulation of p16INKa4 was detected in Tp53-silenced cells 
after eTO treatment. (B) sa-β-gal staining was used to detect sa-β-gal activity 
in response to eTO treatment at indicated time points. Detection of sa-β-gal 
activity was increased by Tp53-silencing and largely mirrored the induction of 
p16INKa4 seen above. (C) higher power image of the cells seen on day 5.  
Bar = 20 μM. Data are representative of > three independent experiments.
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identity determined by direct sequencing after ExoI/SAP treat-
ment (Fermentas, MBI) using the fluorescent Big DyeTerminator 
v. 3.1 Cycle Sequencing protocol on a 3,130 xl Genetic Analyzer 
(Applied Biosystems).
Methods of statistical analysis. Statistical analysis was per-
formed in Minitab. A paired t-test was used to calculate the sta-
tistical significance of difference of means where appropriate. 
Statistical significance was accepted when p < 0.05. Graphs were 
plotted in GraphPad Prism 5 and Statistica 6.
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of denatured protein were subjected to electrophoresis on SDS-
polyacrylamide gels, blotted onto Immobilon-FC transfer mem-
brane and probed with specific primary antibodies listed in Table 
1 and secondary antibodies listed in Table 2. The signal was visu-
alized using a LICOR Odyssey imaging system.
Subcellular fractionation. For cellular fractionation, the 
Subcellular Protein Fractionation Kit for Cultured Cells 
(Thermo Scientific) was used according to the manufacturer’s 
instructions. Cytoplasmic, membrane, nuclear soluble, karyosol 
and chromatin-bound protein extracts were obtained. Protein 
concentrations were determined by Bio-Rad (Bio-Rad Inc.) pro-
tein assay, using a BSA standard set (Fermentas MBI) for quanti-
tation. Proteins (10 or 15 μg) were separated on 10, 12, 5 or 20% 
SDS PAGE gels, followed by electrophoretic transfer onto BA85 
nitro-cellulose membranes (Schleicher and Schuell GmbH) over-
night. Equal protein loading in each lane was verified by Ponceau 
S staining. Blots were probed with specific primary antibodies 
listed in Table 1 and secondary antibodies listed in Table 2. The 
signal was visualized using the Chemiluminescent Nucleic Acid 
Detection Module (Thermo Scientific).
RT-PCR analysis of Oct4-splicing forms. Total RNA was 
extracted from cells using TRIZOL (Invitrogen). cDNA was 
synthesized using First Strand cDNA Synthesis Kit (Fermentas 
MBI) according to the manufacturer’s protocol and then diluted 
10×. The absence of contamination with genomic DNA was 
verified by PCR using actin primers as described.11 cDNA from 
peripheral blood lymphocytes (PBL) as a control of somatic cells 
was kindly provided by Dr Inta Vasiljeva. Amplification was per-
formed with 1–4 μl of diluted cDNA and the following prim-
ers, β-actin F/R; Oct4A AF/AR; Oct4B/B1 BF1/BR2 under 
conditions previously described.11 Amplified PCR products were 
analyzed on an agarose gel after various PCR cycles and their 
Table 2. secondary antibodies
Antibody Conjugate Product nr and manufacturer Use*
Goat anti-mouse IgG alexa Fluor 488 a31619, Invitrogen IF, F
Goat anti-rabbit- IgG alexa Fluor 594 a31631, Invitrogen IF
Goat anti-rabbit IgG hRp 32460, Thermo Fisher scientific W
Rabbit anti-mouse IgG hRp 61-6520, Invitrogen W
Goat anti-rabbit IgG IRDye 800CW 926-32211, IRDye antibodies W
Goat anti-mouse IgG IRDye 800CW 926-32210, IRDye antibodies W
Goat anti-rabbit IgG IRDye 680LT 926-68021, IRDye antibodies W
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Role of stress-activated OCT4A in the cell fate
decisions of embryonal carcinoma cells
treated with etoposide
Anda Huna1, Kristine Salmina1, Jekaterina Erenpreisa1, Alejandro Vazquez-Martin1, Jekabs Krigerts1, Inna Inashkina1,
Bogdan I Gerashchenko1,4, Paul A Townsend2, Mark S Cragg3, and Thomas R Jackson2,*
1Latvian Biomedical Research and Study Center; Riga, Latvia; 2Institute of Cancer Sciences; Manchester Cancer Research Center; University of Manchester; Manchester Academic
Health Science Center; Manchester, UK; 3Cancer Sciences Unit; University of Southampton; Faculty of Medicine; General Hospital; Southampton, UK; 4R. E. Kavetsky Institute of
Experimental Pathology; Oncology and Radiobiology; National Academy of Sciences of Ukraine; Kyiv, Ukraine
Keywords: cell-fate, DNA damage, OCT4A/POU5F1, p53, p21Cip1, p16ink4a, p62, pluripotency, senescence, self-renewal, tumor cells
Abbreviations: AMPK, AMP-activated protein kinase; Baf, bafilomycin; EC, embryonal carcinoma; ES, embryonic stem;
ETO, Etoposide; IF, immunofluorescent; LC3, microtubule associated protein 1 light chain 3; NT, non-treated; NT2, NTera 2; ntg,
non-target; pCHK2, phosphorylated CHK2; PI, propidium iodide; siRNA, small interfering RNA; shRNA, small hairpin RNA;
Sa-b-gal, senescence associated b-galactosidase.
Tumor cellular senescence induced by genotoxic treatments has recently been found to be paradoxically linked to
the induction of “stemness.” This observation is critical as it directly impinges upon the response of tumors to current
chemo-radio-therapy treatment regimens. Previously, we showed that following etoposide (ETO) treatment embryonal
carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and
regulating cell cycle inhibition and senescence, respectively). Here we report further detail on the relationship between
these and other critical cell-fate regulators. PA-1 cells treated with ETO display highly heterogeneous increases in
OCT4A and p21Cip1 indicative of dis-adaptation catastrophe. Silencing OCT4A suppresses p21Cip1, changes cell cycle
regulation and subsequently suppresses terminal senescence; p21Cip1-silencing did not affect OCT4A expression or
cellular phenotype. SOX2 and NANOG expression did not change following ETO treatment suggesting a dissociation of
OCT4A from its pluripotency function. Instead, ETO-induced OCT4A was concomitant with activation of AMPK, a key
component of metabolic stress and autophagy regulation. p16ink4a, the inducer of terminal senescence, underwent
autophagic sequestration in the cytoplasm of ETO-treated cells, allowing alternative cell fates. Accordingly, failure of
autophagy was accompanied by an accumulation of p16ink4a, nuclear disintegration, and loss of cell recovery.
Together, these ﬁndings imply that OCT4A induction following DNA damage in PA-1 cells, performs a cell stress, rather
than self-renewal, function by moderating the expression of p21Cip1, which alongside AMPK helps to then regulate
autophagy. Moreover, this data indicates that exhaustion of autophagy, through persistent DNA damage, is the cause
of terminal cellular senescence.
Introduction
The relationship between cancer cells, normal stem cells,
and cancer stem cells represents a question of substantial cur-
rent interest.1 It has been proposed that transcription net-
works that confer stem cell properties such as self-renewal,
plasticity, or an increased resistance to genotoxic stimuli in
normal stem cells may perform a similar function in cancer
cells.2 This hypothesis is supported by the growing clinical
evidence that expression of key embryonal stem cell (ESC)
transcription factors POU1F5 (OCT4A), NANOG and
SOX2, are associated with poorer prognosis through tumor
resistance, recurrence and progression in a wide variety of
cancers.3-9 Furthermore, it has been demonstrated by several
groups that ESC transcription factors can be upregulated in
response to DNA damage where they likely play a role in
regulating survival.10-12
Conversely, accelerated cellular senescence is a phenomenon
that has also been shown to be induced by genotoxic treatments
of cancer cells.13 Cellular senescence has traditionally been con-
sidered a terminal cell fate.13,14 However, more recently it has
been shown to be reversible at early stages, at least in tumor
cells.15-18 Furthermore, a direct link between senescence and
“stemness,” essential cytological characteristics of a stem cell that
distinguishes it from ordinary somatic cells, emerged in experi-
ments where pluripotency is induced in normal cells.19,20
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The molecular regulators of these processes in normal
embryonal development, such as p21Cip1, are slowly becom-
ing discerned.21 One intriguing observation is that embryonal
cellular senescence is associated with upregulation of the
same pathways which govern the epithelial-mesenchymal tran-
sition (EMT).22 This, apparently paradoxical, link between
opposites in cell fate provides a challenge for scientific
reasoning.
We have previously observed in IMR90 fibroblasts that a
pre-senescent phenotype is associated with the appearance of
self-renewal and senescence markers coupled to DNA dam-
age.23 We also demonstrated co-incident p53-dependent
upregulation of 2 opposing cell fate regulators, p21Cip1 and
OCT4A in embryonal carcinoma PA-1 cells treated with Eto-
poside (ETO).24 We hypothesized that this bi-potential state
favors DNA damage repair (DDR) while preventing full
commitment to either senescence or self-renewal. In this sys-
tem, p53 silencing promoted terminal senescence and prema-
ture mitosis. Together these data support the presence of a
pre-senescent cell state which can arise in response to both
senescence and stemness programmes being coactivated in
response to genotoxic damage.
In the present study, we asked how key regulators of stem-
ness (OCT4A, SOX2 and NANOG) and senescence
(p16inka4a) behave in individual PA-1 cells during the
response of ETO-induced DNA damage. Using siRNA
silencing approaches we addressed the effect of OCT4A and
p21Cip1 expression on each other and subsequent cell fates,
determining the role of autophagy and how OCT4A activa-
tion impacts on the energy and genomic stress sensor and
master metabolic regulator and activator of autophagy AMP-
activated protein kinase (AMPK).
Results
Etoposide-treatment elicits a senescence-like phenotype
in PA-1 cells
Following ETO treatment many PA-1 cells undergo gradual
cell apoptosis and anoikis, while the remainder arrest in G2M
and upregulate p53 and p21Cip.24 G2M arrest and nuclear
swelling were evident on day 3 after ETO treatment, with resto-
ration of normal cell cycle and nuclear size 4 d later (Fig. 1A and
B). Concurrent nuclear area assessments and DNA content meas-
urements demonstrate that the nuclei of ETO treated cells
increased in size irrespective of the stage of the cell cycle, but was
most evident in G2M and polyploid cells (Fig. 1C and D).
Increased nuclear area and DNA content were also accompanied
by an increase in cellular granularity, as determined by an
increase in side scatter detected by flow cytometry analysis
(Fig. 1E), and autophagy (see below). The majority of cells dis-
played flattened morphology (Fig. 1F), but only a proportion
displayed p16Ink4a nuclear positivity (Fig. 1 G, H). Further-
more, p16Ink4a expression was largely confined to the cytoplasm
(Fig. 1 G). All of these features are indicative of senescence.
Heterogeneous expression of OCT4A and p21Cip1
following Etoposide treatment
We previously showed that the senescence marker p21Cip1
and the stemness marker OCT4A simultaneously increase and
co-exist in the same cells following ETO treatment.24 After con-
firming the pre-senescent phenotype of these cells, we next
wished to explore how these critical factors for cell fate were
dynamically regulated, integrated and diversified. As judged by
flow cytometry ~60% of the cells become positive for both
markers at the peak of the response (day 5), thereafter the expres-
sion of both markers and the proportion of double positive cells
gradually decreases (Fig. 2A) as clonogenic, mitotic division
ensues. To exclude the possible impact of the senescence-associ-
ated cytoplasmic and nuclear area changes on the flow cytometry
measurements, semi-automatic image cytometry was undertaken,
measuring the expression of both factors in the cell nucleus (apo-
ptotic cells possessing very high p21Cip1 positivity lacking
OCT4A were deliberately excluded from this analysis as distort-
ing stoichiometry of measurements). Both the expression and
variation of expression of OCT4A and p21Cip1 increased on
day 3 after ETO treatment; and increased further on day 5
(Fig2B and C, Fig. S1) and a high number of double-positive
cells confirmed (Fig. 2B).
OCT4A upregulation is not accompanied by changes in
SOX2 or NANOG
In its function as a master regulator of pluripotency and self-
renewal, OCT4A cooperates with SOX2 and NANOG whose
expression are therefore required for maintaining the embryonic
stem cell phenotype.25 We thus explored the expression of these
transcription factors in the DNA damage response of PA-1 cells.
Immunoblotting confirmed that p53 increased in response to
ETO from day 1, resulting in the induction of p21Cip1, which
reached its maximum on day 5 (Fig 3A). As documented previ-
ously, OCT4A expression was present in control cells and
increased following ETO treatment, coincident with p53 upregu-
lation.24 Weak expression of SOX2 was found in untreated cells
but did not alter following ETO-treatment (Fig. 3A); a result
confirmed by image cytometry measurements in individual cells
(Fig3B, Fig. S1). NANOG was not detected in PA-1 cells by
immunoblotting (Fig 3A) although rare NANOG positive cells
(less than 5%) were found in control and ETO-treated samples
by 3 different antibodies (Supplementary Fig. 1). Intriguingly,
SOX2 failed to show unambiguous antagonism with p21Cip1,
which has previously been reported as directly inhibiting SOX2
in neurodifferentiation.26 Furthermore, SOX2 expression did
not show significant correlation with its self-renewal partner
OCT4A (data not shown). Together, these data suggest a dissoci-
ation of OCT4A from its self-renewal capacity when it is induced
by p53 (in the presence of p21Cip1) in response to DNA
damage.
OCT4A suppresses p21Cip1 and promotes an enhanced
senescence phenotype
Given its potential lack of self-renewal capacity, we next inves-
tigated the role of OCT4A in PA-1 cells following ETO
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Figure 1. Senescent-like phenotype of ETO-treated PA-1 cells. PA-1 cells were treated with 8 mM ETO for 20 h before being replaced with fresh media.
(A-D) DNA content and nuclear area were assessed using toluidine blue staining at indicated time points. (A) Images of toluidine blue stained nuclei at
indicated time points. (B) Histograms of DNA content were produced and used to determine the cell cycle stage of individual cells. (C) Dot-plots of DNA
content versus nuclei area with each cell colored according to cell cycle stage as determined by DNA content histograms: G1 (blue); S phase (green); G2
(red); purple (polyploid). A statistically signiﬁcant difference in nuclear size between treated and non-treated cells was observed in G2 and polyploid frac-
tions (*p < 0.05, n D 3 ). (E) Granularity of cells (SSC) was measured at indicated time points by ﬂow cytometry. (F) Phase contrast microscopy of PA-1
cells displaying a ﬂattened morphology. (G) Immunoﬂuorescence staining for p16ink4a (red) and counterstained with DAPI at indicated time points dem-
onstrating an increase in p16ink4a following ETO treatment. (H) Quantiﬁcation of p16ink4a expression determined in individual cells by image cytometry
displayed as a box plot showing its increase after ETO treatment. Images are representative for at least 3 individual experiments.
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Figure 2. Expression of OCT4A and p21Cip1 following ETO treatment of PA-1 cells. (A) Dual staining for OCT4A and p21cip1 by immunoﬂuorescence 3 d
after ETO treatment. (B) Quantitation of OCT4A and p21Cip1 expression on day 3 and day 5 after ETO treatment as measured by image cytometry. (C)
Detection of OCT4A and p21Cip1 by ﬂow cytometry after ETO treatment. Data collected over 11 d indicate an increasing expression and heterogeneity,
with numerous double positive cells at the time of maximal increase (day 5). Starting from day 7 their expression, double-positive population and degree
of heterogeneity gradually decreases during the recovery of clonogenic growth.
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treatment using siRNA. Prior to this
analysis, we first established which
OCT4 isoforms were expressed in PA-1
cells. Using a panel of specific mAb,
immunoblotting revealed that OCT4B
was undetectable in these cells both
before and after ETO treatment (Fig.
S2), consistent with published previ-
ously RT-PCR data.24
Having established that OCT4B was
not expressed in PA-1 cells, siRNA
silencing was used to assess the role of
OCT4A in their response to ETO treat-
ment. Efficient (80–95%) knock-down
of OCT4A was confirmed with 3 differ-
ent siRNA, in addition to a 3 siRNA
pool (Fig. S3) and the molecular
response to ETO was then examined by
immunoblotting (Fig 4A) for key regu-
lators of DNA damage, (pCHK2, p53,
p21Cip1, and RAD51). These experi-
ments revealed p53, RAD51 and
pCHK2 were all upregulated from day
1 independently of OCT4A expression.
p21Cip1 expression rose gradually from
day 1 throughout the course of experi-
ment as seen in previous experiments. Silencing of OCT4A
resulted in a marked increase in p21Cip1 expression from day 1.
These results imply that the presence of OCT4A induced by
DNA damage suppresses p21Cip1 expression despite comparable
levels of p53 expression and equivalent DNA damage as judged
by RAD51 and pCHK2 expression.
When investigating the cell cycle response, loss of OCT4A
caused an almost identical phenotype to that previously reported
with p53 silencing24 i.e. OCT4A-silenced cells underwent a pro-
found G2M arrest with apoptosis being greatly reduced (Fig. 4B
and C). The cells displayed the large, flattened morphology and
Sa-b-gal staining associated with senescence on day 5 (Fig. 4D),
identical to that previously reported when silencing p53. Thus,
the increase in G2M arrest and increased accelerated senescence
previously observed with p53 silencing appears to be entirely due
to the loss of the induction of OCT4A. Prolonged loss of
OCT4A lead to the polyploidisation of these senescent cells and
a reduction in clonal recovery (Fig. 5). The absence of off target
effects was confirmed by repeating silencing and cell cycle analy-
sis experiments with 3 separate siRNA molecules targeting differ-
ent sequences of OCT4A mRNA (Supplementary Fig. 4).
p21Cip1 silencing does not affect OCT4A expression or cell
cycle arrest
Having established that OCT4A suppresses p21Cip1 and a
senescent phenotype we sought to investigate the possibility of a
reciprocal suppression of OCT4A by p21Cip1. To do this
p21Cip1 was silenced using siRNA. Silencing of p21Cip1 was
efficient as judged by immunoblotting but was not found to
affect the expression of OCT4A in the presence or absence of
ETO treatment (Fig. 6). Furthermore, we detected no difference
in the cell cycle profiles of p21Cip1-silenced cells compared to
control siRNA treated cells following ETO treatment.
In summary, we found that OCT4A tempers p21Cip1 upre-
gulation, restricting entry into senescence, indicating that co-
expression defines the pre-senescent state. While p21Cip1 did
not regulate OCT4A expression or change the cell cycle, deple-
tion of OCT4A profoundly impacted it. We also found that
p53-activated OCT4A does not support the pluripotency net-
work in pre-senescent cells (owing to the lack of SOX2/NANOG
co-ordination), leaving its biological role unclear. We, therefore,
interrogated its possible role as a stress responder where one of
these stresses may be metabolic. AMPK is a key sensor of metabo-
lism and energy status.27 Therefore, we next explored the activa-
tion of AMPK by virtue of its phosphorylation at Threonine 172
(pAMPKThr172), in relation to OCT4A expression.
AMPK and OCT4A are coordinately activated in response
to ETO-treatment
The results of this comparative study are shown in Fig. 7.
Microscopy of control, untreated, cells revealed heterogeneous
pAMPKThr172 activation with expression in some cell nuclei and
also in centrosomes, central spindle and mid-bodies of mitotic
cells as described previously,28 and rarely ( <1% cells), in the
cytoplasm (Fig. 7A, upper row). In ETO-treated cells the stain-
ing for AMPK increased and strikingly coincided with the locali-
zation and intensity of staining for OCT4A in most cells
(Fig. 7A, second row) as also confirmed by IF measurements,
where clear correlation was shown (Fig. 7B). However, while
OCT4A is seen homogenously throughout the nucleus
Figure 3. Analysis of pluripotency transcription factors in response to ETO treatment in PA-1 cells. (A)
Protein expression of p53, p21Cip1, OCT4A, SOX2 and NANOG were analyzed by immunoblotting at
indicated time points after ETO-treatment. GAPDH was used as a loading control NT2 cells were used
as a positive control for pluripotency genes OCT4A, SOX2 and NANOG. p53 and p2Cip1 protein
expression was upregulated in the DNA damage response. An upregulation of the OCT4A protein was
detected from day 1 post ETO treatment, while SOX2 remained low and unchanged post ETO expres-
sion. NANOG was not detected in NT or ETO treated PA-1 cells. Results are representative of 3 inde-
pendent experiments. (B) Semi-automatic image cytometry of SOX2 expression was performed on the
nuclei of individual cells. Box-plots indicate the heterogeneity and expression levels measured. The
data show that SOX2 remains unresponsive to ETO-treatment.
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pAMPKThr172 staining revealed a fine (euchromatic) nuclear pat-
tern, which indicates binding to chromatin, unlike OCT4A.
Intense staining of pAMPKThr172 was also found in apoptotic
cell nuclei and bodies, while OCT4A was not (Fig. 7C). In
arrested metaphases appearing after ETO on day 4,
pAMPKThr172 was localized to multiple centrosomes, while
OCT4A was not (Fig. 7A, second row). This difference in stain-
ing was confirmed by co-staining for g-tubulin and AURORA B
kinase (not shown). Together, these data indicate that OCT4A is
co-ordinately regulated alongside
pAMPKThr172 in interphase cells but
that in apoptotic cells their functions
may differ. Moreover, the concordant
expression of OCT4A and
pAMPKThr172 in interphase cells sug-
gests that the p53-dependent OCT4A
induction is a result of a stress response
following ETO treatment.
As a part of its role as a central meta-
bolic regulator, AMPK is directly
involved in the regulation of autoph-
agy.29 In this regard, previous studies
have shown that autophagy is implicated
in the chemo-resistance to ETO and this
effect is reversed by inhibition of AMPK,
which led to cell death by apoptosis.30
Conversely, cellular senescence is
also associated with autophagy30 repre-
senting another potential cell fate phe-
notype following ETO-treatment.24
p16ink4a is believed to drive irrevers-
ible senescence. 31 Therefore, we next
decided to explore the relationship of
p16ink4a and macroautophagy.
p16ink4a is sequestered by
autophagy in ETO-treated cells
Autophagy was verified using
immunofluorescence for p62 as a
marker of autophagy. Post ETO treat-
ment, an increase in the number of
p62 foci/cell was observed by immuno-
fluorescence (Fig. 8A and B) and mean
number of p62 foci/cell in 3 indepen-
dent experiments was shown to
increase > fold5- (Fig 8C). Bafilomy-
cin A (Baf) halted autophagic flux in
ETO-treated cells (shown as an accu-
mulation of LC3B in relation to
LC3A), confirming functional autoph-
agy and its suppression (Fig. 8D). Baf
treatment also enhanced cell death pre-
venting clonogenic recovery only in
ETO-treated cells (Fig. S5), which
indicates the importance of autophagy
for cell survival after DNA damage.
We then assessed immunostaining for p16ink4a and LAMP2
in the presence and absence of Baf post ETO treatment. LAMP2
is an important regulator of lysosomal biogenesis, required for
the maturation of functional autophagosomes. In control,
untreated cells, p16ink4a was observed in~5% of cells as small
aggresomes, surrounded by LAMP2-positive foci (data not
shown). In ETO-treated cells (day 4), the cytoplasm was highly
enriched with LAMP2, while p16ink4a-positive aggresomes
(larger and more numerous than in control) were sequestered in
Figure 4. OCT4A suppresses p21, G2 arrest and induces senescence. PA-1 cells were treated with ntg-
siRNA or OCT4-siRNA for 24 h before treatment with 8 mM ETO for 20 h and replacement with fresh
media. (A) Protein expression was assessed at the indicated time points by immunoblotting. Cell lysates
were made and assessed by immunoblotting for pCHK2, RAD51, p53, p21Cip1, OCT4A and GAPDH as a
loading control. (B) Cells were ﬁxed, stained with PtdIns and analyzed by ﬂow cytometry. Both ntg-
siRNA treated and OCT4-siRNA treated cells underwent a G2M arrest followibg ETO treatment, which is
more profound at day 3 and 5 in OCT4A-siRNA-treated cells. There is subsequently a much lower extent
of cell death (sub G1) in OCT4A-siRNA treated cells. (C) The G2M arrest was calculated from the DNA
histograms shown in (B) and demonstrate signiﬁcantly higher levels in OCT4A-silenced cells (*p < 0.05,
n D 3). (D) PA-1 cells were treated with ETO as above and assessed for Sa-b-gal activity after 5 d Senes-
cence, as monitored by Sa-b-gal activity, was increased by OCT4A-silencing. Both ntg-siRNA and
OCT4A-siRNA treated cells became large following ETO treatment but non-silenced cells lacked Sa-
b-gal activity.
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autophago-lysosomes (Fig. 9 A and B). Approximately 30% of
cells were seen to accumulate large amounts of p16ink4a in mul-
tiple aggresomes, as measure by >3 aggresomes and/or diffusely
detected within cytoplasm, or in large vacuoles (Fig. 9A-C), and
often showed DNA in cytoplasm (Fig. 9C). The proportion of
such cells, with high levels of p16ink4a, increased fold2- (29 § 6
.5 and 58 § 3 .5, C/¡ Baf, respectively) as measured on day 4.
These observations indicate the important role of autophagy in
sequestering and degrading p16ink4a in ETO-treated PA-1 cells,
thus preventing senescence. They also show that a considerable
proportion of ETO-treated cells suffer from exhaustion of
autophagy.
Failure of autophagy to sequester p16ink4a in the cytoplasm
is accompanied by drastic nuclear changes and loss of DNA
In ETO-treated samples counterstained with DAPI, we noted
that the failure of macroautophagy to control and sequester
p16ink4a in the cytoplasm coincided with prominent changes in
cell nuclei, particularly following Baf treatment. Nuclei became
thinner, less intensely DAPI-stained (e.g. Fig. 9C), or, more fre-
quently, displaced to one of the cell poles by large autophagic
vacuoles (Fig. 9B). Twisting, thinning, and disintegrating cell
nuclei were the main phenotypes of ETOCBaf-treated cells. As
detailed above, in their extreme distortions, the cell nuclei were
displaced and squeezed by large autophagic vacuoles and attained
a sickle-like shape (Fig. 9D). It remains possible that the loss of
sequestration of p16ink4a, distortion of cell nuclei and loss of
DNA are all linked, belonging to a related series of processes
associated with exhausted autophagy, which is further exagger-
ated by Baf where full disintegration of the cell nucleus and alve-
olar LC3-positive cytoplasm are evident (Fig. 10 A).
Trying to understand how the penetrability of the cell nuclei
was related to DNA damage we stained with an antibody (PL2–
6) which detects a unique epitope involving a ternary complex of
histones H2A and H2B and DNA at the site of the chromatin
attachment to lamin B1.32 We applied it to ETO-treated cell
nuclei (day 4) combining it with a label for DNA damage
(pCHK2). The result shows (Fig. 10B) bright nuclear staining
with PL2–6 in cell nuclei without DNA damage and its reduc-
tion in cell nuclei containing DNA damage, possibly suggesting
that binding to lamin B receptors in compromised.
In view of this data, we decided to use detailed stoichiometric
DNA image cytometry following ETO treatment in the presence
or absence of Baf. Typical histograms from one representative
experiment are shown in Fig. 10C, while in Fig. S6 comparative
DNA histograms of selected normal- and sickle-shaped cell
nuclei from ETOCBaf treatment are presented. Measurements
from ETO-treated cells revealed a peak of delay in late S-phase,
which was augmented after Baf treatment showing apparent
redistribution from G2 (4C) into <4C, which was exaggerated
in selected sickle-type nuclei of ETOCBaf-treated cells (Fig. S6).
These data support our microscopic observations that DNA is
preferentially lost from the sickle-like shape nuclei in the cells as
a result of failed autophagic processing with the proportion of
sickle-like nuclei cells with sickle-like nuclei in ETO-treated sam-
ples increased more than 2-fold (2.38 § 0.2) following Baf treat-
ment (n D 3).
Discussion
In this study, we expanded our investigation of the response of
PA-1 embryonal carcinoma cells to DNA damaging chemother-
apy. We previously observed,24 a concurrent p53-dependent
increase in OCT4A and p21Cip1 protein expression after ETO-
treatment, with the resulting cells transiting through an appar-
ently bi-potential state with hallmarks of both premature multi-
centriolar mitoses and senescence. Herein, we extended our anal-
ysis and highlight a hitherto unobserved DNA damage response
(DDR) function of OCT4A following ETO treatment, which is
different from its established pluripotency and self-renewal
functions. This p53-dependant DDR-induced OCT4A is not
coordinated with SOX2 or NANOG activity, but does serve
to suppress p21Cip1. This finding is in accord with the pre-
viously shown observation that OCT4A can directly repress
p21Cip1 expression by binding its promoter in the absence
of SOX2 and NANOG. 33 Although not yet confirmed in
other cell types or following different stimuli, this phenome-
non likely relates to properties evidenced during embryonal
‘stemness’, as similar nuclear accumulation of OCT4A was
similarly recently reported following laser beam damage of
live ESC cells.34
Figure 5. OCT4A silencing inhibits clonal recovery of ETO-treated PA-1
cells. PA-1 cells were treated with ntg-siRNA or OCT4A-siRNA for 24 h
before treatment with 8 mM ETO for 20 h and replacement with fresh
media. Cells were maintained until day 11. Clonal recovery was observed
in non-silenced cells but not in OCT4A-silenced cells, which maintained
a ﬂat senescent like morphology. (B) Cells were ﬁxed, stained with PI and
analyzed by ﬂow cytometry. A return of the G1 peak was observed in
non-silenced ntg cells whereas OCT4A-silenced cells maintained a pro-
found G2 arrest. OCT4A-silenced cells entered rounds of endoreduplica-
tion with genomes as large as 32C observed.
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Our measurements of OCT4A and p21Cip1 expression in
individual cells revealed that cell fate, in response to extensive
DNA damage, occurs with high levels of heterogeneity. Both fac-
tors increase coordinately with huge variations in expression, cov-
ering (at day 5) a wide spectrum of p21Cip1 and OCT4A
expression.35 These observations demonstrate a typical character-
istic of self-organizing, adapting systems, using heterogeneity
over time to provide bifurcations of cell fate choice.36,37 The
increased variance in both factors – from day 3 until day 7 – cor-
responds to the period with most prominent cell death (99% cells
will die and only <1% has the chance to survive, likely represent-
ing the degree of challenge that they must overcome).24 When
OCT4A is silenced the level of p21Cip1 increases, more cells
enter senescence and mitotic recovery is reduced, abrogating frag-
ile balance in bifurcation point and removing the possibility for
rare cells to choose survival as their fate. It is worth noting that
this response was phenotypically identical to that seen when
silencing p53.24 We hypothesize that the loss of p53 or OCT4A
in silencing experiments causes the loss of the embryonal G2M
checkpoint leading to increased mitotic slippage, ultimately end-
ing in terminal senescence rather than executing the G2M check-
point function via apoptosis. Continued silencing of OCT4A
inhibited clonogenic recovery post ETO treatment highlighting
the importance of the pre-senescent G2M arrest for clonogenic
recovery of the small percentage of cells that are able to repair
their DNA damage. Silencing of OCT4A also leads to endorepli-
cation in senescent cells further eluding to the presence of mitotic
slippage.38 p21Cip1 silencing experiments demonstrated that the
observed G2M arrest was independent of p21Cip1 expression.
Mitotic survival of the ETO-treated cells ultimately originates
from metastable pre-senescence. Theoretically, this means that
the self-renewal function of OCT4A is finally restored. The
attractor of self-renewal fate in individual cells is high
NANOG,39 released from direct suppression by p5340 and acti-
vated by OCT4A-SOX2 heterodimer. Although NANOG is
only found in a very small number of PA-1 cells, its role requires
further exploration.
This moderator function of DDR-induced OCT4A occurs
alongside activation of AMPK. AMPK is an evolutionary con-
served low-energy checkpoint that operates as a master regulator
of cellular metabolism and activator of autophagy. AMPK also
acts as a genomic stress sensor that is required for the adaptation
of metabolism switches and the DDR for efficient repair of
DNA.41 We previously observed a bidirectional relationship
between AMPK and ATM/CHK2 pathways that integrates both
the metabolic and DNA damage stress signaling.42 AMPK activa-
tion was previously shown as necessary for maximal stress-
induced transcription of p53-dependent genes that promote cell
Figure 6. p21Cip1 expression does not affect G2M arrest in response to ETO treatment of PA-1 cells. PA-1 cells were treated with ntg-siRNA or p21Cip1-
siRNA for 24 h before treatment with 8 mM ETO for 20 h and replacement with fresh media. (A) Expression of OCT4A, p21Cip1 and p53 were assessed at
the indicated time points by immunoblotting. GAPDH was used as a loading control. (B) Cells were ﬁxed, stained with PtdIns and analyzed by ﬂow
cytomtery. Both ntg-siRNA treated and p21Cip1-siRNA treated cells underwent a comparable G2M arrest after ETO treatment. (C) There was no signiﬁ-
cant difference in G2M arrest between p21Cip1 silenced and non-silenced cells.
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Figure 7. Activation of AMPK and OCT4A in response to ETO-treatment. PA-1 cells were treated with 8 mM ETO for 20 h and replacement with fresh
media. Cells were harvested after 4 d before immunoﬂuorescent staining for OCT4A, pAMPKThr172 and DAPI. (A) Non-treated (upper panel) and ETO-
treated (lower panel) samples were compared. AMPK and OCT4 are both activated by ETO (day 4) in interphase cells, however pAMPK is located in multi-
ple centrosomes of arrested metaphases, while OCT4A does not; (B) scatterplot of image cytometry of OCT4A and pAMPK in individual cells assessed on
day 4. There is a clear correlation between enhanced expression of OCT4A and pAMPKThr172 of ETO-treated cells; (C) OCT4A and pAMPKThr172 immunoﬂu-
orescence in PA-1 cells 4 d after ETO-treatment. OCT4A and pAMPKThr172 are mostly expressed in the same interphase nuclei, but an extremely high sig-
nal of pAMPK but not OCT4A is found within apoptotic cells. Staining of pAMPKThr172 is associated with euchromatin, while the pattern of OCT4A
staining is karyoplasmic (not bound to the chromatin). BRG – a 3-band optical ﬁlter. Bars =20 mm.
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survival.43 Interestingly, AMPK has also been shown to activate
and stabilize p53.44,45 Thus, the energetic stress-response of
AMPK is tightly linked to the DDR of p53. The role of AMPK
in the autophagy and cell death response after ETO has previ-
ously been reported.30
We previously revealed the p53-dependant DDR-induced ele-
vation in OCT4A in PA-1 cells following ETO treatment.
Therefore, it was not unexpected that DDR-induced OCT4A
and AMPK activation should be coordinately regulated by ETO
as we observed here. We found that while autophagy apparently
remains functional, cells retaining both AMPK and DDR-
induced OCT4A in cell nuclei are capable of preventing terminal
senescence. This data are in accordance with the report by Chiti-
kova and colleagues, 46 who demonstrated that silencing mTOR
(the antagonist of AMPK suppressing autophagy) in irradiated,
apoptosis-resistant cells caused a reversal of senescence. Thus
OCT4A moderating p21Cip1 in collaboration with
pAMPKThr172, supporting cells with metabolites and energy
through autophagy and other means, channel cells through disa-
daptation chaos caused by high DNA damage toward a survival
phenotype. ETO-treated PA-1 cells
struggle against terminal senescence in
particular by autophagic sequestration
and removal of its regulator p16ink4a.
There is much controversy regarding
markers of terminal senescence and
even what the process really is. It has
become recently apparent that terminal
senescence is not only growth arrest,47
moreover, it is intrinsically associated
with the origin of EMT22 and predicts
poor clinical outcome after cancer
treatment.48
In our previous and current article
we have partly unravelled a mechanism
showing that in response to DNA dam-
age p53 induces 2 regulators of oppo-
site cell fates. The setting is interesting:
although they both are positively regu-
lated by the same up-stream inducer,
OCT4A suppresses p21Cip1, while the
latter does not directly suppress
OCT4A. Nevertheless, the scattering of
the cells in expression of both through
the phase space ending up in one of 2
cell fates presumes their reciprocity.
The observation of cell-to-cell variabil-
ity can also be a result from biological
oscillations in time.49 The best docu-
mented example of this is the p53-
mdm2 oscillating system in which p53
oscillations are, indeed, crucial for cell
recovery after DNA damage.50 It is,
therefore, possible that heterogeneity in
p53 due to oscillations results in down-
stream heterogeneity of both OCT4A
and p21Cip1 in PA-1 cells.
Senescence is intrinsically associated with macroautophagy
induction (regulated by AMPK and persistent DNA damage). 51
Here, we found that persistent DNA damage was associated with
destruction of the ternary complex of histones (H2A and H2B)
and DNA in their attachment to nuclear lamin B1 using a unique
antibody reagent.32 This observation is in keeping with data of
the thinning and disassembly of lamin B1 and leakage of DNA
from cells as a feature of terminal senescence.52
Our DNA cytometric observations revealed a delay in late S-
phase after ETO, augmented by BafA1. The consequence of this
delay would be under-replication of heterochromatin,53 appear-
ance of single strand DNA breaks, demethylation and activation
of the transposable elements (TE) ALU/LINE 1, whose mobility
after ETO has already been described.54 As sequestering ALU
mRNA and LINE 1 by autophagy in the cytoplasm has been
reported as a mechanism for protecting against transposition,55 it
therefore remains possible, (although purely speculative) that
functional autophagy prevents terminal senescence in this man-
ner also. The model with the scenario of terminal senescence
Figure 8. Assessment of macroautophagy following ETO treatment (day 4). PA-1 cells were treated
with 8 mM ETO for 20 h and replacement with fresh media in the presence or absence of Baf. Cells
were then stained for p62 and the number of p62 positive bodies per cell counted. (A) Immunoﬂuror-
escent examples of staining for p62 showing foci (p62 bodies) in control and ETO-treated cells. (B) Rep-
resentative histograms of p62 bodies/cell. (C) The average number of p62 bodies per cell was
compared for NT and ETO treated cells from 3 independent experiments (* p< 0.05, n D 3 ) indicating
activation by autophagy. (D) Immunoblotting analysis of the ratio of LC3A and LC3B with and without
Baf treatment post ETO treatment. Enhanced levels of LC3B in relation to LC3A as a result of Baf treat-
ment indicates interruption of autophagic ﬂux in ETO treated cells. Bars D 20mm.
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occurring due to activation of TE as
discussed in several other studies.56-58
It follows then that terminal senescence
may in fact be mainly triggered by sev-
eral mechanisms, which potentiate each
other and result from failure of autoph-
agy. Thus, autophagy should be a key
target for preventing resistance of can-
cer stem cells to genotoxic therapies, a
supposition supported by others.59,60
Materials and Methods
Cells
PA-1 is an ovarian teratocarcinoma
(a germline tumor) cell-line, obtained
from ATCC, with a stable near-diploid
karyotype.61 It possesses functional
p53, in spite of possible acquisition of
one mutated allele reported at passages
over 407.62 Importantly it retains the
ability to differentiate into all 3 tissue
types, thus possessing the features of
embryonal carcinoma.61 The NTera 2
(NT2) cell line, obtained from ATCC
and used as a positive control for plur-
uipotency genes OCT4A, SOX2 and
NANOG.
Antibodies
Primary antibodies and their uses
are detailed in Table 1. Secondary anti-
bodies and their uses are detailed in
Table 2.
Cell culture and treatment
PA-1 cells were cultured in Dulbecco’s modified Eagle’s media
(DMEM) supplemented with 10% foetal bovine serum (FBS) if
not otherwise stated. NT2 cells were cultured in Dulbecco’s
modified Eagle’s media (DMEM) supplemented with 10% foetal
bovine serum (FBS). Cells were grown without antibiotics in 5%
CO2 at 37
C. Exponentially growing PA-1 cells were incubated
with 4–8 mM ETO for 20 h. Following ETO treatment, cells
were maintained by replenishing culture medium every 48h.
Bafilomycin A (Baf A, Cayman Chemicals) 50 nM was added to
the culture medium for 24h between day 3 to 4 after 20h treat-
ment with 8 mM ETO.
Flow cytometry
Cells were harvested at relevant time points, washed in cold
PBS and fixed with 70% ethanol for 20 min at room tempera-
ture. After two washes in tris buffered saline (TBS), cells were
permeabilised with TBS/4% bovine serum albumin (BSA)/0.1%
Triton X-100 for 10 min at room temperature. Samples were
then incubated with mouse monoclonal anti-OCT4 antibody
solution (Santa Cruz) and rabbit polyclonal p21Cip1 (Pierce) in
TBS/4% BSA/0.1% Triton X-100 for 1h at room temperature.
Following two washes in TBS, cells were incubated with goat
anti-rabbit- IgG-Alexa Fluor 488 (A31627, Invitrogen) and
Chicken anti-mouse IgG-Alexa Fluor 647 (A21463, Invitrogen)
(1:200) in TBS/4% BSA/0.1% Triton £ 100, for 30 min in the
dark. DNA was counterstained with 10 mg/ml propidium iodide
(PtdIns) in PBS, and assessed by flow cytometry using a FACS
Aria (BD Biosciences) using Cell Quest Pro Software). Data was
analyses using FlowJo analysis software.
Immunofluorescence
Cells were suspended in warm FBS and cytospun onto glass
slides. Cytospins were fixed in methanol for 7 min at ¡20C
and dipped 10 times in ice cold acetone. Slides were then washed
thrice in TBS 0.01% Tween 20 (TBST) for 5 min. Slides were
subsequently blocked for 15 min in TBS, 0.05% Tween 20%,
1% BSA at room temperature. Samples were covered with TBS,
0.025% Tween 20%, 1% BSA containing primary antibody and
incubated overnight at 4C in a humidified chamber. Samples
Figure 9. The relationship between autophagy functionality and senescence marker p16ink4ain ETO-
treated PA-1 cells. PA-1 cells were treated with 8 mM ETO for 20 h without or with Baf, prior to media
being removed and replaced with fresh media; cells were harvested 48h later (day 4). (A, B) imuno-
ﬂuorescent staining for p16ink4a (red), LAMP2 (green) or DAPI (blue). (A) As shown via the BRG optical
ﬁlter, (B) only the green ﬁlter for LAMP2 demonstrating high level of functional autophagy sequestrat-
ing p16ink4a- containing aggresomes. (B, C) show examples of autophagic failure, where on (B)
sequestration of p16ink4a is partly lost, diffusing in to the cytoplasm, while on (C) the dysfunction of
autophagy is evidenced by a large vacuole overloaded with undigested p16ink4a. In all 3 cases, the
nuclei are impaired: (B) ‘laced’; (C) displaced and twisted by a large autophagic vacuole with some
DNA lost from cell nucleus observed. These processes were observed both in ETO-treated (B) and
more commonly in ETOCBAF(c) treated cells. (D) An image showing cell nuclei of normal and sickle-
type shape as stained speciﬁcally for DNA with Toluidine bluein the ETO-teated specimen (sickle-like
shaped nuclei are shown with arrows).
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were then washed thrice in TBST and covered with TBST con-
taining the appropriate secondary antibodies (Goat anti-mouse
IgG Alexa Fluor 488 (A31619, Invitrogen) and Goat anti-rabbit-
IgG Alexa Fluor 594 (A31631, Invitrogen)) and incubated for
40 min at room temperature in the dark. Slides were washed
thrice for 5 min with TBST and once for 2 min in PBS. Samples
were then counterstained with 0.25 mg/ml DAPI for 2 min, and
finally embedded in Prolong Gold (Invitrogen). When staining
for p-AMPKa1/2 (alone or in combination with the antibody
for OCT4), fixation in 4% paraformaldehyde for 15 min was
used, followed by washing thrice in PBS 0,1% glycine. Primary
antibodies and their source are listed in Table 1.
Microscopy and immunofluorescence image cytometry
Slides were evaluated using a Leitz Ergolux L03–10 micro-
scope equipped with Sony DXC 390P color video camera, for
Figure 10. ETO and ETOCBaf impair cell nuclear integrity causing a delay in late S-phase in a proportion of cells with persistent DNA damage. (A) Disinte-
gration of the nucleus is observed in ETO treated cells following prolonged Baf exposure (72h), where impaired autophagic ﬂux is conﬁrmed by alveolar
structure of LC3B-positive cytoplasm in the absence of LC3 foci; Bars D 20 mm. (B) Persistent DNA damage leads to destruction of the epichromatin ter-
nary complex (a speciﬁc conformation of nucleosomes attached to lamin B1) seen by a decrease in staining by the Pl2–6 antibody where Chk2-positive
foci is detected in ETO-treated PA1 cells at day 4. (C) Representative DNA histograms obtained by image cytometry of ETO-treated and ETOCBAF-treated
cells samples (day 4 after treatment); one of 3 independent experiments. BafA alone causes partial arrest in G1 in control (NT)cells and a subsequent
decrease of the G2 fraction; ETO-treatment induces G2-arrest, however, a proportion of cells remain delayed in late S-phase (<4C). Cells with the DNA
content <4C and 4C(G2) still reach peaks of corresponding doubling, <8C and 8C. Suppression of autophagy by Baf in ETO-treated cells favors an
increase of the proportion of cells in the <4C fraction and reduces the number of cells.
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microscopic observations; in addition to separate optical filters, a
3-band BRG (blue, red, green) optical filter (Leica) was used.
Image cytometry was carried out by semi-automatic measuring
fluorescence values for each cell nuclei in all 3 channels and ana-
lyzed using Image-Pro Plus 4.1 software (Media Cybernetics).
Apoptotic cells, determined by nuclear morphology, were omit-
ted from measurements.
DNA image cytometry
For DNA cytometry measurements, stoichiometric toluidine
blue DNA staining was performed as previously.63 In brief,
cytospins were fixed in ethanol:acetone (1:1) for >30 min at
4C and air dried. Slides were then treated with 5N HCl for
20 min at room temperature, washed in distilled water (5 £
1 min) and stained for 10 min with 0.05% toluidine blue in
Table 1. Primary antibodies
Antibody against Description Speciﬁcity/immunogen Product nr and Manufacturer Use*
AURORA B Rabbit polyclonal Peptide derived from within residues 1
– 100 of Human Aurora B
ab2254, Abcam IF
p16INK4a Rabbit polyclonal C-terminus of human p16 ab7962, Abcam IF
pCHK2 (phospho T68) Rabbit polyclonal Epitope around the phosphorylation
site of Threonine 68 (VSTpQE) of
human Chk2
ab38461, Abcam IF, W
GAPDH Mouse monoclonal, clone 6C5 Rabbit muscle GAPDH ab8245, Abcam W
LAMP-2 Mouse monoclonal The details of the immunogen for this
antibody are not available.
ab25631, Abcam IF
LC3A/B Rabbit polyclonal Synthetic peptide between amino
acids 1–100 of the human LC3
protein
PA1–16930, Pierce IF
LC3B Rabbit polyclonal Peptide derived from within residues 1
– 100 of Human LC3B
ab63817, Abcam IF
NANOG Mouse monoclonal, clone
NNG-811
Against human Nanog. N3038, Sigma IF
NANOG (23D2–3C6) Mouse monoclonal Full-length human recombinant
protein expressed in bacteria
MA-1–017, Pierce IF
NANOG H-155 Rabbit polyclonal epitope corresponding to amino acids
151–305 mapping at the C-terminus
of Nanog of human origin
sc-33759, Santa Cruz IF
OCT3/4 Mouse monoclonal Peptide raised against amino acids 1–
134 of Oct-3/4 of human origin non
cross-reactive with Oct-3/4 isoforms
B and B1
sc-5279, Santa Cruz IF, F, W
OCT4 Rabbit polyclonal, ChIP Grade Peptide derived from within residues
300 to the C-terminus of Human
Oct4
ab19857, Abcam IF, W
p21Cip1 Rabbit polyclonal Raised against a peptide mapping at
the C-terminusof p21 of human
origin
sc-397, Santa Cruz IF
p21Cip1 Rabbit monoclonal Synthetic peptide corresponding to
residues near the carboxy-terminus
of human p21
MA5–14949, Pierce IF, F, W
p-AMPKa1/2 (Thr183/
172)
Rabbit polyclonal Epitope corresponding to
phosphorylated Thr 172 of AMPKa1
of human origin
sc-101630, Santa Cruz IF
PL2–6 Mouse monoclonal autoimmune anti-nucleosome
antibody speciﬁcally recognizes the
peripheral surface of interphase
chromatin and mitotic
chromosomes, epichromatin
epitope
A kind gift from Olins.32 IF
SOX2 Mouse monoclonal Full-length human recombinant
protein expressed in bacteria
MA1–014, Pierce IF, W
SOX2 Rabbit polyclonal Epitope corresponding to amino acids
131–195 of Sox-2 of human origin
sc-20088x, Santa Cruz IF
SQSTM1 (p62) Rabbit polyclonal Epitope corresponding to amino acids
151–440 of SQSTM1 of human
origin.
sc-25575, Santa Cruz IF
*W, western; IF, immunoﬂuorescent staining; F, ﬂow cytometry.
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50% citrate-phosphate McIlvain buffer pH 4. Slides were
rinsed with distilled water, blotted dry and dehydrated in
butanol for 2£3 min at 37C. Samples were then incubated
twice in xylene for 3 min each at room temperature and
embedded in DPX (Sigma). DNA content was measured as
the integral optical density with a calibrated Sony DXC 390P
video camera in the green channel. Nuclear area was calculated
using Image-Pro Plus 4.1 software (Media Cybernetics). Apo-
ptotic cells were omitted from measurements. The stoichiome-
try of DNA staining was verified using the values obtained for
metaphases compared to anaphases and telophases (ratio 2.0);
the summary error of the method and device was estimated to
be less than 5%.
DNA flow cytometry
Cells (including those in media) were harvested at indicated
time points, washed in PBS and re-suspended in hypotonic fluo-
rochrome solution [50 mg/ml propidium iodide (PI), 0.1% (w/
v) sodium citrate, 0.1% (v/v) Triton-X-100] and stored for at
least 1 h in the dark at 4C. Flow cytometry was performed using
a FACScan (BD Biosciences) or AccuriTM C6 Cytometer (BD
Biosciences). Data was analyses using FlowJo analysis software.
Detection of sa-b-galactosidase activity
The senescence b-galactosidase (sa-b-gal) staining kit (Cell
Signaling Technology, UK) was used to detect sa-b-gal activity
in cells according to the manufacturer’s protocol.
Immunoblotting
For whole-cell lysates, cells were harvested, washed once with
PBS and lysed using RIPA buffer containing protease inhibitor
cocktail (Sigma P8340). Protein concentrations were determined
by Bradford assay (Thermo Scientific), with 10–30 mg of total
protein separated on 20% SDS polyacrylamide gels followed by
electrophoretic transfer onto BA85 nitrocellulose membranes
(Schleicher & Schuell GmbH) overnight. Equal protein loading
in each lane was confirmed by Ponceau S staining. Blots were
probed with appropriate antibodies primary and secondary
detected using ECL Western Blotting Substrate (PierceTM,
32106).
For comparison of OCT4 isoforms protein was transferred
onto immobilon-FC transfer membrane and probed with pri-
mary antibodies. Blots were then probed with fluorescent second-
ary antibodies and the signal was visualized using a LICOR
Odyssey imaging system.
Small interfering RNA (siRNA) silencing
FlexiTube siRNA (SI04950274, SI04950267, SI04153835
and SI00690382; Qiagen) was used to silence OCT4A expres-
sion, and FlexiTube siRNA (SI00604905, SI00604898 and
SI00299810; Qiagen) was used to silence p21Cip1 expression.
ON-TARGET plus non-targeting siRNA #1 (Dharmacon) was
used as a negative control. Cells were transfected with siRNA
using HiPerfect (Qiagen) according to the manufacturer’s
protocol.
Methods of statistical analysis
Statistical analysis was performed in GraphPad (GraphPad
Software Ltd). Student t-test was used to calculate the statistical
significance of difference of means where appropriate. Statistical
significance was accepted when p < 0.05. Graphs were plotted in
GraphPad Prism 5 and IBM SPSS statistics 22.
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Abstract
‘Neosis’ describes the process whereby p53 function-deficient tumour cells undergo self-renewal after genotoxic damage
apparently via senescing ETCs (endopolyploid tumour cells). We previously reported that autophagic digestion and
extrusion of DNA occurs in ETC and subsequently revealed that self-renewal transcription factors are also activated under
these conditions. Here, we further studied this phenomenon in a range of cell lines after genotoxic damage induced by
gamma irradiation, ETO (etoposide) or PXT (paclitaxel) treatment. These experiments revealed that chromatin degradation
by autophagy was compatible with continuing mitotic activity in ETC. While the actively polyploidizing primary ETC pro-
duced early after genotoxic insult activated self-renewal factors throughout the polygenome, the secondary ETC restored
after failed multipolar mitosis underwent subnuclei differentiation. As such, only a subset of subnuclei continued to express
OCT4 and NANOG, while those lacking these factors stopped DNA replication and underwent degradation and elimination
through autophagy. The surviving subnuclei sequestered nascent cytoplasm to form subcells, while being retained within
the confines of the old ETC. Finally, the preformed paradiploid subcells became released from their linking chromosome
bridges through autophagy and subsequently began cell divisions. These data show that ‘neotic’ ETC resulting from
genotoxically damaged p53 function-deficient tumour cells develop through a heteronuclear system differentiating the
polyploid genome into rejuvenated ‘viable’ subcells (which provide mitotically propagating paradiploid descendents) and
subnuclei, which become degraded and eliminated by autophagy. The whole process reduces aneuploidy in descendants
of ETC.
Keywords: autophagy; neosis; p53 mutant tumour; polyploidy; self-renewal; senescence
1. Introduction
Somatic polyploidy (endopolyploidy) and autophagy are paradox-
ically involved in execution of the opposing effects on tumour
growth. While most ETC (endopolyploid tumour cells) induced after
genotoxic or spindle damage of tumour cells lacking wild-type p53
function are lost for reproduction through mitotic death, apoptosis,
necrosis or accelerated senescence (Ianzini and Mackey, 1997;
Mackey and Ianzini, 2000; Shay and Roninson, 2004;
Vakifahmetoglu et al., 2008), the capability of a small fraction of
ETC to depolyploidize and provide clonogenic descendants has
been repeatedly demonstrated (Baroja et al., 1998; Illidge et al.,
2000; Sundaram et al., 2004; Puig et al., 2008; Ianzini et al. 2009;
Vitale et al., 2010). In turn, although autophagy is a hallmark of
cellular senescence (Kondo and Kondo, 2006; Vellai, 2009), it is
activated upon acute induction of senescence (Galluzzi et al., 2009;
Young et al., 2009) and may be oncosuppressive in certain contexts
(Morselli et al., 2009; Galluzzi et al., 2010) or, when excessive, may
accompany cell death (Scarlatti et al., 2009); both chemotherapy-
and metabolic stress-induced activation of the autophagic pathway
reportedly contributes to the survival of tumour cells (Edinger and
Thompson, 2004; Debnath et al., 2005; Morselli et al., 2009;
Galluzzi et al., 2010). In addition, autophagy extends organismal
lifespan (Madeo et al., 2010).
Several years ago Sundaram, Rajaraman and colleagues
(Sundaram et al., 2004; Rajaraman et al., 2006; Rajaraman et al.,
2007) proposed the ‘neosis’ hypothesis to explain the rejuvenation
and restoration of immortality through the descendents of sup-
posedly senescing ETC based upon their interpretations of live cell
imaging experiments. Subsequently, Tam et al. (2007) suggested
that the reverse of cellular senescence may be associated with the
capability of aging somatic cells to reactivate key embryonal
proteins. Blagosklonny (2007) suggested that proliferating progeni-
tors of cancer stem cells can be activated to become ‘stemloids’.
There are many indications in literature that cancer cells
1 To whom correspondence should be addressed (email katrina@biomed.lu.lv).
Abbreviations: ELCS, envelope-limited chromatin sheet; ETCs, endopolyploid tumour cells; ETO, etoposide; FCS, fetal calf serum; FMM, failed multipolar
mitosis; IF, immunofluorescence; MDC, monodansylcadaverin; PXT, paclitaxel.
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can overcome senescence (for example, Elmore et al., 2005;
Roberson et al., 2005; Sabisz and Skladanowski, 2009). We
recently (Salmina et al., 2010) found that up-regulation of
embryonal self-renewal factors occurs in ETC induced after
genotoxic insult and that this up-regulation is transmitted to the dau-
ghter cells upon depolyploidization. On the whole, up-regulation of
pluripotency and self-renewal transcriptional factor NANOG was
shown to antagonize activation of senescence regulator p16, and
the latter further takes over only in a proportion of ETC (Salmina
et al., 2010). These observations supported our previous finding
that while a proportion of p53-deficient ETC activate senescence-
associated b-galactosidase and down-regulate Aurora B-kinase,
the other ETC continue its expression and division activities into the
second week post-irradiation (Erenpreisa et al., 2008). Moreover, we
and others also demonstrated (Erenpreisa et al., 2005; Kalejs et al.,
2006; Ianzini et al., 2009; Erenpreisa et al., 2009; Vitale et al., 2010)
that meiosis-specific genes and proteins are activated by stress-
induced mitotic catastrophe and in resulting ETC, which are capable
to undergo reduction divisions. Through live cell imaging, we further
demonstrated that the progeny originated via depolyploidization
retain proliferative capacity evidenced by their ability to produce
colonies of mitotically dividing cells (Ianzini et al., 2009)
The central issue in this process of neosis is how depolyploi-
dization and survival can be executed in a potentially mortal ETC, at
the cellular and molecular level. Our first insight into the facet of this
problem came over a decade ago where we demonstrated the dual
activities of ETC in producing mitotic descendents and simulta-
neously undergoing partial chromatin degradation. In this latter
process, a considerable portion of genetic material in viable ETC
undergoes autophagic digestion and extrusion, indicating some
form of sorting (Erenpreisa et al., 2000; commented by Wheatley,
2006). Further EM (electron microscopy) analysis showed that
autolysosomes degrading the DNA are frequently induced in the
cytoplasmic pockets of the nuclear ELCSs (envelope-limited
chromatin sheets) (Erenpreisa et al., 2002), the structures whose
role may be right in settling the chromosomes in the cell nuclei
(Olins and Olins, 2009; Olins et al., 2011). Here, we extend our initial
observations by revealing that different parts within the same
multigenomic ETC can undergo degradation or self-renewal in
order to give rise to viable clonogenic paradiploid survivors.
2. Materials and methods
2.1. Cell lines
Namalwa, Ramos and HeLa cell lines were obtained from the
ATCC. The lymphoblastoma WI-L2-NS was obtained from Dr P.
Olive (Canada). All cell lines are p53 function deficient. Lymphoma
cell lines (Namalwa, Ramos, WI-L2-NS) were maintained in RPMI-
1640 containing 10% heat-inactivated FCS (fetal calf serum;
Sigma) at 37uC in a 5% CO2 humidified incubator. HeLa S3 cells
were grown in suspension under constant rotation in Joklik’s MEM
containing 10% heat-inactivated calf serum (Hyclone) and anti-
biotics. The adherent HeLa cells were cultured on glass cover
slides in HAM-1 (Sigma) medium supplied with 10% FCS.
2.2. Cell treatments
For experimental studies, cells were maintained in log phase of
growth and treated with a single acute 10 Gy dose of gamma
irradiation (1–2 Gy/min, Clinac 600 C, Varian Medical Systems
or using a Gulmay D3 225 X-ray source at a dose rate of 0.77
Gy/min), ETO (etoposide; Sigma) – 8 mM for 20 h or PXT
(paclitaxel, Ebewe Pharma) – 50 nM for 20 h. Cell cultures were
further fed every 2–3 days and sampled over a 2-week period
posttreatment. To determine the capacity of cells to replicate
DNA, BrdU was added at 5 mM to the cell culture for,24 h prior to
fixation of cytospins with methanol as described previously
(Erenpreisa et al., 2009).
2.3. Microscopy
A fluorescence light microscope (Leitz Ergolux L03-10) equipped
with a colour videocamera (Sony DXC 390P) and a confocal laser
microscope (Leica DM600) were used to capture fluorescent
images. Phase contrast photography was performed using a light
microscope (AxioImager A1, Carl Zeiss).
2.4. Cytological staining and DNA cytometry
For cytological studies, the cells were suspended in warm FCS
and cytospun onto glass slides, fixed in cold ethanol/acetone
(1:1) and air dried. Slides were hydrolysed with 5 N HCl for 30–60 s
and stained with 0.05% Toluidine Blue in McIlvain 50% buffer pH
4–5 for 10 min, rinsed, dehydrated in warm butanol and xylene
prior to embedding in DPX (Sigma–Aldrich).
To reveal NORs (nucleolar organizers), prefixed cytospins were
stained with a 50% aqueous solution of AgNO3 (Ural Factory of
Chemical Reagents) diluted with 2% gelatin (2:1) at 60uC for 5–6
min and counterstained with 0.1% Methyl Green (Sigma–Aldrich)
at room temperature for 1 min. This method is recognized as the
universal indicator of NOR activity (Bancroft and Stevens, 1996).
Lysosomal activity and autophagic vacuoles were detected by
staining for cathepsin B (see below) and with MDC (monodansyl-
cadaverin, Sigma). For MDC staining, cell cultures were incubated
with 0.05 mM MDC at 37uC for 1 h followed by fixation in 4%
paraformaldehyde and two washes in PBS. The slides were
counterstained with PI (propidium iodide; BD Biosciences
Pharmingem), mounted into Permount (Thermo Fisher Scientific)
and immediately imaged.
For conventional DNA staining, prefixed cytospins were
hydrolysed with 5 N HCl at room temperature for 20 min and
stained for 10 min with Toluidine Blue (pH 4.0). For DNA image
analysis of mitotic cells where vacuoles were visualized in the
cytoplasm, the hydrolysis with 5 N HCl was shortened to 30 s.
DNA content was measured as the integral optical density in the
green channel of the calibrated video camera using Image Pro
Plus 4.1 software (Media Cybernetics; REO 2001). After shortened
hydrolysis, interactive segmentation of mitotic figures was
applied. Stoichiometry of DNA staining was verified using rat
hepatocytes. With conventional 20-min acid hydrolysis, the 4C:2C
ratio was 1.970; measurement error 1.5% (n5309); with 30-s
hydrolysis, the 4C:2C ratio was 1.994; measurement error 0.3%
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(n5182). Diploid DNA values for tumour cells determined after
shortened hydrolysis were calculated by measuring metaphases
and anaphase halves in 50 untreated cells, in which the variability
coefficient was 7.7%.
2.5. IF (immunofluorescence)
Standard IF staining was performed according to procedures
detailed previously (Erenpreisa et al., 2008). The primary and
secondary antibodies used are given (Table 1). To detect protein
disulfide isomerase, SelectFX Alexa Flour 488 Endoplasmic
Reticulum Labeling Kit (S34200, Molecular Probes) was used
according to the manufacturer’s instructions.
3. Results
3.1. DNA-digesting autolysosomes appear in ETC late
on after genotoxic and spindle damage
Following genotoxic insult, Ramos, Namalwa, and WI-L2-NS cells
all undergo extensive polyploidization (Illidge et al., 2000; Ivanov
et al., 2003), form ETC and subsequently begin chromatin
extrusion coincident with the appearance of autolysosomes at
the nucleo-cytoplasmic border as previously described
(Erenpreisa et al., 2000, 2002). Many autophagic vacuoles could
be stained for both DNA and for the lysosomal activation marker
cathepsin B (Figure 1a) as well as for MDC, a marker of auto-
phagic vacuoles (Figure 1b; for control, see Supplementary
Figure S1 at http://www.cellbiolint.org/cbi/035/cbi0350687add.
htm). The chromatin eliminated by autolysosomes was shown to
be both TUNEL- (Erenpreisa et al., 2000) and c-H2AX-positive
(Figure 1c) indicating its selective nucleolytic degradation. The
degradation and extrusion of large amounts of DNA from viable
ETC was observed in lymphoma cell cultures after extensive cell
loss through apoptosis or necrosis from the end of the first week
postirradiation. In the control, untreated cells, polyploidy remained
at low levels (,4%), and chromatin extrusion was extremely rare.
These experiments were repeated on each lymphoma cell line at
least six times with similar results.
A similar phenomenon was observed in HeLa cells at 6–14
days postirradiation (Figures 1d, 1e; data from one of four similar
experiments) and at 4–6 days in WI-L2-NS and Namalwa cells
after ETO and PXT treatments (exemplified in Figure 1f; data from
one of three similar experiments). These data demonstrate that
in these surviving ETCs, chromatin is sorted into two categories –
one for preservation and the other for autodigestion and
Table 1 Antibodies: source and usage
Primary antibodies: Secondary antibodies (dilution, if not stated otherwise, 1:400)
Rabbit polyclonal anti-hOCT4 (ab19857, Abcam) 1:75–400
Blocking peptide (ab20650, Abcam)
Goat anti-rabbit-IgG Alexa Fluor 594 (A31631, Invitrogen)
Mouse monoclonal anti-hNANOG (N3038, Sigma) 1:50–75 Goat anti-mouse IgG-Alexa Fluor 488 (A31619, Invitrogen)
Rabbit polyclonal anti-hAurora B-kinase (Abcam, ab2254), 1:300 Goat anti-rabbit-IgG-Alexa Fluor 594 (A31631, Invitrogen)
Mouse monoclonal anti-hRAD51(ab213, Abcam) 1:100 Goat anti-mouse-IgG-Alexa Fluor 488 (A31619, Invitrogen)
Mouse monoclonal anti-h-b-TUBULIN (Neomarkers; clone DM1B) 1:100 Goat anti-mouse IgG-biotin antibody (1:100) (Vector Labs, UK)
and by streptavidin-FITC antibody (1:150) (Vector Labs, UK
Mouse monoclonal anti-a-tubulin mouse (Sigma, B-512) 1:2000 Goat anti-mouse IgG-Alexa Fluor 488 (A31619, Invitrogen)
Rabbit polyclonal anti-g-H2AX (Trevigen; AMS Biotechnology, U.K.
or 4411-PC-100, R&D Systems) 1:50
Goat anti-rabbit-IgG-Alexa Fluor 594 (A31631, Invitrogen)
Mouse monoclonal anti-bromodeoxyuridine (BdU) (A21300, Invitrogen) 1:200 Goat anti-mouse-IgG-Alexa Fluor 488 (A31619, Invitrogen)
Goat polyclonal anti-hRAD52 (C-17) (sc-7674, Santa Cruz) 1:50 Donkey anti-goat IgG-Alexa Fluor 488 (A11055, Invitrogen)
Rabbit polyclonal anti-hCATHEPSIN B (ab30443, Abcam) 1:100 Goat anti-rabbit-IgG-Alexa Fluor 594 (A31631, Invitrogen)
Figure 1 Chromatin extrusion, mitotic activity and DNA repair in ETCs
WIL-L2-NS ETC generated after irradiation (a) or ETO treatment (b) stained on day 8
with either DAPI (blue on ‘a’) or propidium iodide (red on ‘b’) to detect DNA and either
cathepsin B (red on ‘a’) or monodansylcadaverin (blue on ‘b’), as markers of
autophagy. These data indicate that autolysosomes contain DNA. (c) Namalwa ETC
induced by irradiation stained on day 5 for c-H2AX (red) and DAPI, indicating the
degradation of extruded chromatin (arrow); (d) HeLa ETC induced by irradiation stained
on day 14 with Toluidine Blue (pH 5) after short acid hydrolysis, displays mitotic
features and autophagic vacuoles (arrowed); (e) HeLa ETC stained with Toluidine Blue
(pH 5) after short acid hydrolysis on day 9 after irradiation, reveals multipolar bridged
anaphase and autophagic vacuoles (arrows); (f) WI-L2-NS ETC undergoing multipolar
mitosis on day 5 after paclitaxel treatment, a-tubulin (green), Aurora B-kinase (red) and
DNA (blue); multiple cytoplasmic ‘bubbles’ can be seen with destructured tubulin
containing the DAPI-positive DNA remnants (arrows); (g–h) Namalwa ETC stained 6
days after irradiation for Rad 51 or Rad 52 (labelled in green) repair foci and extrusion
of these recombinases are shown (arrows). In the inset to (h) only, the DAPI channel of
the same cell is showed to indicate the location of DNA in the marginal vacuoles at the
nucleo-cytoplasmic border (arrowed). The extruded chromatin is enriched with inactive
DNA repair factors; DNA repair foci are evident in the other ETC depicted in the figure.
Bars510 mm.
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elimination. Furthermore, it should be noted that the amounts of
chromatin degraded can be considerable, for example, greater
than 50% of a 16C ETC DNA content can be lost, and the whole
subnuclei may be extruded in this way (Figure 1e, see also in
Erenpreisa et al., 2000). As these cells possess the hallmarks
of lysosomal and autophagic activity, often used as markers of
senescence (Vellai, 2009), the question arises: are these cells
senescing and entering irreversible growth arrest?
3.2. Compatibility of chromatin extrusion and mitotic
activity in ETC
To address this question, we further analysed the ETC for signs of
mitosis and chromatin extrusion. As shown, it is clear that ETCs
are able to undertake mitotic activity (metaphase features in panel
d; multipolar mitosis in panel e) (in Figures 1d–1e). This appear-
ance was observed for all four cell lines. The question remains,
however, as to whether these cells are also actively engaging in
chromatin extrusion. Because of the proximity of what appears to
be autophagic vacuoles (arrowed bodies in Figures 1d and 1e), it
is tempting to speculate that the latter were extruded by the
former. Although this conclusion can only be inferred; neverthe-
less, the features present (Figure 4e) would account for such
interpretation. Thus, it is possible that chromatin extrusion may be
compatible with mitotic activity in ETC and that the latter are not
bone fide senescent cells (growth arrested by definition).
3.3. Chromatin extrusion in ETC is compatible with
DNA repair and may participate in chromatin
sorting
To address whether ETCs undergoing chromatin extrusion/
degradation were capable of undergoing DNA repair, we stained
ETC of Namalwa, HeLa and WI-L2-NS for the presence of DNA
repair foci as labelled by the twin recombinases RAD 51 and RAD
52. These experiments were repeated for each cell line at least
twice with similar results in each case. Again, because of the
vicinity of the features present (Figures 1g, 1h), it is tempting to
speculate that a portion of the ETC exerts both DNA repair and
autophagic activities. Rad 51 staining appears in autolysosomal
vacuoles as bundles of linearly arranged polymeric fibres
(Figure 1g), possibly due to the loss of its proper association with
Rad52 and DNA in the rejected chromatin (West, 2003). These
observations imply a prior chromatin sorting process, which may
occur during attempted DNA repair. It has been shown (Ivanov
et al., 2003) that this repair occurs extensively in 40–80% of ETC
before depolyploidization proceeds and requires suppression of
p53 function; thus, we were further interested as to how these
processes might relate to our recent findings regarding ETC and
stem cell gene transcription (Salmina et al., 2010).
3.4. Diverse fate of sub-nuclei in late ETC
Most (,90%) ETC, which are formed by mitotic slippage from p53
function-deficient lymphoma cells after gamma irradiation begin to
up-regulate the key germline transcription factors OCT4 and
NANOG on days 3–5 postirradiation. These findings were
observed in WI-L2-NS and Namalwa cells in greater than six expe-
riments. In a similar fashion, HeLa cells displayed an up-regulation
of these transcription factors (from a very low background level
in untreated controls cells; data not shown), with an enhanced
cytoplasmic expression (mostly in the centrosome) seen on days
4–5 postirradiation in most cells (Supplementary Figure S2a at
http://www.cellbiolint.org/cbi/035/cbi0350687add.htm). However,
nuclear up-regulation of OCT4/NANOG as exemplified (Supple-
mentary Figure 2b) was found in only 5–10% of endopolyploid
HeLa cells in three similar experiments.
Up-regulation was also found after treatment of WI-L2-NS cells
with the radiomimetic ETO (not shown) and the stabilizer of
microtubules PXT, where 98 and 85% of ETC, respectively,
demonstrated a 2- to 3-fold increase of these germline transcrip-
tion factors (typical staining is shown in Supplementary
Figures 2c, 2d; representative of greater than three experiments).
From day 5 to day 6 after these treatments, the surviving ETC of all
cell lines initiated depolyploidization such that ETCs were found in
bipolar and multipolar divisions, some after skipping S-phase
(Erenpreisa et al., 2005, 2008, 2009; Ianzini et al., 2009). At these
times, chromatin extrusion became observed. However, late on,
large ETC displaying radial cleavage furrows during multipolar
anaphase often do not complete cytotomy, and the restituted
daughter nuclei assume a radial or horseshoe-like position in the
ETC, while the furrows partly or completely regress (Figures 1e, 2;
see also Erenpreisa et al., 2008, Figures 1d, 1e). This is a
previously reported phenomenon, which is due to the hindrance
of abscission by the chromosome bridges that exist between
Figure 2 Differential rejuvenation and senescence of subnuclei in ETC after
FMM
(a) Namalwa ETC stained on day 8 after irradiation for OCT4; the OCT4-positive
subnuclei are found at the periphery of the ETC, while the OCT4-negative subnuclei
occupy the centre (*); (b) BrdU uptake in Namalwa cells (following a 24 h pulse from
day 7 to 8 after irradiation) revealed by immunofluorescence shows both replicatively
active (green) and inert (*) chromatin within the ETC; (c, d) HeLa ETC observed on day
13 after irradiation stained for Ag-NORs, counterstained with Methyl Green and imaged
in phase contrast. (c) Multinuclear ETC after FMM with five to seven subnuclei and still
intact cytoplasm; (d) post-FMM ETC presenting degradation of the outer (old)
cytoplasm and distribution of the inner cytoplasm enclosing the individual subnuclei (*);
the remnant of the old cytoplasm is indicated by the arrow. Bars510 mm.
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subnuclei (Steigemann et al., 2009). In these ETC subnuclei, we
see multiple Ag-positive NORs (Figures 2c, 2d), implying that
these cells have recently passed mitosis and that the subnuclei
have the capacity for further formation of ribosomes and
ergastoplasm (see below). In late ,16C–32C ETC days 8–14
postirradiation, which, as judged by the radial cytoplasmic clefts
and/or triangular-shaped nuclei, have undergone similar FMM
(failed multipolar mitosis), we observed signs of the chromatin
differentiation. Some subnuclei become rounded and separate
from the remainder. They display markers of reproductive
potential such as nuclear OCT4 (Figure 2a) and NANOG (data
not shown) and replicate DNA (incorporating BrdU, Figure 2b).
However, not all of the subnuclei stain positively for OCT4, and a
region of (usually close to the centre) or even entire subnuclei are
commonly OCT4 negative (Figure 2a, asterisk) and fail to include
BrdU even in a 24-h incubation period (Figure 2b, asterisk). In our
earlier pulse-chase experiments with 3H-thymidine, we noted that
the DNA in the extruded chromatin had been previously replicated
in the ETC but had stopped replication prior to its expulsion from
the cell (Erenpreisa et al., 2000). In practically all of the late ETC,
derived from each cell line, we observed chromatin extrusion and
the remaining vacuoles invaginating into the cell nuclei.
3.5. Diverse fate of cytoplasm parts in ETC
Next, we studied the fate of the ETC cytoplasm. We found that not
only subnuclei but also the associated cytoplasm undergoes
differentiation and separation in ETC undergoing FMM, whereby
the external layer of cytoplasm becomes discarded, as the inner
cytoplasm sequesters its territory around rejuvenated rounded
subnuclei (compare Figures 2c and 2d). Furthermore, during the
segregation of the cytoplasm, the nucleoli of rejuvenated cells
become highly active, enriching the inner cytoplasm with
ribosomes (Figures 3a, 3b); the rejuvenated subnuclei activate
their surrounding ergastoplasm (Figure 3c) and organize the
cytoskeleton with its own centrosome (Figure 3d). Thus, rejuve-
nated daughter subcells arise and become preformed within an
old mother ETC prior to their release. This same phenomenon was
observed in lymphoma cell lines and the HeLa cells.
3.6. Autophagy releases ETC daughter subcells from
their constraining chromosome bridges
Depolyploidization of ETC is a poorly understood multistep
process, where the multipolar divisions are suggested to play a
role (Gisselsson et al., 2008; Vitale et al., 2010). As described
before, ETCs undergo meiosis-like bi- and multipolar divisions
(Erenpreisa et al., 2005, 2008, 2009; Ianzini et al., 2009); however
the sequence, relationships and contribution of the various types
of ETC divisions in the clonogenicity are currently far from clarity
(Erenpreisa and Cragg, 2010). Here, we describe a particular facet
of this complex process showing that after failed multipolar
divisions, ETC sort and extrude some subnuclei, discard the
original cytoplasm and preform rejuvenated daughter subcells
with their own nascent cytoplasm. However, after failed multipolar
mitosis, the chromosome bridges between daughter subcells are
linked by the Aurora B-aided radial cleavage furrows into one or
more knots (Figure 1e; 4a; also illustrated by Erenpreisa et al.,
2005, Figures 1a, 1e, 1d; 2008, Figure 8a), preventing final
abscission. As these structures do not persist, it appears that
autophagolysosomes can engulf and digest not only the inert
chromatin but also these knots. The formation of the autolyso-
some in the cell centre between preformed subcells is commonly
observed during the disintegration of these ETC in all studied cell
lines (Figure 4b). The process likely releases free energy leading to
repulsion of daughter subcells (Figure 4c) and possibly even a
flare of lysosomic autofluorescence (Figure 4d). The repulsion of
the daughter subcells is reminiscent of budding (see also in
Erenpreisa et al., 2005, Figure 1f). Importantly, the budding
subcells are enriched with the self-renewal factors OCT4 and
NANOG (Figures 4c, 4d) and resume cell divisions (Figures 4d–4f).
The mitotic cells released from ETC mostly contain a paradiploid
amount of DNA reducing aneuploidy characteristic for ETC as
determined by interactive image cytometry on WI-L2-NS after
ETO treatment (Figure 5). Broadly similar things happen in HeLa
cells (data not shown).
4. Discussion
There is a view that polyploidy may serve as a link between quite
opposite biological processes as cellular senescence and self-
renewal, thereby paving the road to cancer or its progression
(Rajaraman et al., 2006; Mosieniak and Sikora, 2010). Here, we
Figure 3 Differential rejuvenation and senescence of cytoplasm in ETC
(a) HeLa ETC on day 8 after irradiation stained with Toluidine Blue, pH 5, after a short
acid hydrolysis; splitting off the outer layer of cytoplasm (the fissure is arrowed) from
the inner area enriched in ribosomal RNA is visible (*); (b) HeLa ETC on day 8 after
irradiation stained as on Figures 2c, 2d; nuclei are actively engaged in ribosomal
synthesis (Ag-NOR positivity of the developed nucleolonema), while the outer
cytoplasm is splitting from the inner (the fissure is arrowed); (c) WI-L2-NS ETC
observed 8 days after ETO treatment, immunostained for the ergastoplasmic marker
protein disulfide isomerase (PDI); the high activity of PDI (green) around single rounded
subnuclei (asterisk) is evident. (d) Confocal microscopy image of Namalwa ETC
observed 6 days after irradiation and stained for b-tubulin and DNA using propidium
iodide; a separating subcell (*) can be seen within its own cytoskeletal network (arrow)
distinct from the linked network containing several other subnuclei. The latter displays
converging microtubular branches – possibly the result of incomplete multipolar
mitosis. Bars510 mm.
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have addressed this conundrum in p53-deficient ETCs induced
after genotoxic and spindle damage. Our observations indicate
that a proportion of the multinucleated ETCs induced after such
damage through mitotic catastrophe do not undergo growth
arrest even though they possess such hallmark features of
senescence as polyploidy and autophagy. These ETCs, in fact,
seem to be able to provide paradiploid mitotic survivors. In
particular, the autophagy observed during this process (which is
coupled with the chromatin extrusion) is non-senescent in nature,
as it is compatible with the mitotic activities of these cells. So,
stricto sensu senescence is not induced in these cells. Rather, our
data suggest that the genomically unstable ETC use this process
to rid themselves of excessive and/or irreparable genetic material
following a DNA repair and sorting processes that precede
polygenomic separation. Furthermore, it appears likely that
autophagy is also directly involved in the final stages of
depolyploidization when the chromosome bridges linking sub-
nuclei are dissolved. These autophagic functions may favour
survival of tumour cells after genotoxic damage and are in keeping
with reports on the cytoprotective function of autophagy and its
contribution to tumour cell survival after chemotherapy (Morselli
et al., 2009; Galluzzi et al., 2010).
Coexistence of this partial chromatin elimination with activation
of an embryonal self-renewal programme in ETC is interesting from
the ontophylogenic point of view. Partial elimination of chromatin
(‘chromatin diminution’) was first described over 100 years ago by
Theodor Boveri in Ascaris lumbricoides (Boveri, 1887). It represents
one way in which somatic cells in the embryo can undergo
differentiation, while the full DNA/chromosome complement
remains preserved in the cells of the germline. Diminution has
been found in more than 200 families of invertebrates. During this
process, whole or selected portions of chromosomes, comprising
up to 25–85% of the total DNA, become eliminated from somatic
cell precursors (Akifyev et al., 2002; Burt and Trivers, 2006; Kloc
and Zagrodzinska, 2008; Gilbert, 2010). In plant hybrids, a
Figure 5 Reduction of aneuploidy in late ETC and their descendents, in the
time-course after genotoxic damage
Mitotic DNA content of WI-L2-NS cells at three time points: in non-treated cells, on day
3 after ETO treatment and recovering on day 14 after ETO treatment. WI-L2-NS cells
were treated with ETO, and then, the mitotic content of dividing cells was examined 3
and 14 days later and compared with control (Ctl) untreated cells. All day 14 post-ETO
mitotic cells bore the remnants of autophagic vacuoles as shown (Figure 4f). Mitotically
active paradiploid cells are present in the cell population at this time posttreatment.
The graphs show an increase of aneuploidy on day 3 and its decrease on day 14,
returning most dividing cells to the paradiploid DNA content. NB: 20% of the mitotic
cells on day 14 ETO-treated group displayed deranged disseminated chromosomes
and were omitted from these measurements for technical reasons.
Figure 4 Potential role of autolysosomes in the final disintegration of ETC
(a) HeLa ETC on day 5 after irradiation stained with Toluidine Blue pH 5 after short acid hydrolysis; after incomplete multipolar mitosis, daughter subcells
remain linked by a series of chromosome bridges (arrowheads). (b) Cells on day 9 after irradiation stained for cathepsin B and DNA; distinct cathepsin-
positive foci can be seen in the central cytoplasmic area between subnuclei (arrow). (c) WI-L2-NS ETC on day 8 after irradiation stained for cathepsin B,
DNA and NANOG; cathepsin-positive autolysosome (arrow) is apparently dissociating NANOG-positive subcells. (d) WI-L2-NS ETC stained on day 9 after
irradiation for OCT4, NANOG and DNA (DAPI); a flare of autofluorescence is observed in the central autolysosome (V) possibly repulsing the OCT4/NANOG-
positive subcells, one of which is in metaphase (arrow). (e) Namalwa cells on day 14 post-ETO treatment stained with Toluidine Blue pH 4 after shortened
acid hydrolysis; separation of subcells by a central autophagic vacuole; the arrows indicate two separated anaphase halves. (f) WI-L2-NS cells on day 14
post-ETO treatment stained with Toluidine Blue pH 4 after shortened acid hydrolysis; a distinct ETC daughter cell in anaphase with the remnants of
autophagic vacuoles (arrowed) is shown; the DNA content (IOD) is indicated and reveals paradiploidy. Bars510 mm.
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potentially analogous process occurs, whereby a complement of
uniparental chromosomes can become assembled, degraded and
eliminated (Gernand et al., 2005). In Tetrahymena pyriformis, the
genomically rearranged chromatin of macronuclei disrupting DNA
replication, becomes extruded (reviewed by Raikov, 1995) com-
bining with features of autophagy (Levy and Elliott, 1968) and
nucleolysis (Mpoke and Wolf, 1996, 1997). Elimination of mitotic
chromosomes through autophagy has been described in human
Chang liver cells after a burst of free radicals (Sit et al., 1996).
Crucially, in all known cases of chromatin diminution, there is a
dependence on cell division (Gilbert, 2010) much as we have seen
here in ETCs produced after genomic insult.
As alluded to previously, this particular autophagy may also
play a key role in the chromatin-sorting process. DNA sorting in
ETC has been suggested previously based upon the presence of
micronuclei enriched with Rad 51 (Haaf et al., 1999) and the
elimination of amplified DNA sequences by this process (Shimizu
et al., 1998). Although not reported as such, these events may
be related to the autophagic chromatin extrusion detailed here.
Other related important results are experimental observations
(Kalejs et al., 2006; Ianzini et al., 2009; Erenpreisa et al., 2009;
Vitale et al., 2010) that demonstrate the ability of cancer cells
to escape from genotoxin- or spindle-damage-induced mitotic
death by activating a depolyploidization programme facilitated by
the action of meiosis-specific genes that results in the production
of proliferating progenies. In keeping with our findings, Walen
(2008, 2010) recently reported cytological observations in pre-
senescent cultures of human embryonal fibroblasts, showing both
degrading and mitotic subnuclei in the same, albeit rare (1–4%),
endopolyploid cells. In addition, chromatin sorting and extrusion
might also favour the decrease of aneupolyploidy and genomic
stabilization during ETC depolyploidization. Decrease of aneu-
ploidy was described in ETCs of colorectal cancer after
nocodazole treatment by Vitale et al. (2010, commented by
Erenpreisa and Cragg, 2010) and shown here in lymphoblastoma
by DNA image cytometry after ETO irradiation treatments. It may
further be aided by the activity of dynamic ELCS moving along the
perinuclear space and forming autophagy-inducing loops and
pockets enrolling extrachromatin (Erenpreisa et al., 2002); the
latest data show that ELCS are engaged in the balanced docking
of chromosomes to the nuclear envelope (Olins et al., 2011).
Conversely, compromised autophagy was shown to promote DNA
damage and aneupolyploidy of tumour cells in response to
metabolic stress (Mathew et al., 2009).
Following the chromatin-sorting process in the ETCs, indi-
vidual subcells become separated and released. Sundaram,
Rajaraman and colleagues (Sundaram et al., 2004; Rajaraman
et al., 2006) previously interpreted the final budding of subnuclei
from disintegrating giant mother cells to be amitotic fragmenta-
tion. That interpretation is partially true as autophagic release of
daughter nuclei/cells from the chromosome bridges is indeed
amitotic. However, our observations (Erenpreisa et al., 2005,
2008, 2009, and here) show that prior to budding, the genetic
material has already been segregated in a more regulated manner
involving multipolar and bipolar divisions that use meiotic/mitotic
machinery (Ianzini et al., 2009; Erenpreisa et al., 2009). Moreover,
our observations revealed that chromatin extrusion is compatible
with activation of the embryonal self-renewal program and the
transfer of its key constituents (OCT4 and NANOG) into the de-
polyploidized descendents. As we demonstrated through live cell
imaging experiments (Ianzini et al., 2009), some of these subcells
re-enter normal mitosis and are capable of further propagation
ensuring clonogenic survival. However, further studies are needed
to clarify the exact role of chromatin extrusion and the sequence
of events occurring during ETC divisions.
Importantly, we report here that differentiation of subnuclei is
accompanied by a re-synthesis of fresh cytoplasm and the
formation of rejuvenated individual subcells, while they still reside
within the cytoplasm or detritus of the original ETCs. Presumably,
this diversification of subnuclear fate in these ETC can occur by
two pathways: (i) by the second FMM, which follows the first and
involves only part of the chromatin after its re-sorting between the
two events; (ii) by asymmetric bipolar divisions of the subnuclei
identifying them as either immortal (extending self-renewal) and
mortal through features characteristic of stem cells. Formation of
individual cytoplasm territory around the ‘stemloid’ daughters
allows the compartmentalization of the self-renewal/mitotic
activators into the individual rejuvenated subcells within the
deteriorating mother ETC facilitating the rejection of the excluded
subnuclei and old cytoplasm. In this respect, a single ETC at this
stage behaves like a developing multicellular system, which may
be due to the prolonged activity of embryonal factors. As a result,
the new generation is born from, and comes to substitute for, the
previous generation of tumour cells. This is the essence of both
‘neosis’ (Sundaram et al., 2004; Rajaraman et al., 2006) and the
‘cancer life cycle’ (Erenpreisa and Cragg, 2007, 2010) and reveals
how these processes occur cytologically. However, although we
have demonstrated this process in several p53 non-functional cell
lines, the question remains as to whether primary tumours are
capable of developing in this way.
In conclusion, the data presented here further outline the
complex cytological processes which occur when ETC undergo
depolyploidization and rejuvenation of their descendents through
a coupled sorting and autophagic elimination of superfluous
genetic material revealing the way (or at least one of the ways)
in which these cells are able to return to the clonogenic
paradiploidy.
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a  b  s  t  r  a  c  t
The  exposure  of  tumour  cells to high  doses  of  ionizing  radiation  can  induce  endopolyploidization  as  an
escape  route  from  cell  death.  This  strategy  generally  results  in  mitotic  catastrophe  during  the  ﬁrst  few  days
after  irradiation.  However,  some  cells  escape  mitotic  catastrophe,  polyploidize  and  attempt  to  undergo
genome  reduction  and  de-polyploidization  in  order  to create  new,  viable  para-diploid  tumour  cell  sub-
clones.  In search  for the  consequences  of ionizing  radiation  induced  endopolyploidization,  genome  and
chromosome  architecture  in  nuclei  of  polyploid  tumour  cells,  and  sub-nuclei  after  division  of  bi- or  multi-
nucleated  cells  were  investigated  during  7 days  following  irradiation.  Polyploidization  was  induced  in
p53-function  deﬁcient  HeLa  cells  by  exposure  to 10 Gy of  X-irradiation.  Chromosome  territories  #1, #4,
#12  and  centromeres  of  chromosomes  #6,  #10,  #X  were labelled  by  FISH  and  analysed  for  chromosome
numbers,  volumes  and  spatial  distribution  during  7 days  post  irradiation.  The  numbers  of interphase
chromosome  territories  or centromeres,  respectively,  the  positions  of  the most  peripherally  and  centrally
located  chromosome  territories,  and  the  territory  volumes  were  compared  to  non-irradiated  controls  over
this  time  course.  Nuclei  with  three  copies  of several  chromosomes  (#1, #6,  #10,  #12,  #X) were  found  in
the  irradiated  as well  as non-irradiated  specimens.  From  day  2 to day  5  post  irradiation,  chromosome
territories  (#1,  #4,  #12)  shifted  towards  the nuclear  periphery  and  their  volumes  increased  16- to 25-
fold.  Consequently,  chromosome  territories  returned  towards  the  nuclear  centre  during  day  6 and  7 post
irradiation.  In comparison  to non-irradiated  cells  (∼500  m3),  the  nuclear  volume  of  irradiated  cells was
increased  8-fold (to ∼4000  m3) at day  7 post irradiation.  Additionally,  smaller  cell nuclei  with  an  average
volume  of  about  ∼255 m3 were  detected  on day  7. The  data  suggest  a  radiation-induced  generation  of
large  intra-nuclear  chromosome  territories  and  their  repositioning  prior  to genome  reduction.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
Somatic mammalian cells possess a diploid genome, whose
propagation is regulated by a tightly controlled cell cycle. Cell cycle
control involves several checkpoints that ensure genomic integrity
and an ordered cell division. The tumour suppressor protein p53
plays a key role in the regulation of the cell cycle and activation of
apoptotic pathways [1]. Furthermore, p53 is involved in cell differ-
entiation [2], senescence, and DNA repair processes [3].
Abbreviations: ETC, endopolyploid tumour cell; MNGC, multi-nucleated giant
cells; NT, non-irradiated; FISH, ﬂuorescence in situ hybridization; SSC, saline sodium
citrate buffer; PBS, phosphate buffered saline; pCT, most peripherally located chro-
mosome territory; cCT, most centrally located chromosome territory.
∗ Corresponding author. Tel.: +49 6221 549824; fax: +49 6221 549112.
E-mail  address: hausmann@kip.uni-heidelberg.de (M.  Hausmann).
When exposed to high doses of ionizing radiation, tumour cells
show different escape routes that bypass cell cycle checkpoints and
apoptosis, especially when p53 is dysfunctional [4]. Tumour cells
can escape cell death by endopolyploidization [5]. Although most
of these endopolyploid tumour cells (ETC) run into mitotic catas-
trophe [6] and cell death, some can activate survival strategies that
include genome reduction and the generation of viable para-diploid
tumour cells. These cells resume mitotic cell cycle and are often
more resistant to ionizing radiation [7–9].
Erenpreisa et al. [10,11] have described profound cell cycle
changes in HeLa cells after 10 Gy of X-irradiation:
• On  day 1–2 post irradiation, the cells undergo mitosis followed by
the  cleavage furrow regression and reunion of sister nuclei into
bi-nucleated  cells.
1383-5718/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
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• On  day 2–3 post irradiation, the individual sub-nuclei in bi-
nucleated  cells start to undergo intra-cellular asynchronous
a-cytotomic bi-polar mitosis forming multi-nucleated giant cells
(MNGC). At that time, the cell population consists of 70% MNGC,
which  may  contain individual sub-nuclei with 1C, 2C, 3C, 4C, and
6C DNA content. In addition a smaller proportion of mononuclear
giant  cells emerge at that time point.
• On  day 3–5 post irradiation, there is an increase of polyploidy due
to  endoreduplication cycles reaching in sum up to 24–32C in giant
cells;  from day 5 onwards, a wave of bi-polar and a-cytotomic
multi-polar mitoses occurs; the latter forms secondary MNGCs.
• From  day 6 to 9 post irradiation, the majority of giant cells stop
endoreduplication and undergo senescence, while some release
para-diploid  mitotic sub-cells, starting clonogenic regrowth
[10,11].
These complex changes in irradiated polyploidizing tumour
cells are accompanied by increased expression of Aurora B-kinase,
a core component of the chromosomal passenger complex. The
up-regulation of Aurora B-kinase occurs between day 3 and day
6 post irradiation and may  play a signiﬁcant role in late mitotic
activity of ETCs which may  lead to genome reduction [10]. Aurora
B has been shown to play a role in sister chromatid cohesion and
homologue segregation in meiosis [12,13]. Likewise, there was  an
up-regulation of the meiotic REC8 cohesin in ETCs and MNGCs dur-
ing day 3 to day 6 [14]. REC8 mediates sister chromatid cohesion
and thereby the correct chromosome disjunction in meiosis [14].
Beyond these ﬁndings, the activation of other meiosis speciﬁc genes
was noted during de-polyploidization phase of ETCs [15].
Ionizing  radiation exposure elicits DNA damage response up-
regulating different repair processes which are known to be
correlated with changes in chromatin compaction states (e.g.,
heterochromatin or euchromatin) [16], chromosome association
[17,18], and nuclear architecture [19–22]. In irradiated p53-
deﬁcient endopolyploidizing cells, additive rounds of the DNA
double strand break repair by homologous recombination were
occurring during replication cycles [23]. Thus, the genome architec-
ture of acutely irradiated ETCs may  also be inﬂuenced in a certain
way by DNA repair mechanisms.
It is well established that in the interphase nucleus of diploid
somatic cells chromosomes and sub-chromosomal units occupy
non-randomly positioned distinct, largely mutually exclusive ter-
ritories and sub-domains [24–27] which are arranged dynamically
depending on gene expression [28]. The intra-nuclear position of
chromosome territories is described by the relative radial distance
to the nuclear centre or border, respectively. Positioning of chro-
mosome territories and sub-chromosomal domains is generally
non-random, and seems to follow special functionally correlated
constraints; for instance, a correlation of a chromosome territory’s
radial position with its gene density [29] or gene activity [30]
has been observed. Relative chromosome positioning and inter-
chromosome compartment form an intra-nuclear network [31]
that is well preserved within a particular cell type [30,32]. It has
also been shown that radiation-induced translocations seem to
depend on the neighbourhood of the involved chromosome ter-
ritories [33,34], so that larger chromosomes may  participate more
frequently in exchanges than smaller ones [19].
Changes in the spatial chromosomal organization in irradiation-
induced polyploidizing tumour cells have so far not been
systematically investigated. Several ﬁndings indicate that DNA
damage at larger doses may  induce local re-positioning that leads
to clustering of damaged sites [17,18,35] and increasing of mis-
repair rates at larger doses [36]. However, little is known about
the spatial events and constraints that chromosomes undergo dur-
ing polyploidization of irradiated tumour cells. Here, we exposed
p53-deﬁcient HeLa cells to 10 Gy of X-radiation and analysed the
numbers,  sizes, and positions of chromosome territories (#1, #4,
#12) during 7 days for radiation-induced changes.
2. Materials and methods
2.1.  Cell culture
HeLa clone 3 cells of human cervix carcinoma were kindly provided by Ianzini
[37]. The cells were grown on slides in Ham’s F12 medium (Sigma–Aldrich, Stein-
heim, Germany) medium supplied with 10% FCS (Biochrom, Berlin, Germany) and
penicillin/streptomycin (Life Technologies, Darmstadt, Germany) at 37 ◦C in a 5%
CO2 humidiﬁed incubator (Binder, Tuttlingen, Germany). For experimental studies
the cells were maintained in log phase of growth for at least 24 h prior to irradiation.
At  ∼60% sub-conﬂuence, the cell cultures were irradiated at room temperature, and
further cultured for 1–7 days post irradiation.
2.2. Irradiation
The cells grown on sterilized glass slides (Menzel Gläser, Braunschweig,
Germany) were irradiated in medium in Quadriperm culture dishes (Nunc, Roskilde,
Denmark) at room temperature. The cells were exposed to 10 Gy of 240 kV X-rays
at  a dose rate of 1 Gy/min. The Roentgen tube was ﬁltered with 3 mm beryllium and
driven at 13 mA current (Isovolt 320/10; Seifert, Ahrensberg, Germany), and the
delivered dose was measured with a Duplex dosimeter (PTW, Freiburg, Germany).
After  irradiation the cells were further cultured for the time indicated and subse-
quently  ﬁxed with ice-cold acetic acid:methanol (1:3) (Merck, Darmstat, Germany;
J.T.  Baker, Deventer, Netherlands).
2.3. Chromosome preparation and FISH painting of metaphases
Half conﬂuent HeLa clone 3 cultures were arrested at metaphase with
0.05  mg/mL  Colcemid (GIBCO, Carlsbad, CA) for 3 h and then harvested by Trypsin
(Invitrogen, Karlsruhe, Germany) treatment. Chromosome spreads were obtained
according to standard acetic acid:methanol (1:3) ﬁxation protocols. Slides were
stored at −20 ◦C until use. Three-colour chromosome painting (FISH) with a com-
bination of chromosome #1, #4 and #12 paint probes (MetaSystems, Altlussheim,
Germany)  was done as published [38,39]. Brieﬂy: The hybridization mix  was heated
to 72 ◦C for 5 min  and then incubated at 37 ◦C for 10 min prior to applying the
mixture  to the denatured chromosomes. Metaphase chromosomes were denatured
on  slides for 2 min  at 72 ◦C in 70% formamide/2× SSC (Sigma–Aldrich, Steinheim,
Germany;  Invitrogen, Karlsruhe, Germany) and then dehydrated in a series of 70%,
90% and 100% ethanol (J.T. Baker, Deventer, Netherlands). Slides carrying denatured
chromosomes  were pre-warmed to 37 ◦C prior to the application of the dena-
tured  hybridization mixture, then covered by a 20 mm × 50 mm coverslip (Menzel
Gläser,  Braunschweig, Germany) and sealed with rubber cement (Marabu, Tamm,
Germany). Hybridization was performed overnight at 37 ◦C in a moist chamber. The
slides were then washed three times in 50% formamide/2× SSC, pH 7.0, at 42 ◦C
for 15 min  each followed by washes at 42 ◦C in 2× SSC, pH 7.0, for 15 min, in PN
buffer  (100 mM Na2HPO4, 50 mM NaH2PO4, 0.1% Triton X-100 (v/v))/0.1% Nonidet
P40  (Sigma–Aldrich, Steinheim, Germany) pH 8.0, for 15 min, and in 3% bovine serum
albumin (Sigma–Aldrich, Steinheim, Germany) in 2× SCC for 30 min. At least 20
metaphases were analysed visually.
2.4. FISH probes used for chromosome labelling in cell nuclei
Chromosome territories in ﬁve different specimens [non-irradiated control
cells  (NT); irradiated HeLa cells at day 2, 5, 6 and 7 (d2, d5, d6, d7) post radia-
tion  exposure] were hybridized with chromosome painting probes (MetaSystems,
Altlussheim,  Germany). The slides of NT and d2 were hybridized with a combi-
nation  of three chromosome painting probes (#1, #4 and #12). This combined
probe  set had the following spectral signatures: (a) Chromosome #1: Texas Red
(red signature: ex/em = 586 nm/605 nm); (b) chromosome #4: FITC (green signa-
ture:  ex/em = 488 nm/518 nm); (c) chromosome #12: 1/1 mixture of Texas Red and
FITC  resulting in a yellow signature (Fig. 1a).
The slides of d5, d6, and d7 were simultaneously hybridized with two probes
for  chromosome #1 (Texas Red) and chromosome #4 (FITC). Chromosome #12 was
separately hybridized with a probe showing the same spectral signature as the
chromosome #4 probe.
In  addition to whole chromosome painting probes also pericentric satellite
probes  (QBIOGENE – Molecular Cytogenetics/Diagnostics, Illkirch Graffenstaden,
France)  for chromosomes #6, #10, and #X were applied and hybridized accord-
ing  to the manufacturer’s protocol. Slides of non-irradiated control cells (NT), and
irradiated specimens at day 1 and 2 (d1, d2) were inspected visually for chromosome
counting.
2.5.  FISH (chromosome painting, centromere labelling) of cell nuclei
For  quantitative microscopy, the cells ﬁxed on SuperFrost Plus slides (Menzel
Gläser,  Braunschweig, Germany) were treated according to the following proto-
col: For permeabilization of the membrane, the slides were incubated in 0.7 mL
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Fig. 1. (a) Microscopic image of a typical cell nucleus (NT) after chromosome painting with a triple probe for the CTs #1 (red), #4 (green), and #12 (yellow). (b) Microscopic
image of a typical metaphase spread after chromosome painting with a triple probe for chromosomes #1 (red), #4 (green), and #12 (yellow).
Triton-X100/99.3 mL  1× SSC (Merck, Darmstat, Germany; Invitrogen, Karlsruhe,
Germany)  for 30 min  and washed with 2× SSC for 5 min. The specimens were incu-
bated in RNase A (Sigma–Aldrich, Steinheim, Germany) for 30 min  at 37 ◦C [2 l
stock solution (100 mg/mL) and 98 L 2× SSC per slide]. After washing with 2×
SCC  for 3 min  and 1× PBS (Invitrogen, Karlsruhe, Germany) for 5 min, proteins
were  digested in pepsin (Sigma–Aldrich, Steinheim, Germany) [21 L stock solution
(100  mg/mL) + 70 L 0.01 M HCl in PBS] for 45 s. This was followed by a washing pro-
cedure in 1× PBS for 5 min, and in an ethanol series of 70%, 90%, and 100% for 3 min
each. Denaturation was  done in 70% formamide/2× SSC (at pH 7–7.2) for 5 min  at
75 ◦C. Afterwards the slides were washed in 70%, 90%, and 100% ice-cold ethanol for
3 min  each. In the case of the slides NT and d2, 2 L of the probe mix  combined with
2 L of 60% formamide were dropped on the specimens. The in situ hybridization
took  place for 48 h at 37 ◦C. For the specimens d5, d6, and d7, the procedure was
slightly  different: 7 L or 14 L, respectively, of the probe mix  were denatured dur-
ing incubating at 75 ◦C for 5 min. The tubes were shortly cooled on ice. After that, the
probes were incubated at 37 ◦C for 30 min  and centrifuged for a short time. Then, the
probe mix  was pipetted onto the thermally denatured specimens and hybridized at
37 ◦C for 24 h.
For post hybridization treatment, all slides were washed with 1× SSC at 75 ◦C
and  2× SSC/0.01% Tween at room temperature.
The cell nuclei were either counterstained with DAPI (Sigma–Aldrich,
Steinheim, Germany) or with TO-PRO®-3 (Invitrogen, Karlsruhe, Germany)
(ex/em = 642 nm/661 nm)  1:1000 in 1× PBS. The specimens NT, d1 and d2 were incu-
bated  with the antifade reagent ProLong® Gold (Invitrogen, Karlsruhe, Germany) at
37 ◦C for two  days. The specimens d5, d6, and d7 were mounted in Immuno MountTM
antifade solution (GeneTex Inc., Irvine, USA).
2.6. 3D-Microscopy
Up to 50 cells of NT and d2 each were imaged with a Leica TCS NT confocal
laser  scanning microscope using a high numerical aperture lens (63×/NA 1.4 oil)
and appropriate ﬁlter settings. Up to 50 cell nuclei each of the data sets d5, d6, und
d7 were imaged with the Nikon TE2000-E Perkin Elmer UltraVIEW ERS Spinning
Disc  confocal microscope also using high numerical aperture lenses (63×/NA/1.2
water)  and appropriate ﬁlter settings. For 3D-reconstructions the axial step size
was 203 nm for all z-stacks.
2.7. Image evaluation and statistical analysis
The numbers and positions of the chromosome territories #1, #4, and #12
in  the irradiated specimens d2, d5, d6, and d7 were analysed and compared to
data obtained from non-irradiated control cells (NT). 3D-microscopy image data
stacks were evaluated by means of the freely available software ‘Nemo’, version
1.5  (https://www-lgc.toulouse.inra.fr/nemo/) implemented into the image analy-
sis software package “ImageJ”. For the different ﬂuorescent objects within the cell
nuclei, the shortest geometrical distances of the barycentres to the nuclear bor-
der were calculated. For all chromosomes, a difference or change of ploidy did not
inﬂuence the result since only the distances of the most peripherally (pCT) and the
most centrally (cCT) located chromosome territories were always determined. These
values were statistically compared over the time course.
The  results were expressed as cumulative frequency histograms of distances.
For  the statistical pairwise analysis of these histogram curves, which show different
shapes, the most appropriate test was the Kolmogorov–Smirnov test [40]. The null
hypothesis of this test is that two samples are drawn from the same frequency
distribution.  On acceptance of the alternative hypothesis, namely that two fre-
quency histograms belong to different distributions, the signiﬁcance level of this test
deﬁnes an error probability for the two distance distributions being equal, i.e. two
distributions being of the same entity [41]. In general, this error level was taken to
be up to 5% or even less because the Kolmogorov–Smirnov test tends to be conser-
vative.  On the other hand, the test is robust and can be easily applied to distributions
with  rather large deviations in sample numbers. Its applicability and usefulness in
histochemistry and cytochemistry has been widely demonstrated (e.g. [42,43]).
For the volume calculations of the cell nuclei and chromosome territories, the
voxels covered by the object were counted and multiplied with the respective voxel
volume of the image (for details see e.g. [44]). Finally, the average volumes of all
detected nuclei or chromosome territories were determined.
3. Results
3.1. Metaphase karyotyping using whole chromosome painting
The  numerical karyotype of non-irradiated HeLa clone 3 cells
was studied in more than 100 DAPI stained cells. A modal number of
65 chromosomes per cell were observed, verifying its hypotriploid
nature without radiation treatment (non-irradiated control). The
metaphase analysis of 126 metaphase spreads shows the occur-
rence of two  chromosomes #1, two translocated chromosome
arms #1q, two chromosomes #4 and three chromosomes #12 per
metaphase (Fig. 1b).
3.2.  Interphase FISH and chromosome numbers
Chromosome painting experiments on interphase cell nuclei
of NT cells corroborate the metaphase analysis data for chromo-
some #1 (2 or 3 FISH labelled territories/cell) and #4 (mostly 2
FISH labelled territories/cell). For chromosome #12, two  labelled
Fig. 2. Frequency (%) of cell nuclei vs. number of chromosomes #6, #10 and #X
counted  by visual inspection of centromere labels. The columns refer to the speci-
mens NT (Contr.), d1 (24 h), and d2 (48 h) for each chromosome.
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Fig. 3. Frequency of cell nuclei vs. number of automatically segmented painting territories referring to chromosome #1 (a), #4 (b), and #12 (c). The different columns
represent the data at the respective day post IR. Note that the most notable shift of the number of chromosome territories is observed on day 5.
territories were mostly observed in the NT specimen. Since
metaphase analysis suggests three chromosomes #12 in HeLa clone
3 cells, it cannot be excluded that two chromosome territories were
spatially associated into one detectable territory.
In order to further study the hypotriploid nature of the HeLa
clone 3 cells in use, 440–850 interphase cell nuclei were analysed
each after centromere-speciﬁc FISH of chromosome #6, # 10, and
#X. For all three chromosomes, more than 92% of the cell nuclei
showed three signals in the NT specimens. The hypotriploid karyo-
type for chromosomes #6, #10, and #X was maintained on day 1
and 2 (Fig. 2: 24 h, 48 h) post irradiation, which was displayed by
more  than 86% of the cells with three centromere-speciﬁc signals
(Fig. 2).
Automated image analysis of the chromosome painting exper-
iments revealed an increase of cells with higher numbers of
chromosome territory #1 with advancement of time post irradia-
tion. The most notable shift was observed up to day 5. From day 5 to
day 7 the majority of the cells showed 3 or 4 distinctly labelled terri-
tories #1. In contrast, the number of chromosome territories #4 was
found to be constant over the complete time course and revealed
two clearly labelled territories in most nuclei (Fig. 3a and b). For
chromosome #12, mostly two  painted territories were observed
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Fig. 4. Examples of segmented images of hybridized and DAPI-stained cell nuclei at d2, d5, and d7. Territories of chromosome #1 are labelled in red; territories in green
represent chromosome #4. Upper row: maximum projection of the lateral (xy) image sections through a cell nucleus. Lower row: maximum projection of the axial (yz) image
sections  through a cell nucleus. Note the differently scaled bar for comparison of the cell nuclei.
in d2. With increasing nuclear and chromosome territory volumes
from day 5 to day 7, the average number of the detected chromo-
somes #12 shifted to three copies. This, however, could be the result
of a better image segmentation of the highly jagged staining pat-
tern of this chromosome in larger cell nuclei (Fig. 3c). Thus, this data
conﬁrmed the previous observations [9,10] that polyploidization
of irradiated HeLa cells was mostly occurring by multi-nucleation
(through a-cytotomic mitoses) and in a smaller proportion of giant
cells by multiplication of the chromosome numbers at the peak of
polyploidy (day 5).
3.3.  Volumes of chromosome territories and cell nuclei
Nuclear and chromosome territory volumes were determined
from the segmented 3D images. In Fig. 4 typical examples for d2,
d5 and d7 are shown. Size and shape for non-irradiated control (NT;
data not shown) and d2 cell nuclei appeared to be similar, whereas
d5, d6, and d7 nuclei appeared to be much larger and in many cases
also ﬂattened. This means that the z-dimension was  not consider-
ably increased in d5, d6, and d7 compared to d2, which might be
due to the morphology of the adherently growing HeLa clone 3
cells. The frequency distributions of the nuclear volumes showed a
more pronounced bimodal distribution for NT and d2 than for d5,
d6 and d7, indicating the status of the cell nuclei before or after DNA
duplication (Fig. 5a–e), when most cells became arrested at G2 and
polyploidized by mitotic slippage. The range of nuclear volumes
increased with advancement of time post irradiation. The aver-
age volume of non-irradiated cell nuclei (NT) was about 500 m3,
which was still maintained 2 days post irradiation (d2). Thereafter,
the average nuclear volume increased with advancing time. At day
7 post irradiation it reached an 8-fold volume of about 4200 m3
(Fig. 5f). Aside from the larger nuclei at d7, smaller cell nuclei with
an average volume of 255 m3 were detected, which seem to have
no small progenitors from day 3 to day 6 post irradiation. Most
of these small cell nuclei were found to be adjacent to a large cell
nucleus and often to be bridged to it (Fig. 6). This indicates that they
result from the selective de-polyploidization of the mother cell. The
occurrence of such asymmetric cell divisions was  very typical for
HeLa clone 3 cells after high dose IR exposure [10]. The smaller cell
nucleus might be interpreted as a daughter nucleus of a senescing
mother cell [11].
The  most signiﬁcant ﬁndings, however, are presented in Fig. 7:
Chromosome territory volumes increased up to 25-fold in case of
chromosome #12 (Fig. 7a), 21-fold for chromosome #4 (Fig. 7b),
and 16-fold for chromosome #1 (Fig. 7c). The average nuclear vol-
ume  increased from d2 to d7 only by a factor of about 10. These
ﬁndings indicate a differential loss of compaction and/or enlarged
entanglement of the chromosome territories, which may  reﬂect the
extensive DNA repair processes during that time. In particular, a
sharp increase of chromosome territory volumes was observed at
the peak of polyploidization at day 5 (5- to 9-fold), while the nuclear
volumes increased only 3-fold. On the further days the nuclear
volumes increased more signiﬁcantly.
3.4. 3D radial positions of painted chromosome territories #1, #4,
and #12
The absolute distances of the barycentres of the painted ter-
ritories to the nuclear edges were determined and compared for
NT (control), d2, d5, d6, and d7. The results are summarized by
normalized cumulative frequency distributions (Fig. 8). The most
peripheral (pCT) and the most central (cCT) chromosome territo-
ries were compared because all other territories were located in
between. A shift of a frequency distribution curve to the left indi-
cated a territory position closer towards the nuclear periphery;
a shift to the right a position closer towards the nuclear centre.
Compared to NT, all tested chromosome territories changed their
3D-positions during the time course post irradiation (d2–d7). In
Table 1 the statistical results for the Kolmogorov–Smirnov test are
summarized:
• Chromosome  #1: the positions of the pCTs in d5 were signiﬁ-
cantly  different (p = 0.0001) to their positions in NT and d2. A
similar  result was  obtained for the cCTs in d5 compared to NT
(p  = 0.001) and to d2 (p = 0.013). The distance distributions of the
cCTs  of d6 and d7 compared to NT and d2 did not show any
statistically signiﬁcant difference.
• Chromosome  #4: from d2 to d6 the distance frequency distri-
bution  of pCTs signiﬁcantly shifted to the periphery of the cell
nucleus  (p = 0.0001); the positions in d7 appeared to be compat-
ible  with NT. The distance frequency distributions of cCTs in d2
and  d5 were signiﬁcantly different (p = 0.0001) compared to the
distance  frequency distributions of cCTs in d6 and d7. Again for
d6  and d7 no signiﬁcant difference was found in comparison to
the distribution of NT.
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Fig. 5. Frequency histograms of nuclear volumes for NT (a), d2 (b), d5 (c), d6 (d), d7 (e). The columns represent volume values in steps of 100 m3 (a and b), 300 m3 (c and
d), and 500 m3 (e). (f) Average volumes of cell nuclei obtained from the values of a–e. Note: the nuclear volumes on d7 refer only to the large nuclei detected. The modal
values of nuclear volumes increase 3- to 5-fold on day 5.
• Chromosome  #12: the frequency distribution curves of the pCTs
showed  shifts similar to those of the corresponding curves of
chromosome  #1 and #4. The distance frequency distributions of
d5, d6, and d7 signiﬁcantly differed from the distance frequency
distribution of NT (p = 0.0001). In contrast to the pCTs the dis-
tance  frequency distributions of the cCTs were not statistically
different from those of NT.
4. Discussion
Recent investigations of the nuclear architecture and the
positions of chromosome territories have demonstrated non-
randomness and dynamic functionally correlated changes [24–32].
Here, dynamic features of the nuclear and chromosome architec-
ture in p53-deﬁcient, polyploidizing HeLa cell nuclei during 7 days
following high dose (10 Gy) X-ray radiation exposure have been
studied for the ﬁrst time. It should be noted that only mononuclear
endopolyploid cells or single sub-nuclei of multi-nucleated cells
were investigated. In general, the data suggested that irradiation-
induced endopolyploidization is accompanied by 3D intra-nuclear
chromosome re-positioning in p53-deﬁcient tumour cells.
Although  high dose ionizing radiation causes massive DNA dam-
age, a signiﬁcant change in the numbers of chromosome territories
was not observed in individual nuclei. This may  be explained by
DNA damage-induced re-replication during the polyploidization
phase, which involves the maintenance of interchromosomal inter-
actions (e.g. diplochromosomes) and gross chromosome territorial
re-organization, and by multi-nucleation of most cells through a-
cytotomic mitoses as well.
In  contrast to territory numbers, signiﬁcant increases of nuclear
and territory volumes were found in the specimens d5, d6, and
d7. Day 5 was the last day when endoreduplication cycles occurred
and DNA repair took place, followed by a wave of de-polyploidizing
mitoses [11]. Thus, this sharp increase in chromosome territory
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Fig. 6. Example of cell nuclei after DNA staining (blue) showing DNA bridges
between  the large and the two  small cell nuclei indicating their origin from the
larger  mother nucleus.
volumes may  be due to the particular changes of the nuclear
chromatin preparing through DNA endoreplication/repair [23] and
epigenetic changes of the interphase chromosomes for the upcom-
ing divisions. In support, the activation of stem cell transcription
factors in radiation induced polyploid tumour cells persisting in
secondary descendents was observed. Irradiation of tumour cells
was shown to induce stemness transcription proﬁles only in the
endopolyploidy fraction [45]. Such a response has recently been
Table 1
Kolmogorov–Smirnov signiﬁcance levels for two cumulative frequency distribu-
tions  of bary centre distances to the nuclear edge for CTs #1, #4, and #12. The
numbers  represent the signiﬁcance level of two compared distributions (NT, d2, d5,
d6, d7) being statistically different. Values for cCT above diagonal (indicated by ‘-’),
for pCT below diagonal.
#1 NT d2 d5 d6 d7
NT “-” 0.000 0.000 0.000 0.000
d2 0.154 “-” 0.000 0.072 0.015
d5 0.000 0.013 “-” 2.567 5.552
d6 11.710 3.455 0.004 “-” >50
d7 2.714 23.524 1.480 26.634 “-”
#4 NT d2 d5 d6 d7
NT “-” 0.001 0.000 0.002 26.032
d2 0.000 “-” 1.366 0.867 0.002
d5 0.000 31.789 “-” 7.633 0.000
d6 >50 0.000 0.004 “-” 0.042
d7 10.999 0.000 0.000 >50 “-”
#12 NT d2 d5 d6 d7
NT “-” 0.205 0.000 0.000 0.000
d2 5.722 “-” 0.006 0.098 0.401
d5 3.192 >50 “-” 17.784 44.757
d6 25.315 >50 17.784 “-” >50
d7 4.677 0.140 0.027 0.317 “-”
conﬁrmed on irradiated clinical material from breast cancer [46].
Polyploidy as such characterized by considerable change of the
transcription proﬁle [47] and the presence of chromosomes and
molecular networks in duplicates may favour this phenotypic
switch for escape of DNA damage resistant cells. On  the other hand,
Fig. 7. Average volumes of CTs #1 (a), CTs #4 (b), and CTs #12 (c) for NT, d2, d5, d6, and d7. On day 5 an increase (12- to 25-fold) of the average chromosome territories
volumes is observed.
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Fig. 8. Normalized cumulative frequency histograms of the measured distances in m of the CT bary centre to the nuclear border. The positioning of ﬁxed FISH-labelled CTs
#1,  #4, and #12 in HeLa clone 3 cells before and after 10 Gy -radiation exposure was measured. For the analysis, the most peripherally (pCT) and the most centrally (cCT)
located chromosome territories were compared over the time course. Left column: distributions of the pCTs #1, #4, and #12. Right column: distributions of the cCTs #1, #4,
and  #12.
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de-compacted chromatin states may  reﬂect a stem cell-like nuclear
organization that may  contribute to enhanced DNA repair capabil-
ities. It may  also be a cause of the chromosome territory volume
enlargement in reprogrammed HeLa ETCs observed in our study.
The increase of the analysed territory volumes was  much stronger
than the simultaneous increase of nuclear volumes. Under the
assumption that this would also be the case for all other chromo-
somes, a stronger intermingling would be expected. In complement
with the observed chromosome territory contour jaggedness espe-
cially on day 5 and 6, these three most important changes of
the chromosome parameters (increase of volumes, partial shar-
ing of the territories and fringy contours) should be attributed to
endopolyploidization as such. On day 6 and day 7 several cell nuclei
continued to increase their volumes; however, many cell nuclei
also became ﬂattened, changing the ratio of x and y diameter to z
diameter presumptively due to senescence [48].
Chromosomes in the interphase nucleus of normal human cells
occupy speciﬁc 3D positions in correlation to their gene density
and size, with the gene-rich and small chromosomes being located
more centrally than gene-poor and larger chromosomes [26–28].
Radiation treatment as well as exposure to DNA strand breaking
chemicals leads to chromosomal aberrations and to movements
of the chromatin, changing the nuclear architecture [17,18]. Over
a period of 2 h after low dose irradiation, chromosome domains
were found to join together and subsequently drift apart from each
other [49–51]. In the investigation presented here, the generation of
large polyploid cell nuclei with increased chromosome territories
and nuclear volumes were associated with a considerable change
in the genome architecture. This was correlated to a movement of
the positions of chromosome territories #1 and #4 to the nuclear
periphery until 5 days after irradiation. In d6 and d7 most chro-
mosome territories showed a repositioning towards the nuclear
centre, a position that was comparable to the one in non-irradiated
cells (NT). This effect was less pronounced for chromosome terri-
tories #12 that were always located peripherally. Those territories,
being positioned around the nuclear centre prior to ionizing radi-
ation exposure, seemed to show stronger repositioning processes
during the post radiation phase. The change of the nuclear archi-
tecture back to the mode of non-irradiated cells may  reﬂect that
the cells exit endopolyploidization and approach metaphase.
In  conclusion, our results using high dose ionizing radiation
exposure together with 3D image analysis of chromosome pos-
itions and architecture in HeLa cells undergoing endoreduplication
provided quantitative data showing that interphase chromosomes
in polyploidizing cells undergo enlargement of the territories
and chromosome speciﬁc spatial repositioning during the post
radiation period. This correlates with the previously observed
upregulation of proteins and factors of cellular DNA repair and
survival. Further investigations should elucidate the relationship
between the observed chromosomal movements as well as vol-
ume changes and de-polyploidization and the production of viable
para-diploid daughter cells.
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ABSTRACT
Recently, it has become clear that the complexity of cancer biology cannot 
fully be explained by somatic mutation and clonal selection. Meanwhile, data have 
accumulated on how cancer stem cells or stemloids bestow immortality on tumour 
cells and how reversible polyploidy is involved. Most recently, single polyploid tumour 
cells were shown capable of forming spheroids, releasing EMT-like descendents 
and inducing tumours in vivo. These data refocus attention on the centuries-
old embryological theory of cancer. This review attempts to reconcile seemingly 
conflicting data by viewing cancer as a pre-programmed phylogenetic life-cycle-like 
process. This cycle is apparently initiated by a meiosis-like process and driven as an 
alternative to accelerated senescence at the DNA damage checkpoint, followed by an 
asexual syngamy event and endopolyploid-type embryonal cleavage to provide germ-
cell-like (EMT) cells. This cycle is augmented by genotoxic treatments, explaining 
why chemotherapy is rarely curative and drives resistance. The logical outcome 
of this viewpoint is that alternative treatments may be more efficacious - either 
those that suppress the endopolyploidy-associated ‘life cycle’ or, those that cause 
reversion of embryonal malignant cells into benign counterparts. Targets for these 
opposing strategies are components of the same molecular pathways and interact 
with regulators of accelerated senescence.
“The aim of science is to seek the simplest 
explanations of complex facts. We are apt to fall into 
the error of thinking that the facts are simple because 
simplicity is the goal of our quest. The guiding motto 
in the life of every natural philosopher should be, ‘Seek 
simplicity and distrust it”
(Alfred North Whitehead, The Concept of Nature, 
1929) 
After more than 40 years of the “war on cancer” 
progress in achieving long-lasting cures and treating 
advanced, late stage, disease is still unsatisfactory. This 
failure likely stems from our limited understanding of 
the true complexity of the disease [1]. Attempts to define 
the basis behind cancer are many and varied, dating back 
centuries. One particular concept, the embryological 
theory of cancer, has existed for more than 150 years 
and was developed during the 19th century by prominent 
scientists of that time [2, 3]. Amongst these, David von 
Hansemann, wrote in 1890 that normal somatic cells can 
undergo de-differentiation and transform into cancer cells, 
which acquire “egg-like” features [4].
The biological equivalency between embryos 
and tumours was experimentally established in 1964 
by Leroy Stevens who showed that normal pluripotent 
embryonic stem cells from murine blastocysts, could 
develop into teratomas/teratocarcinomas if they were 
injected into an adult testis or into an embryo if injected 
back into a uterus [5]. The same year, Barry Pierce and 
colleagues demonstrated the ability of a single malignant 
teratocarcinoma cell to form a primitive embryoid body 
with the capacity to give rise to the three major germ-
cell layers [6, 7], subsequently showing these embryonal 
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properties for other carcinomas [8]. It was also shown 
that teratocarcinoma-embryo chimeras can be produced 
if the malignant cells are placed into the environment of 
a normal blastocyst [9, 10]. Although these experiments 
were forgotten for many years, in modern times induced 
pluripotent stem cells (iPSC) have been tested for their 
ability to cause teratomas and teratocarcinomas. Given 
all of these observations, and the current frustrations in 
our ability to understand the complexity of cancer and 
establish effective cures, even with our sophisticated 
ability to unpick their underlying somatic mutations and 
clonal architecture, it may be time to revisit the half-
forgotten embryological theory of cancer. 
The currently popular cancer stem cell (CSC) theory 
of tumourogenesis assigns the property of immortality 
(self-renewal) to adult stem cells that due to genetic 
mutations, or epigenetic changes, de-differentiate to a state 
similar to very early embryonal (ESC-like) cells [11, 12]. 
However, although this concept explains how proliferation 
capacity is extended, it does not explain why immortality 
is supported in tumours again and again. The only 
known natural process capable of supporting immortality 
indefinitely is the life cycle, which transfers the germ-line 
through one generation to the next. Recognition of this 
basic biological law formulated by August Weismann more 
than a century ago lies at the core of the embryological 
theory of cancer and its many variants [13].
Through more than a decade of research in our 
and other labs, it has been seen that meiotic genes are 
activated in TP53 mutant tumours, enhanced by genotoxic 
treatments or spindle inactivation and associated with 
reversible polyploidy capable of recovering clonogenic 
diploid cells [14-16]. Earlier induction of c-Mos by 
paclitaxel in SKOV3 cells was shown by Ling et al., 
[17], while Gorgoulis et al.,[18] found it in primary 
small cell lung cancer. Similarly, data on the presence of 
the so-called cancer testes-associated antigens (CTA) in 
tumours, among them meiotic, embryonal and placental 
gene products, revealed a link between gametogenesis 
and cancer [19, 20]. These data tempted Lloyd Old to 
provocatively entitle one of his commentaries “Cancer is 
a somatic cell pregnancy” [21]. He wrote: “Because many 
of the cardinal features of cancer are also characteristic 
of gametogenesis/placentation, e.g. migration, invasion, 
immune subversion, apoptosis resistance, induction of 
angiogenesis, etc., it takes little imagination to think that 
cancer-testes gene products controlling these processes 
during gametogenesis confer these same capacities on the 
cancer cell”. This statement contains a frank recognition 
of the embryological theory of cancer. 
The last decade has added yet more complexity. 
In addition to activation of the main meiotic kinase Mos 
and genes of meiotic prophase, certain division features 
characteristic for meiosis (cohesion of sisters and omission 
of one S-phase) were observed in genotoxically-treated 
cancer cells with the involvement of the meiotic cohesin 
REC8 and recombinase DMC1[22]. Mos activation was 
also found during endomitosis [23] or multi-polar mitosis 
of TP53-mutant tumours[16, 24].Our initial speculations 
on these data were that cancer is associated with a 
programmatic recapitulation of the ancient ploidy-cycles 
and asexual life-cycles of early protists [23, 25, 26]. 
Some researchers described somewhat similar changes, 
but did not associate them with meiosis. Formation of 
endo-tetraploid cells with diplochromosomes through 
cohesion of sisters as a consequence of DNA damage 
was substantiated by Davoli and Lange [27]. Walen 
described (in normal senescing or glutamine-deprived 
cells) a-spindled co-segregation in endotetraploid cells 
of entire (haploid) genome complements (2x2C1n) 
and suggested the significance of this process for 
carcinogenesis  [28, 29]. However, further studies revealed 
that not only meiotic genes but also the key genes of early 
embryogenesis were induced by genotoxic treatments in 
various tumour cell lines, (both male and female), and 
associated with reversible polyploidy [30-32]. ESC-like 
gene signatures were also revealed in aggressive primary 
tumours [33-36] and it was shown that neoplastic non-
stem cells could spontaneously convert into CSCs through 
epigenetic regulation [37-40].
Two important new aspects were subsequently 
added to our understanding: (1) as predicted by 
Blagosklonny (2007) differentiated tumour cells were 
shown to have the capacity to de-differentiate and 
become CSC (or “stemloids”) [41]; (2) induction of 
stemness by DNA or spindle damage was shown to be 
associated with the activation of meiotic genes coupled 
to reversible endopolyploidy (in TP53 function deficient 
cells). So, along with meiosis, life-cycle features were 
coupled to reversible polyploidy as evidenced by the 
ectopic ESC gene expression in somatic tumour cells. 
To unite these aspects, we proposed that cancer-related 
polyploidy appeared at the same point in macro-evolution 
at which multicellularity occurred (formed by reversible 
endopolyploidy) in unicellular organisms [42].The 
rationale for this was because this evolutionary period 
coincides with the diversification of somatic and gametic 
lineages, simultaneous with the emergence of sexual 
reproduction and gastrulation [43].
While reversible polyploidisation of tumour cells 
through aborted mitoses (“mitotic slippage”) is now 
established [44, 45] currently, it is unclear how the giant 
polyploid tumour cells de-polyploidise. Various proposals 
have been made including; meiosis-like reduction 
divisions [15, 22]; reduction through diplochromosomes 
and haploidy [28, 29]; multi-polar mitoses [16, 46, 47]; 
and “a-mitotic budding” of descendent sub-cells [48-
51]. Recently, we attempted to unite and order most of 
these various events as a necessary sequence of steps in 
a prolonged process of specific rearrangements [31, 52]. 
However, the mechanisms associated with survival of 
resistant tumour cells after the emergence of reversible 
Oncoscience5www.impactjournals.com/oncoscience
polyploidy under genotoxic stresses remain hitherto 
ill-defined, at least in part because of the complexity, 
extension in time, and rarity of the process (as most cells 
die), and so the full picture remains obscure. 
Furthermore, despite the substantial progress in 
understanding the crucial role of polyploidy in cancer, 
recently reviewed by Coward and Hardings [53], clearly, 
we are currently unable to answer many questions. For 
example: Is the meiosis-like response of TP53-mutant 
tumours to genotoxic treatments followed by any syngamy 
(fertilization-like) event(s)? If so, how and when do 
they take place?; Why is stemness induced in somatic 
tumour cells by DNA damage, and why is it associated 
with transient (reversible) polyploidy?;Why do the sub-
nuclei of polyploid giants cells behave autonomously and 
undergo asymmetric divisions [31, 54, 55];How and why 
do multinucleated tumour cells sequestrate cytoplasm to 
their individual sub-nuclear descendants [31]?; How do 
they identify and sort the sub-nuclei containing viable or 
non-viable genetic material [31, 42, 55]?; Why does the 
extent of reversible polyploidisation have an apparent 
limit of ~32C which coincides with the cell number in the 
morula (blastulation) stage of embryogenesis [42] and are 
these somehow related?; Why is accelerated senescence 
coupled to induced stemness in these DNA damaged 
cells [52, 56-58]?; What explains the kinetics of MOS 
and REC8 activation during the polyploidisation and de-
polyploidisation processes [14, 15]? 
Most of these questions can potentially be addressed 
in terms of the parthenogenetic theory of cancer, which 
stemmed from the embryonal theory. We have occasionally 
seen visual evidence that could be interpreted in this way 
in our own studies; some examples of which are presented 
in Fig. 1. 
Parthenogenesis (“virgin birth” in Greek) is a 
special reproductive strategy widely used in the plant 
and animal kingdom, in which an unfertilized egg is 
reunited with a polar body, and undergoes embryogenesis 
to develop adult offspring. The parthenogenetic theory of 
cancer was first suggested by Beutner [60] (cited from 
Erenpreiss [2]) and updated more recently by Vladimir 
Vinnitsky [3, 61]. This link is also made more apparent 
with a series of recent studies reporting the spherogenicity 
and malignancy of endopolyploid tumour cells (ETC). In 
these experiments, polyploid giant cancer cells were sorted 
either manually [62], or chemically – using the hypoxia 
mimic CoCl2 [50, 63] or by serial selections in etoposide 
[51]. These ETC displayed increased resistance to chemo-
radiotherapy, expressed key ESC and germline factors 
(Oct4/Nanog, Sox2, SCF, c-kit), and surface markers 
(CD44, CD133) as well as an ESC-like microRNA 
profiles. These single ETC were shown capable of forming 
tumour spheroids which could undergo differentiation 
into the three germ layers and critically to form tumours 
in immunodeficient mice with high efficiency [50, 62]. In 
other words, the revelations of Barry Pierce and colleagues 
detailed earlier for single carcinoma cells have now been 
shown to be attributable to single ETC. These experiments 
were performed on tumour cell lines representing 
almost all cancer types (breast, ovarian, bladder, colon, 
glioblastoma, fibrosarcoma, osteosarcoma, retinoblastoma, 
lymphoma). Moreover, it was shown that these giant 
polyploid tumour cells possessing large subnuclei 
ultimately bud smaller cells [51] of fibroblastic shape and 
with markers of epithelial-mesenchymal transition (EMT) 
[50].The occurrence of asymmetric mitotic divisions 
in the late ETC which precede cellularisation and the 
release of rejuvenated sub-cells was also suggested by 
us previously [31]. Thus, through the generation and 
reversal of polyploidy coupled to this embryonal-type 
stemness induction, these tumour cells potentially elicit an 
“invasion” phenotype in their descendants. Theoretically 
and based on our cancer cell “life cycle” hypothesis 
wherein reversible polyploidy releases the germline [24-
26] it means that the cells undergoing EMT with ‘embryo-
like” features are the biological equivalent of a germ cell, 
as also concluded by Zhang and colleagues [50].
These observations and conclusions largely fit the 
embryonal theory of cancer. Its oncogerminative variant is 
proposed by Vladimir Vinnitsky [3, 61] and illustrated in 
Fig.2. Within the scheme, three main tenets are outlined: 
reproduction of the oncogerminative cell by an embryonal 
cleavage-like process (with the parthenogenetic origin of 
the tumour initiating CSC); the equivalence between the 
tumour spheroid and the a-vascular blastocyst-stage of 
embryogenesis; and the invading potential of the germline 
(EMT) mimicking the biological properties of primordial 
germ cells (PGC) in normal embryogenesis. The similarity 
between PGC and migrating tumour cells was previously 
supposed by John Beard in 1902 [64], cited from Beckett 
[65] highlighting the embryological theory as a gateway to 
the cancer stem cell theory. Notably, cycles of MET- EMT 
epigenetic transitions interspersed by this embryonal life-
cycle are proposed by Vinnitsky as the mechanism behind 
the observed ongoing cancer relapses.
Although Vinnitsky did not consider the 
polyploidisation of tumour cells as a participant in this 
embryological process, the very idea of parthenogenesis 
provides a place for the observed activation of meiotic 
genes and meiotic-like divisions in the DNA damaged 
tumour cells because parthenogenesis needs first 
formation and maturation of an oocyte. Moreover, the 
main driver of oogenesis, Mos-kinase, was shown to 
be induced by genotoxic treatments in tumour cells of 
various origins, as described above. Therefore, a somatic 
meiosis-like process* seems to be the first step in the 
DNA damage response. Mos can also arrest cells in a 
‘mitotic checkpoint” protecting them from apoptosis as 
an alternative to mitotic catastrophe [24]. Given the 
evidence outlined above relating to ETC, the polyploid 
giant cells appear to represent pathological analogs of the 
early embryo. Subsequently, a syngamic event is required 
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to occur between “meiosis” and “embryo cleavage”. A 
hypothetical scheme of how these key events may occur 
in sequence is presented in Fig.3.
* somatic meiosis does not necessarily need 
recombination between homologs, which may be 
substituted by recombination between sister chromatids 
[66].
A polyploid giant cell leading to the formation 
of a tumour spheroid, when put into the context of the 
embryological process (coined a pseudo-morula and 
pseudo-blastocyst by Vinnitsky 2014), coincides with 
our previous notion that the development of a giant 
tumour cell (through endopolyploidisation) is equivalent 
to the embryonal cleavage (endo-)cycles that reach 
“a developmental checkpoint of totipotency” at 32C. 
This represents ~4 abortive mitoses, which occur by 
day 5, the point from which the reverse of polyploidy, 
ultimately ending in de-polyploidisation and release of 
mitotic descendants, is initiated [31, 55, 67]. This period 
of five days may represent a checkpoint of tumour cell 
endopolyploidisation of embryonal origin and is seen in 
several other models [32, 68]. Here, we should explain 
why tumour ‘pseudo-blastomeres’ are polyploid. During 
cleavage of the tumour pseudo-embryo the pseudo-
blastomeres do not undergo full cytotomy until the 
blastula-equivalent stage, after which the giant cell sub-
nuclei undergo cellularisation (sequestration of individual 
cytoplasm territories) preceding the ‘budding’ of daughter 
cells (described in [26, 31, 48, 50, 51]. This type of 
cleavage where a syncytial blastoderm is formed and 
shortly afterwards a cluster of germ cells is separated along 
with cellularisation is well-characterised in Drosophila, 
perhaps the best understood of all developmental systems 
[69]. Endopolyploidy, multi-nucleation with multiplication 
of pronuclei and/or polar bodies are seen in pathological 
human eggs (numerous examples are seen in the pictures 
from the Advanced Fertility Center of Chicago http://
www.advancedfertility.com/abnormal-ivf-egg-pictures.
htm). These pictures resemble those of multi-nucleated 
(“pregnant”) giant tumour cells presented by Diaz-
Fig.1: Embryonal features of endopolyploid tumour cells induced by DNA damage: A) Namalwa cells (44, X, -Y) (post 
10 Gy irradiation). Two asymmetric reduction divisions are observed which resemble the formation and subsequent division of the first 
polar body (PB) in the maturing oocyte (2 hour treatment with lactocystin before fixation allowed the preservation of both mid-bodies, 
arrowed), republished from [54]; B) WI-L2-NS (47, XY) cells (post 10 Gy irradiation). The induced giant polyploid cell resembles a 4-cell 
embryo; C) HeLa S3 (68, XXX) cell line (post 10 Gy irradiation). A tumour-spheroid that resembles a morula is observed; (republished 
from [15] ; D) Namalwa cells 14 days post 10 Gy irradiation. Transmission EM of a giant polyploid tumour cell following aborted radial 
division. Two types of subnuclei are observed; one with a conventional structure and another with a juvenile-like structure (not present in 
non-treated controls, arrowed); E) A431MetforR (metformin-resistant) cells were selected as indicated [59], (72, XX). A giant cell showing 
mild autophagic activity and actin-enriched individual cytoplasmic regions around small sub-nuclei; F) Namalwa polyploid giant cell 
budding a cellularised descendant that has been sequestered from the parent’s cytoplasm 13 days post 10 Gy irradiation, republished from 
[26]. Bars =10 μm.
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Carballo, et al. [51] and Zhang, et al. [50]. Interesting 
changes are observed in giant tumour cells after reaching 
“the totipotency checkpoint”. Radial divisions (incomplete 
cytotomy) described previously by us in late ETC occur 
which precede casting off the external layer of cytoplasm 
along with cellularisation and release of small descendants 
by ‘budding’ [31, 44, 67]. In some way, this process is 
associated with diversification (by asymmetric divisions) 
of the giant cell sub-nuclei into two types, larger (not 
individualizing cytoplasm) destined to degenerate, and 
smaller (proliferative, endowed by stemness factors and 
decompacted chromatin, acquiring their own cytoplasm 
and actin ring) for shedding with the aid autophagy (Fig. 
1D-F). Radial cleavage furrows is a well-known feature of 
the animal cleavage pattern which situates the blastomeres 
in a doughnut pattern where they remain totipotent and 
bridged up to the 32 cell stage as reported in Volvox [70]. 
Curiously, fossils of early animals dated ca. 570- 620 Ma 
were found to show 32-cell blastula [71]. The genealogy 
of cancer may therefore be truly ancient!
However, there are two key points in the scheme 
of Vinnitsky that require further clarification. 1) How 
do settled MET cells return to the parthenogenetic life-
cycle again, and what drives their entry/exit; 2) what is 
the role of the reversible accelerated senescence reported 
by multiple observers [58, 68, 72-75] which accompanies 
reversible polyploidy in this process and paradoxically can 
favour survival? The latest data demonstrate that tumour 
cells can shuttle between low and high malignant states 
according to their MET/EMT status through epigenetic 
changes of bi-stable chromatin [40]. This addresses the 
biochemical aspects of the phenomenon. Here, we would 
like to suggest that biologically the MET cells, previously 
produced from EMT, may undergo accelerated cellular 
senescence due to accumulation of ROS and DNA strand 
breaks. The accumulation of DNA damage is a hallmark 
of accelerated senescence [76]. However, DNA damage 
is also considered as a major cause for the evolution of 
DNA repair by recombination, which gave rise to meiosis 
through ploidy cycles [23, 66, 77]. Interestingly, a simple 
doubling in the amount of ROS is sufficient to induce the 
genes which initiate the facultative sexual reproduction 
cycle in Volvox carteri [78], indicating the ancestral role 
of sexual reproduction as an adaptive response to stress 
and ROS-induced DNA damage [77].
Markers of accelerated senescence and DNA 
damage were unexpectedly found to be linked to markers 
of stemness in senescing IMR-90 fibroblasts [56] and 
etoposide-or irradiation treated tumour cells arrested in 
G2-phase [57, 58]. The p21-dependent senescence related 
to stemness pathways (TGF-β and PI3K) was revealed 
in normal embryogenesis [79]. Moreover, senescence 
Fig.2: The figure and legend are reproduced from [3], with consent of Vladimir Vinnitsky. Stages of the life cycles of 
germline cells (A) and oncogerminative cells (B). (A) Z, zygote; CSE, cleavage stage embryo; MSE, morula stage embryo; ABSE, 
avascular blastocyst-stage embryo; IBSE, implanted blastocyst-stage embryo; F, fetus. SMB, sexually mature body. (B) CSC, cancer stem 
cell (i.e., oncogerminative cell); PCSC, parthenogenetic cancer stem cell (a pseudo-cleavage-stage embryo); TG, tumor germ (a morula-
stage embryo-like structure); TS, tumor spheroid (an imitation avascular blastocyst-stage embryo); VTS/VT, vascularized tumor spheroid 
and/or vascularized tumor (an implanted blastocyst-stage embryo-like entity). 
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markers are predictors of poor prognosis in lung cancer 
patients after neo-adjuvant therapy [74]. All of this 
highlights the close link between accelerated senescence 
and stemness and their relationship to carcinogenesis [52].
The origin of sexual reproduction is a complex 
and much debated issue. DNA recombination by meiosis 
coupled with sex (i.e. the fusion of paternal gametes), 
although costly in energetic terms, apparently provides the 
optimal balance between DNA repair and genetic variation 
[80]. Polyploidy as such provides the advantage of 
masking deleterious mutations [66], resistance to toxicity 
and energy depletion [81] and therein better survival of 
polyploid tumour cells in unfavourable conditions [53]. 
Reversible polyploidy coupled with the generation of 
immortal germ cells therefore captures the advantages of 
both. We propose that mammalian cancer cells use exactly 
this phylogenetic program ensuring immortality (by a 
life-cycle) and genome plasticity and heterogeneity (by 
stemness) through epigenetic and genetic variation (and 
subsequent clonal selection) as a basis for developing 
resistance to treatments.
It can be suggested that accelerated senescence of 
genotoxically damaged tumour cells serves as a bridge 
and stochastic option for the initiation of the next (cancer) 
life-cycle, which is also accelerated (starting from meiotic- 
and syngamic-like events and ending with the blastula/
spheroid through formation of the germ-like EMT tumour 
cells in a process akin to early embryogenesis carried out 
in approximately one-two weeks). Interestingly, our recent 
research on etoposide-treated embryonal carcinoma cells 
showed that a potential regulator and trigger for this switch 
is OCT4 (POU5F1), a carrier of life-cycle totipotency 
[82]; and induced in a TP53-dependent manner alongside 
p21CIP1. The choice between the two opposite cell fates 
(reinitiate cell divisions or undergo terminal senescence) in 
transiently bi-potential cells is undertaken in G2 arrest [57] 
and this barrier can become adapted to start polyploidy 
[56]. When the tetraploidy barrier is overcome, the TP53 
tumour-suppressing function becomes surpassed [83], 
likely by methylation of its promoter [84], while mTOR 
linking to p21-mediated senescence becomes suppressed, 
thus allowing the reversal of senescence [58]. We suggest 
that the cancer cell ‘life cycle’ is therefore initiated by 
meiosis and locked by accelerated senescence with the 
opposing outcomes diverging from the same DNA damage 
checkpoint [52] supporting the earlier supposition that 
“Carcinogenesis always is started with immortalisation. 
That is a possibility to overcome senescence” [2, 85]. 
We therefore arrive at the same conclusion suggested by 
Rajaraman [49] that immortality of cancer cells is not 
perpetual but becomes cyclically renewed.
Intriguingly, an ~5 day period of ‘stochastic’ 
choice between senescence/MET and self-renewal/EMT, 
separated by a longer rate-limiting period of further 
determination of self-renewal has also been reported 
during the induction of pluripotent stem cells (iPSC) [86], 
Fig.3: Hypothetical scheme of cancer cell ‘life cycle’ based on embryological concept and experimental observations 
of TP53 dysfunctional tumour cell lines after genotoxic treatments.
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with the whole process taking ~30 days.
One further consideration of the parthenogenetic 
origin of cancer is that parthenogenesis is typically viewed 
as a female privilege. Although commonly believed, this 
is not quite true. Mammalian primordial germ cells (PGC) 
of either XX or XY karyotype are sexually dimorphic 
and have the potential to enter either spermatogenesis or 
oogenesis. In a female genital ridge, or in a non-gonadal 
environment in vivo, as well as autonomously in tissue 
culture both 46XX and 46XY PGCs develop as meiotic 
oocytes [87] and can therefore initiate parthenogenesis. 
Only male gonadal somatic cells, which differentiate, 
through SRY (sex determining gene on Y chromosome) 
instruction to SOX9, into Leydig and Sertoli cells 
producing and stabilizing testosterone inhibiting PGCs 
from entering oogenesis, are directed to a spermatogenic 
fate [88]. Therefore, it should be no surprise that male 
ECS cells can undergo development until the blastula 
stage as described by Hubner and Scholer[89] and that 
male lymphoblastoma cells, like WI-L2-NS, induce key 
drivers of oogenesis such as Mos[14],and OCT4 [30] and 
can develop after genotoxic damage into early embryo-
like OCT4-positive giant cells (Fig.1B). Interestingly, 
there are reports of the frequent loss of Y chromosomes in 
male cancers, for example at initial diagnosis of myeloid 
malignancies, with restoration of the normal karyotype 
(46XY) at remission [90].
An additional facet to be considered relates to 
aneuploidy. Aneuploidy is a typical hallmark of cancer, 
accompanying polyploidy and is usually explained by 
the instability of the cancer genome losing or gaining 
chromosomes during proliferation [91, 92]. However, 
this approach does not explain the “aneuploidy paradox”: 
given its inherent anti-proliferative potential, why is 
aneuploidy obstinately retained in proliferating tumours 
[93, 94]?.Why do many cancers keep to para-triploidy, 
which in childhood neuroblastoma is associated with less 
chromosomal aberration and more favourable outcome 
[95], while other tumours are para-haploid [28, 96]? This 
paradox may be also resolved within the parthenogenetic 
theory of cancer. 
Animals use multiple mechanisms of 
parthenogenesis, most of which depend on polar bodies 
that do not degenerate. So, besides several variants of 
parthenogenetic fusions leading to restoration of 2n 
chromosome number, there are also other variants allowing 
triploid cells to form [97]. Notably, ESCs resulting from 
haploid mouse parthenogenesis can also acquire germline 
potency after diploidisation [98], which can thus lead to 
loss of heterozygosity and loss of tumour suppression. 
The essence of meiosis is genetic recombination, so that 
each meiotic division produces a distinct sibling. Embryos 
that retain their polar bodies during development thus 
have two or more different genomes enabling genetic 
variation a-sexually. If tumour cells are involved in 
a macroevolutionary predetermined life-cycle with 
parthenogenetic components, then segregation of haploid 
paternal genomes and their variable combinations during 
the parthenogenetic fusions may be nearly an inevitable 
component of this process recovering the immortal germ-
line. In turn, losses and gains of separate chromosomes 
are only secondary acquisitions of tumour microevolution, 
driven by instability and stochastic events, which may 
be counterbalanced by the recombinative process of 
meiosis [24]. Interestingly, the “triploid bridge” has been 
established in plants as facilitating a shift from polyploid 
to diploid generations [99].
CONCLUSION
Accumulating data favours a change to the view 
of the phylo-ontogenetic origin of cancer as a pre-
programmed life-cycle process. This view provides 
a conceptual framework within which to explain the 
origin of cancer cells, their immortality and resistance to 
genotoxic treatments, and allows resolution of much of the 
complexity behind cancer phenomenology. It furthermore 
allows us to place the current knowledge on CSC, the 
reversible polyploidy of giant polyploid tumour cells, and 
the ectopic induction of meiosis-like processes into a non-
contradictory hypothesis. 
Perspectives
Accepting this concept of cancer cell embryonality 
and its life-cycle-like process of immortality provides us 
with new ways of understanding and treating cancer. On 
one hand, the embryonal-type plasticity and heterogeneity 
allows tumour cells to bypass many targeted therapies by 
substituting them with alternatives and thereby allowing 
time to undergo genetic drift and clonal selection [100, 
101]. Moreover, genotoxic treatments actually favour 
the embryonalisation of tumour cells, thus promoting 
resistance, relapse and metastases [102-105] causing them 
to become entrapped in the embryonal “cancer attractor’ 
[106-108]. Therefore, truly targeted therapy should be 
designed to hit the ontogenetic root of the cancer life-
cycle and maybe even its phylogenetic origin in early 
multicellularians [26, 42]. 
The view that the genes of cellular cooperation 
that evolved with multicellularity about a billion years 
ago are the same genes that malfunction to cause 
cancer is positioned as the atavistic theory of cancer, 
which is substantiated from both paleontology and 
genetics [109]. It is supposed that this program became 
suppressed in advanced Metazoans by newer genes, 
which are undoubtedly tumour suppressors. Multiple 
atavistic theories did not take into account the polyploidy 
component, however, we suggested previously and 
substantiated here that reversible polyploidy is an essential 
component of this evolutionary-originated cancer cell 
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“life-cycle” program. This consideration brings us 
to the c-myc protooncogene, whose overexpression 
uncouples DNA replication from mitosis, thus leading to 
endopolyploidy [110]. C-myc is one of the most ancient 
genes of early Metazoans [111], linked during evolution 
to the Warburg effect [112]. It is also the main oncogene 
imposing immortality to cancer cells and a master 
regulator of stemness [52]. Importantly, c-myc is a gene, 
whose suppression in in vivo models eliminates “oncogene 
addiction” and cures experimental cancer [113, 114]. 
Therefore, the targets for interrupting the cancer cell ‘life-
cycle’ at its evolutionary root should likely focus around 
c-myc.
On the other hand, if a tumour cell can undergo an 
epigenetic embryonalisation, its epigenetic reverse to a 
differentiated cell should be also possible. This strategy 
- not to fight but to tame tumour cells- seems logical. 
Such studies have been undertaken since the beginning 
of the 20th century; (for rev. see [8, 115-117]. Recently, 
a very interesting experiment was performed showing 
that paclitaxel could induce both EMT and formation of 
benign fibroblasts in an ovarian cancer model [118]. The 
best known and widely applied example of this treatment 
strategy is the differentiation inducer all-trans-retinoic acid 
(RA). Intriguing this is an old Chinese medicine against 
cancer and capable of curing acute myeloid leukemia 
[119]. 
Tumours can be “normalized” by an embryonic 
morphogenetic field [120] or by putting them within 
a normal 3D stroma [121, 122]. The influence of a 
regenerative environment was seen by the insertion of 
sarcoma cells into a fractured rat tibia; the cartilage calus 
formation enslaved them and interrupted their invasive 
growth [123]. 
The most important thing is that while genotoxic 
treatments convert malignant tumour cells into even 
more malignant variants [105], the opposite strategy may 
convert a malignant tumour into a benign one and prevent 
metastases. The epigenetic reprogramming of tumor cells 
by inducing differentiation (f.ex. by cytokines) show 
that epigenetics wins over genetics [124]. This facet in 
principal confirms the notion that embryonalisation is the 
only essential biological feature of tumour cells [2, 42, 
107].
The experiments with nuclear cloning of embryonal 
carcinoma cells revealed that both malignant and 
embryological potentials can co-exist [125]. Therefore 
although it may be impossible to obtain the irreversible 
normalization of genotypically altered tumour cells by 
epigenetic means [126], it should be possible to stop 
tumour progression [117]. 
However, the most exciting thing is that the 
potential targets for these opposing strategies, as well as 
the pathways for genotoxically induced resistance and 
accelerated senescence, all converge at the same molecular 
pathways, around c-myc. Suppression of Wnt/ β-catenin 
signalling (which up-regulates c-myc to promote cell 
proliferation), favours the RA-dependent differentiation 
of embryonal carcinoma [127]. Potential normalization 
targets in spontaneous TP53 mutant tumour revertants 
lead to, among others, presenilin1 activating Notch1 
substrate ɤ-secretase, up-stream of c-myc stress signaling 
[117]. In turn, Notch1, which directly regulates c-myc 
is co-operating with Wnt in enhancing tumorigenesis 
[128] enriches mammospheres induced in breast cancer 
by irradiation [129]. In addition, it was also found that 
p21CIP1, involved in regulation of cellular senescence, 
functions as a negative transcriptional regulator of WNT4 
downstream of Notch 1 [130] and that p21CIP1 potentially 
reorganizes the nucleus during tumour reversion [117]. 
So, at the molecular level, all roads meet. This provides 
the hope that a single key, unavoidable, pathway may be 
targeted to finally cure cancer.
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4. Discussion 
In recent years studies have revealed there are two contrary phenomena in tumour cell 
response to the dosages of conventional genotoxic therapy applied for treatment of cancer patients: 
on one hand, cessation of growth by induction of cellular senescence and, on the other hand, 
induction of resistance and propagation of cancer stem cells. It turned out, that induction of 
polyploidy may unite these two opposites. Collaborative studies in our laboratory revealed that 
induced in TP53 mutant tumour cells polyploidy is reversible (Illidge et al., 2000) and moreover, 
that induction of reversible polyploidy is associated with activation of embryonal stem cell key 
transcription cassette (Salmina et al., 2010). This data were confirmed and extended by other 
researchers, who showed that induced polyploid cells can grow as spheroids, give tumours at 
xenotransplantation, even ofone giant cell, and produce epithelial-mesenchymal transition (EMT) 
descendants by de-polyploidisation (Weihua et al., 2011; Ghisolfi et al., 2012; Lagadec and Pajonk 
2012;  Zhang et al., 2013c).  However, the relationship between stemness and senescence, which 
also turned out to be reversible and associated with polyploidy (Puig et al., 2008; Mosieniak et al., 
2012; Wang et al., 2013), as well as the role of the main constituent of senescence, autophagy 
(Capparelli et al., 2012; Mosieniak et al., 2012; Young et al., 2009)  for resistant tumour growth is 
remaining entangled and unclear. Gaining a better understanding of the relationship of these 
complex phenomenon is the subject of the current study (original paper 1) we used in vitro 
senescence of normal human fibroblasts IMR90 as our first model.  Surprisingly, we found the co-
expression of embryonal self renewal transcription factor NANOP and senescence markers 
p21CIP1 and P16INK4a in the same pre-senesent cells signalling DNA damage by γ-H2AX. In 
particular, we found that this co-expression of opposites was associated with overcoming the G2/M 
barrier of tetraploidy.  It was for the first time that self- renewal signaling has been revealed in 
normal senescing cells in association with G2 DNA damage checkpoint and its adaptation for 
polyploidy. When gradualy entering deeper senescence most IMR90 cells loose NANOG from cell 
nuclei; rare giant cells still continue to express it in paralel with senescence markers. NANOG, an 
activator, and P16INK4a, inhibitor of cyclin kinase complex cyclin D/cdk4,6 have adverse roles in 
initiation of the cell cycle (Neganova and Lako 2008). NANOG was also shown to suppress 
promoter of TP53 (Lin et al., 2005), which is the main protector from polyploidy and aneuploidy 
(Aylon and Oren 2011), while polyploidy, in turn, causes inactivation of  TP53 (Park et al., 2011) 
(Zheng et al., 2012). Therefore, the expression of NANOG in normal pre-senescent cells carrying 
DNA damage shows potential of compromising natural senescence barrier to malignant growth 
(Collado and Serrano 2010; Erenpreisa and Cragg 2013). Notably, this transition of wt TP53 normal 
cells occurs through adaptation of  G2 damage checkpoint,  likewise shift to stemness and resistance 
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of genotoxically damaged TP53-mutant tumour cells (Salmina et al., 2010) and both are united by 
emerging polyploidy (Figure 1). 
 
 
Figure 1. The left part of the scheme shows the tumorigenesis through senescence of normal cells, and 
theright part of the scheme shows the resistance of tumour cells to genotoxic therapy  through 
senescence and polyploidy. DNA damage is a leading cause, while polyploidisation is associated with 
acquisition of CSC phenotype. 
 
 Next, we took the model of cancer stem cells with functional TP53, embryonal carcinoma 
PA1 andtreated it with inhibitor of topoisomerase II etoposide (original paper 2). After DNA-
damage induced by etoposide, self-renewal transcription factor OCT4A and growth 
arrest/senescence regulator P21CIP1 were found highly increased in the same cells. 
Silencing of mRNA TP53 in this model prevented the upregulation of P21CIP1 and, 
suprisingly, of stemness factor OCT4A as well, returning its levels back to control. This drove us to 
conclusion that activation of OCT4 by DNA damage in embryonal carcinoma cells is P53 
dependent. That goes together with discovery by others, that OCT4 may have role in stress response 
(Bártová et al., 2011). TP53 silencing also led cells to increased DNA damage and polyploidy. 
Premature exit of G2 arrest, mitosis, micronucleation and senescence (marked by sa-β-
galactosidase) were all enhanced after TP53 silencing. Induction of senescence was confirmed by 
upregulation of CDKN2A/P16INK4A. Mitoses enhanced by TP53 silencing were shown to be 
multicentrosomal and multi-polar, containing fragmented and highly deranged chromosomes, 
indicating loss of genome stability, which otherwise was supported by TP53-dependent balance 
between two factors of opposite cell fates.  
In further research on this model (original paper 3) we studied interactions between 
OCT4A and P21CIP1. Via  silencing experiments, we found that OCT4A suppresses P21CIP1 but 
P21CIP1 does not directly influence OCT4A. Withdrawal of OCT4A led cells to irreversible 
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senescence and significally increased polyploidy and cancelled mitotic regrowth, although also 
showed decreased apoptosis. The latter effect can be caused byantiapoptotic effects of P21CIP1 
(Shim et al., 1996; Suzuki et al., 1998). 
It follows that the role of P53-dependant OCT4A is to keep a cell resisting terminal 
senescence by tempering P21CIP1. Down-regulation of P21CIP1 by OCT4A inducing methylation 
of its promoter was shown earlier (Lee et al., 2010). So, this is a real mechanism of resistance of 
embryonal and cancer stem cells, which equip them with advantage, by giving more time for DNA 
repair, in comparison with normal cells where this mechanism is absent. If both - P53 and OCT4A 
can keep the DNA damaged cells in G2-arrest, then when removed, the cells with still persisting 
DNA damage can overcome this barrier and move into malignant aneupolyploidy. Therefore, this 
mechanism has a role in guarding stemness from the genome instability. 
Next the question arose - what determines the limit of this capability, if P21CIP1 does not 
suppress OCT4? Our studies on this model with application of autophagy inhibitor Bafilomycin A1 
showed that the limit is the capacity of autophagy to support cell by providing energy and 
metabolites. Suppression of autophagy abolished recovery of clonogenic growth after etoposide 
treatment (original paper 3).  
Moreover, we revealed a novel mechanism of sequestration and digestion of P16INK4a in 
cytoplasm by functional autophagy, thus postponing onset of terminal senescence (original paper 3). 
This finding is in accord with the data that inhibition of autophagy leads to accumulation  of 
P16INK4a  and other markers of irreversible senescence (Kang et al., 2011).  As autophagy is the 
main constituent of cellular senescence ensuring metabolic activity of growth arrested cells, we 
conclude that autophagy is a key to the fate decision of DNA damaged tumour cells. This 
conclusion fits well with the data on the role of mTOR, the inhibitor of autophagy and AMPK, its 
activator and cell energy sensor (Galluzzi et al., 2014; Sui et al., 2013). In particular, after etoposide 
treatment, inhibition of  pAMPK in G2-arrested hepatoma cells triggers apoptosis through 
suppression of autophagy (Xie et al., 2011). Therefore our discovery of the pAMPKthr172 
activation and its coordination with OCT4A expression, in the PA1-Etoposide model was very 
notable and in line (original paper 3). The  link between OCT4A and pAMPK may be explained by 
the role as regulator of pAMPK in the DNA damage response (Sanli et al., 2014) and in 
stabilisation of activated P53 (Bungard et al., 2010).   
        We found another facet of autophagy associated with reversible polyploidy induced 
by genotoxic treatment (irradiation  or etoposide) of tumour cells in the earlier study (original paper  
4)  – autophagic digestion and extrusion of sub-nuclei leaving behind the subnuclei, which 
accumulated stemness markers (OCT4A and NANOG). The latter were able to restart  mitosis and 
were released from giant mothers as free subcells.  
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Hitherto, nucleophagy has been also observed in a small percentage of non-treated cells 
(Park et al., 2009). It may be due to release of small portions of extrachromosomal DNA of 
telomeric origin found in senescing cells (Kunisada et al., 1985; Gaubatz 1990); extrusion of small 
patches heterochromatic DNA from senescing cells was also found by Adams and colleagues 
(Ivanov et al., 2013). 
However, in our research sorting of the whole sub-nuclei from multi-nucleated tumour 
cells were found and they were  preceded by multi-polar a-cytotomic mitosis. It was suggested that 
polyploid cells are able to re-assort and selectively remove more damaged sub-nuclei by autophagy 
and/or use this material for re-utilisation by  neighbour sub-nuclei recovered as descending cells. 
Thus, much discussed paradoxical nature of autophagy in tumours (both pro-senescing and pro-
survival)  (Hanahan and Weinberg 2011) and their tendency to promote aneu-polyploidy in spite of 
its anti-proliferative effect may be explained by each other. 
So, our findings of new facets of the role of autophagy in both TP53 wild type and mutant 
cancer cells indicate to its paramount role in genotoxic resistance provided by  collaboration 
between senescence, polyploidy, and stemness. It follows that  autophagy should be a key target for 
preventing resistance of cancer cells to genotoxic therapies, a supposition supported by others (Sui 
et al., 2013; Dörr et al., 2013).  
The genotoxically treated tumour cells acquire stemness features through polyploidy and 
we have possibly revealed  a structural aspect of it.  We found significant (up to five-fold) 
expansion of chromosome territories in induced endopolyploid cells reaching maximum on day 5 
(original paper 5) on the model of irradiated HeLa cells using the whole chromosome in situ 
fluorescent painting probes. Such rewiring should change function of the whole genome (Giuliani 
2014). This data characterises the conformation of the chromatin in polyploid cells as highly open 
(unfolded), which fits well with the observed activation of embryonal stemness found earlier in this 
model (Salmina et al., 2010) and results described here (original paper 5). The bivalent and open 
conformation of the chromatin in embryonal stem cells (Bernstein et al., 2006)  was shown to keep 
transcription of most genes initiated (Guenther et al., 2007).  Loose chromatin conformation is 
likely induced by activated c-Myc, which both favours endopolyploidy (Li and Dang 1999) and 
acetylation of core nucleosome histones (Martinato et al., 2008). This epigenetic chromatin feature 
of the embryonal stemness provides these cells with plasticity to easily adapt transcription 
development programs and to stress conditions,  including genotoxic and proteoxic stress of 
anticancer treatments. 
Furthermore, the dual response of PA1 embryonal carcinoma cells to etoposide eventually 
determining two opposite cell fates, termination or survival, revealed high heterogeneity of 
expression in individual cells of eto-treated population (original paper 3) in our experiments and 
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this should be discussed.  Detection of the DNA damage-P53-dependant OCT4A and P21CIP1 
shows the apparently bi-potential state where the space spanned by OCT4A and P21CIP1 covers 
(on day 5) all the spectrum of relationships, while later cells separate for survivors and those which 
die. It indicates the disadaptation caused by high DNA damage (Gorban et al., 2010; Giuliani et al., 
1998), and  to the  involvement of chaotic regulations. The traectory of individual cell in this state 
of instable bi-potential state between two opposites preceding bifurcation might be near-random 
(Huang 2004) and highly susceptible to intrinsic and extrinsic factors. The thermodynamics of 
instable self-organising systems developed by the Nobel Prize laureate (1977) Ilya Prigogine 
highlights an advantage of coherating fluctuations emerging in such self-organising systems, which 
due to positive feed-back loops may involve cell population to one or another equilibrium attractor 
of cell fate.  Cell-to cell variability, due to ergodic theorem, corresponds temporal variability (Brock 
et al., 2009). Indeed, OCT4A (Sustáčková et al., 2012) and activator of both – OCT4A and 
P21CIP1, P53 (Purvis et al., 2012) have been shown to fluctuate after DNA damage. Apparently, 
this chaotic regulation may be critical for the plasticity (adaptability) of the stem cell-like phenotype 
in the control of linear choice (Huang 2009; Brock et al., 2009; Chang et al., 2008) So, it appears 
that chaotic regulation, assigned together with epigenetic plasticity to tumour cells by stemness 
phenotype, is used for their escape from genotoxic treatments.  
This raises the question, which evolutionary traits gave the origin to the biology of tumour 
cells and its resistance to genotoxic damage, characterized in this study by induced cellular 
senescence,  polyploidy, and embryonal type stemness and acting as a whole? This conundrum was 
analyzed in the review paper included in this study (review paper 1). The apparent driver of this 
evolution is DNA damage repair relation to the origin of sex (Kondrashov 1994; Bernstein et al., 
1985). Therefore, molecularly, all three phenomena converge to DNA damage G2 checkpoint 
(Erenpreisa and Cragg 2013). The capability of induced polyploidy tumour cells to express the 
meiotic and early embryo genes (Ianzini et al., 2009; Erenpreisa and Cragg 2010) and capability to 
grow as spheroids (Weihua et al., 2011; Lagadec et al., 2012; Zhang et al., 2013) giving rise to 
differentiated tissues (Zhang et al., 2013a; Zhang et al., 2013b) drives us back to the roots - 
embryological theory of cancer (Cohnheim 1880, after Erenpreiss 1993). This, in turn, puts the 
possibility ofusing these embryonal properties of malignant tumours for epigenetic reverse to 
benign condition applying differentiating inducers back on the agenda (Pierce and Wallace 1971). 
Accumulating data favours a change of current paradigm of  the origin of cancer from 
purely stochastic (mutation-driven) to  an  evolutionary pre-programmed life-cycle-like process as 
discussed in our review (review paper 1). 
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5. Conclusions 
• Coupling of the expression of embryonal self renewal transcription factor NANOG with 
senescence regulators P21CIP1 and P16INK4a in pre-senescent human fibroblasts coincide with 
DNA damage and overcoming the G2/M barrier of polyploidy. 
 
• Activation and coupling of self renewal and senescence regulators  OCT4A and P21CIP1 
revealed  in the cells of etoposide-treated teratocarcinoma PA1 is P53 dependant.  
 
• The heterogenous  pattern of the dual activation of the opposing regulators OCT4A and 
P21CIP1 after DNA damage  indicates to metastable bi-potentiality as a mechanism of non-linear 
regulations  in stress response of cells with properties of embryonal stemness. 
 
• The role of P53-dependant OCT4A induced by DNA damage in  PA1 cells  is partial 
suppression of P21CIP1 preventing terminal senescence and genome destabilisation.  
 
• P53-dependant OCT4A induced by DNA damage in  PA1 cells  is  co-expressed and co-
ordinated with activated AMPK thr172 -  a master sensor of energy deficit, regulator of cellular 
metabolism and activator of autophagy. Dependance on P53 and co-operation with pAMPK 
indicates to a novel stress function  of OCT4A in DNA-damaged  cancer stem cells. 
 
• Functional autophagy supports vitality of DNA-damaged cells,  sequestrates the inducer of 
terminal senescence P16INK4a in cytoplasm. Irreversible senescence of DNA damaged tumour 
cells counterbalanced by stemness is mainly triggered by failure of autophagy.  
 
• Selective chromatin degradation by autophagy in polyploid tumour cells  favours their  de-
polyploidisation and resistant re-growth . 
 
• Chromosome territory expansion in DNA damage induced poyploidy indicates nuclear 
architecture switch towards stem-like plasticity. 
 
• Accumulating data favour the view on cancer as the phylogenetically pre-programmed life-
cycle-like process.  
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6. Main thesis of defence 
• Simultaneous activation of self renewal and accelerated senescence occurs in normal 
presenescent human fibroblasts in G2 damage checkpoint accompanied by overcoming the  barrier 
to tetraploidy. 
 
• Simultanous P53 dependent activation of self-renewal OCT4A and senescence P21CIP1 
proteins  in etoposide treated teratocarcinoma PA1, the model of damaged cancer stem cells, 
indicates the generality of coupling between senescence and stemness programs ocuring in DNA 
damage response. 
 
• Stress activated  P53-dependent OCT4A of eto-treated teratocarcinoma PA1 cells restricts 
expression of P21CIP1 and is coordinated with metabolic stress sensor and autophagy activator 
pAMPK, thus is acting as a DNA stress-responser. 
 
• Adaptation to genotoxic stress is regulated through enormous heterogeneity in dual      
expression by individual cells of OCT4A and P21CIP1. This phenomenon reflects the features of 
population regulation by self-organisation principles. 
 
• Autophagy is part of accelerated senescence, however prevents terminal senescence,  while 
its failure overcomes resistance of tumour cells. Therefore, autophagy should be a key target for 
preventing resistance of cancer stem cells to genotoxic therapies. 
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Primary antibody table 
Antibody against Description 
Product nr and 
Manufacturer Use* 
AURORA B  Rabbit polyclonal ab2254, Abcam  IF 1:300 
bromodeoxyuridine (BdU) Mouse monoclonal A21300, Invitrogen IF 1:200 
b-TUBULIN Mouse monoclonal Neomarkers; clone DM1B IF 1:100 
CATHEPSIN B Rabbit polyclonal ab30443, Abcam IF 1:100 
CDKN2A/p16INK4a Rabbit polyclonal ab7962, Abcam IF 1:100 
CHK2 (phospho T68) Rabbit polyclonal  ab38461, Abcam IF 1:100, W 
1:500 
GAPDH Mouse monoclonal, 
clone 6C5 
ab8245, Abcam W 1:500 
LAMIN B1  Rabbit polyclonal ab16048, Abcam IF 1:300 
LAMP-2 Mouse monoclonal ab25631, Abcam IF 1:500 
LC3A/B Rabbit polyclonal PA1-16930, Pierce IF 1:100 
LC3B Rabbit polyclonal ab63817, Abcam IF 1:100 
NANOG Mouse monoclonal, 
clone  NNG-811 
N3038, Sigma 
IF 1:50 
NANOG (23D2-3C6) Mouse monoclonal MA-1-017, Pierce IF 1:50 
NANOG H-155  Rabbit polyclonal sc-33759, Santa Cruz IF 1:50 
OCT3/4  Mouse monoclonal  sc-5279, Santa Cruz IF 1:50, F 
1:100 
OCT3/4  Goat polyclonal sc-8630X, Santa Cruz IF 1:200 
OCT4  Rabbit polyclonal,  
ChIP Grade 
ab19857, Abcam 
IF 1:200-400 
p21  Rabbit polyclonal  sc-397, Santa Cruz IF 1:50 
p21 Waf1/cip1 Rabbit monoclonal MA5-14949, Pierce IF 1:100 F 
1:100 
p-AMPKα1/2 (Thr183/172) Rabbit polyclonal sc-101630, Santa Cruz 
IF 1:100 
PL2-6 Mouse monoclonal A kind gift from Olins IF 1:100 
PML Mouse monoclonal sc-966, Santa Cruz IF 1:150 
RAD51 Mouse monoclonal ab213, Abcam IF 1:100 
RAD52 Goat polyclonal sc-7674, Santa Cruz IF 1:400 
SOX2 Mouse monoclonal MA1-014, Pierce IF 1:50 
SOX2 Rabbit polyclonal sc-20088x, Santa Cruz IF 1:50 
SQSTM1 (p62) Rabbit polyclonal  sc-25575, Santa Cruz IF 1:200 
TERT Mouse monoclonal ab5181, Abcam IF 1:100 
β-ACTIN Rabbit polyclonal ab8227, Abcam W 1:200 
γ TUBULIN  Mouse monoclonal ab11316, Abcam IF 1:2000 
γ-H2AX Rabbit polyclonal 4411-PC-100, Trevigen IF 1:200 
*W, western; IF, 
immunofluorescent staining; 
F, flow cytometry 
 
 Secondary antibody table 
Antibody Conjugate Product nr and Manufacturer Use * 
Goat anti-mouse IgG Alexa Fluor 488 A31619, Invitrogen IF 1:300-400 
Goat anti-mouse IgG Alexa Fluor 594 A31623, Invitrogen IF 1:300-400 
Goat anti-rabbit IgG Alexa Fluor 488 A31627, Invitrogen IF 1:300-400 
Goat anti-rabbit IgG Alexa Fluor 594 A31631, Invitrogen IF 1:300-400 
Rabbit anti-goat IgG Cy3 C2821, Sigma IF 1:500 
Donkey anti-goat IgG Alexa Fluor 594 A-11058, Invitrogen IF 1:300-400 
Chicken anti-rabbit IgG Alexa Fluor 488 A-21441, Invitrogen IF 1:300-400 
Donkey anti goat IgG Alexa Fluor 488 A11055, Invitrogen IF 1:300-400 
Chicken anti-rabbit IgG Alexa Fluor 594 A-21442, Invitrogen IF 1:300-400 
Chicken anti-mouse IgG FITC sc-2989,  Santa Cruz IF 1:200 
sheep anti-human IgG FITC 
 
IF 1:100 
Rabbit anti-mouse IgG HRP 61-6520, Invitrogen W 1:500 
Goat anti-rabbit IgG HRP 32460,Thermo Fisher Scientific W 1:500 
Goat anti-mouse IgG Biotin Vector Labs, UK IF 1:100 
Streptavidin FITC Vector Labs, UK IF 1:150 
*W, western; IF, immunofluorescent staining; F, flow cytometry 
 
 
